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Abstract 
In the past two decades only modest advancements in glioma treatment have been made, with 
patient prognosis and median survival time following diagnosis only increasing from 3 to 7 
months. A substantial body of clinical and preclinical evidence has suggested a role for 
aspirin in the treatment of cancer with multiple mechanisms of action. Aspirin is one of the 
most widely used drugs, successfully taken as an analgesic, antipyretic, anti-inflammatory 
agent and for prevention of strokes and ischemic diseases. The effects on cell viability, 
proliferation, apoptosis and migration of aspirin and aspirin derivatives were tested 
on primary glioblastoma cell cultures, BTNW911 and BTNW 914, and the well-established 
cell lines, SVG-p12, 1321N1, GOS-3, U87 MG, using the PrestoBlue assay, CFDA-SE, 
PI/annexin V, and live imaging receptively. The effects on cell viability following 24 and 48 
hour incubation of four aspirin derivatives (PN508, PN517, PN526 and PN529) were 
compared to cisplatin, aspirin and di-aspirin, establishing IC50 values, showing PN517 to be 
the most potent analogue, and in some cases greater efficacy than cisplatin. Aspirin analogues 
showed greatest efficacy in the first 24 hours, while cisplatin increased in efficacy with time 
showing a lower IC50 value in all cell lines at 48 hours. Cell proliferation was assessed over 
3 to 10 days, with each treatment decreasing proliferation and the largest effect of PN517 
found in BTNW914 cells. PN517 treatment decreased the population of G0/G1 phase cells 
in cell cycle analysis, decreased cyclin D1 and EGFR activation, and total EGFR expression. 
Apoptosis was induced by PN517 in a concentration and time dependent manner in both the 
cell lines and short term cultures, with activation of both intrinsic and extrinsic pathways. 
Finally, PN517 reduced migration in both the Boyden chamber and scratch assays, but did 
not inhibit invasion. In conclusion, these data support the further development of PN517 as 
a novel therapeutic drug for the treatment of glioma.  
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1.1 Brain Tumours  
There are over 130 types of tumour that can occur in the brain and other parts of the CNS or 
intracranial region with around 9400 people diagnosed with a brain, other CNS or intracranial 
tumour in 2011 in the UK (26 people every day), half of which were males, and half females. 
The UK annual incidence rate of brain tumours ranges from 14.8 per 100,000 for males and 
14.6 per 100,000 for females (Cancer Research UK, 2014). Of those diagnosed in 2011 
approximately 4500 died of brain cancer, (13 people a day) 100 of which are children. The 
greatest incidence was reported in over 65s (57%), however, 400 children were diagnosed, 
and this accounts for the second most common childhood cancer. The most common types 
of brain, other CNS and intracranial tumours in England in 2006-2010 were astrocytomas 
(34%) and meningiomas (21%) (Cancer Research UK, 2014). Primary brain tumours, those 
arising within the central nervous system (CNS) represent 1.6% of all the tumours diagnosed, 
whereas secondary brain tumours, resulting from metastasis of non CNS tumours, represent 
6% of all tumours detected in the UK (Cancer Research UK, 2014).  
 
Primary brain tumours that originate in the brain only rarely metastasize; and secondary, or 
metastatic tumours arise from other cancer sites in the body, such as lung cancer, breast 
cancer, kidney cancer, melanoma and other types (Cancer Research UK, 2013). In addition, 
primary brain tumours can be benign or malignant. Benign tumours are typically slow-
growing, usually grade I and II, and rarely spread to other areas of the body.  They often have 
well-defined borders, so they can be surgical removed effectively. Benign brain tumours can 
be considered malignant if they are located in areas of the brain that control vital functions 
like breathing (NHS Choices, 2013). Malignant tumours tend to grow faster, are typically 
grade III and IV, and can be more invasive than benign tumours (Cancer Research UK, 2013). 
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Metastatic or secondary brain tumours are carried to the brain by the blood, or spread from 
adjacent tissue and are the most common type of brain tumour, particularly in the elderly 
(NHS Choices, 2013). The most commonly metastasizing primary cancers to the brain, are 
lung cancer (50%), breast cancer (20%), melanoma (10%), and colon cancer (5%). Around 
80% of brain metastases occur in the cerebral hemispheres, 15% occur in the cerebellum, and 
5% occur in the brain stem (Patchell et al., 2003).  Primary brain tumours rarely spread to 
other areas of the body, but they can spread to other parts of the brain and to the spinal axis. 
Low grade tumours that are slow growing with well-defined borders can usually be removed 
surgically; however, their location within the CNS presents challenges due to the risk of 
significant neurological sequelae (Veeravagu et al., 2013). This risk increases with high 
grade tumours that grow rapidly and are highly invasive, but most studies show a significant 
improvement in survival that correlates the extent of tumour resection (Hervey-Jumper and 
Berger, 2014). Improvement has been seen in the last four decades in patient survival with 
approximately 40% of patients diagnosed with malignant brain tumours surviving more than 
a year, 15% surviving five years, and 10% up to ten years from diagnosis (Cancer Research 
UK, 2014). However the chances of surviving longer relates to the age of the patient as more 
than 70% children survive for at least five years, 50% of young adults will survive five years, 
but only 2% of over 70s. The main cause of brain tumours still remains unidentified. 
However, several risk factors have been established which include exposure to radiation, 
previous incidence of cancer or  genetic conditions such as neurofibromatosis (Reilly, 2010).  
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1.2 Tumour Grading 
Classifying, grading and staging of tumours are helpful to determine the appropriate 
treatment and to better understand the patient's current health and prognosis. Grading helps 
the understanding of the aggressiveness, or malignancy of a tumour with grading classified 
as Grade I through Grade IV and the more aggressive and dangerous the tumour is, the higher 
the grade (Scheithauer, 2008).  The description of tumour grade is based on the World Health 
Organization (WHO) grading system (Louis et al., 2007). 
 
Grade I: These are the least malignant tumours and are usually associated with long-term 
survival and the potential for cure following surgical resection alone. They grow slowly and 
have an almost normal appearance when viewed through a microscope.  
 
Grade II: These tumours are slow-growing and look slightly abnormal under a microscope. 
Typically these neoplasms are infiltrative in nature, often recur following treatment, and can 
develop into higher grade tumours. 
 
Grade III: Although there is not a big difference between grade II and grade III tumours, 
these tumours display a malignant phenotype. The cells of a grade III tumour are actively 
reproducing abnormal cells which invade normal brain tissue and following treatment tend 
to recur, often as a grade IV. 
 
Grade IV: These are the most malignant tumours that reproduce rapidly, have an abnormal 
appearance when viewed under the microscope, and invade normal brain tissue. The 
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neoplasm is associated with a necrotic core and the formation of new blood vessels to 
maintain their rapid growth.  
 
In spite of the relative clarity of this grading system it must be recognised that tumours can 
contain more than one grade of cell where the highest or most malignant grade of cell 
determines the overall grade of the tumour (Scheithauer, 2008). A summary of CNS tumour 
type and their current WHO grading can be found in the review by David Louis and 
colleagues, the authors of the official WHO publication (Louis et al., 2007). 
  
1.3 Glioma 
There are more than 130 different types of primary brain tumours, named by the type of 
normal cell they most closely resemble, cell location, and grading from the least aggressive 
to the most according to World Health Organization (WHO) classification system (Louis et 
al., 2007). While there is no single definitive cause of brain tumours, there are trends among 
people who get them such as age, environment influences, geography and genetics (Cancer 
research UK, 2013). Gliomas, neoplastic glial cells, are responsible for the majority of 
malignant brain tumours, and are the most common type of primary brain tumour. They are 
classified by cell type as astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and 
ependymoma (Figure 1.1) (Louis et al., 2007).  
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Figure 1.1 Classification of primary brain tumours by histology (Shonka and Gilbert, 2010). 
 
Primary glioblastoma multiforme (GBM) represents approximately 95% of cases, with the 
remaining 5% of cases being secondary GBM typically arising over a period of years from 
either low grade astrocytoma (WHO grade II), or from anaplastic astrocytoma (WHO grade 
III) (Rivera et al., 2008; Jaeckle et al., 2011). Following diagnosis, the 5-year survival rate 
for low grade glioma is 97% after surgical resection of greater than 90% of the tumour, but 
in high grade glioma where the tumour is more aggressive and recurrence more common, the 
median survival is 1-3 years (Hervey-Jumper and Berger, 2014).  
 
1.3.1 Astrocytoma 
This form of tumour originates from astrocytes, which are star-shaped glial cells found 
throughout the CNS that have a variety of functions including maintenance of extracellular 
ion levels and tissue repair. Astrocytic tumours are the most common type of glioma and are 
divided into encapsulated (e.g. non-invasive pilocytic astrocytoma) and diffuse tumours (e.g. 
glioblastoma multiforme (GBM)). While this form of glioma can occur at any stage, the risk 
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increases with age (Macmillan Cancer Support, 2013). Examples of glioma at each WHO 
grade are: 
 Pilocytic astrocytoma (WHO grade I): typically found in the cerebellum, 
hypothalamus and optic nerve, and while uncommon, have favourable life expectancy 
 
 Diffuse astrocytoma (WHO grade II): strongly associated with the TP53 mutation 
(Peraud et al., 2002), survival is linked to progression to higher grade astrocytoma. 
 
 Anaplastic (malignant) astrocytoma (WHO grade III): represents a progression of low 
to high grade lesion and characterised by progression to GBM, on average within 2 
years (Ohgaki et al., 2004). 
 
 Glioblastoma multiforme (WHO grade IV): the most prevalent form of brain tumour 
with a median survival time of 1 year (Ohgaki et al., 2009), strongly associated with 
mutations in NADP+-dependent isocitrate dehydrogenase 1 (IDH1) (Parsons et al., 
2008; Dang et al., 2010). In addition to IDH1 mutations, overexpression and mutation 
of the epidermal growth factor receptor (EGFR) is a hallmark of GBM (Ohgaki et al., 
2004) 
 
1.3.2 Oligodendroglioma 
This type of glioma originates from oligodendrocytes, the cells which form the myelin sheath 
covering the axons of nerve cells within the CNS. It is the second most common form of 
primary brain tumour (Ohgaki et al., 2009), and can be found as grades II 
(oligodendroglioma) and III (anaplastic oligodendroglioma) (Louis et al., 2007). In addition 
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to being found more often in males that in females, the most common marker of this type of 
glioma is the frequent loss of heterozygosity on the short arm of chromosome 1 (1p) and the 
long arm of chromosome 19 (19q) (Jeuken et al., 2004). This loss is associated with up to 
90% of oligodendrogliomas and approximately 60% of anaplastic oligodendroglioma 
(Cairncross and Jenkins, 2008), and is thought to be as a result of translocation between 
chromosomes 1 and 19 (Griffin et al., 2006; Jenkins et al., 2006). In the UK population, this 
form of glioma occurs in approximately 5% of glial tumours (Macmillan Cancer support, 
2013). 
 
1.3.3 Ependymoma 
Ependymomas are a rare type of glioma, constituting approximately 5% of all 
neuroepithelial tumours, including tumours of grade I, II and III (Louis et al., 2007).  
 Myxopapillaryependymoma and subependymoma (WHO grade I) 
 Ependymoma (low-grade) (WHO grade II) 
 Anaplastic (malignant) ependymoma (WHO grade III) 
 
These tumours arise from the ependymal cells, which line the ventricles (fluid-filled spaces 
in the brain), and from the central canal of the spinal cord. Spinal ependymomas are more 
common in adults and have a more favourable prognosis than intracranial tumours, the 
majority of which are paediatric cases, which have a five year survival rate of less than 70% 
(Korshunovet al., 2004). Unlike astrocytoma, ependymoma is not associated with any 
unique molecular changes, but overexpression of EGFR in intracranial tumours and TP53 
in anaplastic ependymoma is associated with a poorer prognosis (Mendrzyk et al., 2006; 
Korshunov et al., 2002). 
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1.4 Symptoms 
Intracranial pressure is usually the first symptom, which may be caused by a blockage in the 
ventricles and build-up of the cerebrospinal fluid (CSF). Raised intracranial pressure can 
cause headaches and seizures, sickness (vomiting) and vision problems. There are also 
symptoms involved according to the area of the brain affected, for instance, the frontal lobe 
may cause changes in mood and personality, weakness or numbness of one side of the body. 
The temporal lobe can cause problems with coordination and speech, and it may affect 
memory, and the parietal lobe may cause problems with writing and weakness or numbness 
of one side of the body (Macmillan UK, 2014; National Cancer Institute, 2014).  A study 
analysing 103 patients from glioma grade II- IV, showed that patients often experienced more 
than one symptom, while 40% had presented only one symptom; ophthalmological 
symptoms in 28.8%), impaired coordination (28.8%), paresis (21.2%), pain (21.2%), gait 
ataxia (18.3%), dysarthria and dysphagia (13.5%), signs of raised intracranial pressure 
(12.5%), organic psycho-syndrome (7.7%), nausea and vomiting (6.7%), myoclonus (2.9%), 
tinnitus or auditory disturbances (1.9%), incontinence (1.9%) (Reithmeier et al., 2014). By 
the time a glioma becomes symptomatic, it has progressed to the end of its biological course 
with stem cells having migrated far beyond the imaging-defined tumour mass (Kelly, 2010). 
 
1.5 Diagnosis 
In the first stage, diagnosis typically is assessing the history of symptoms followed by a basic 
neurological exam, including an eye and tests of vision, balance, coordination and reflexes, 
and the ability to think and remember (Taylor, 2010). Diagnosis is confirmed using either a 
computerized tomography (CT) scan or magnetic resonance imaging (MRI) of the patient's 
brain. CT helps direct differential diagnosis. MRI has superior soft-tissue resolution and can 
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better detect isodense lesions or tumour enhancement.  In post therapy imaging, single-
photon emission computed tomography (SPECT) and positron emission tomography (PET) 
may be useful in differentiating tumour recurrence from radiation necrosis (Hutter et al., 
2003; Schaefer et al., 1996).  
 
Once a brain tumour is detected on CT or MRI scans, a biopsy for examination under a 
microscope can be done either before surgery by needle biopsy or at the time of surgery, to 
identify the tumour type and grade. This would determine treatment options, and also give 
important information about prognosis (Brain Tumour Centre USA, 2005).  
 
1.6 Treatment  
The best treatment for each individual patient should take into account the tumour location, 
symptoms, and age to assess the different treatment options. Surgery is usually the initial 
treatment for glioma (Johns Hopkins Medicine, 2014). It has been suggested that patients 
with smaller solid tumours, have better prognosis when undergoing other treatments such as 
chemotherapy and radiation therapy. Radiation therapy is an important part of the treatment 
of high-grade gliomas, and would begin radiation treatments within 2 to 4 weeks after 
tumour resection, and will be done for around 4 to 6 weeks. After radiotherapy, patients 
usually obtain an MRI scan to assess the effect of the treatment (Brain Tumour Centre USA, 
2005). Studies showed a significant survival benefit with adjuvant chemotherapy with an 
increase in survival of 10% at 1 year (Lonardi et al., 2005). The most commonly used drugs 
today are: temozolomide (TMZ), procarbazine, carmustine (BCNU), lomustine (CCNU), 
vincristine and cisplatin (Cancer Research UK, 2014).  
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1.6.1 Temozolomide  
Temozolomide is derived from dacarbazine, was first synthesised in 1984 by Aston 
University as one of a series of novel imidazotetrazinones (Stevens et al., 1984), and is orally 
administered (O’Reilly et al.,1993; Friedman, 2000). These agents were structurally unique 
because of their three adjacent nitrogen atoms which conferred unique physicochemical 
properties and much greater antitumor activity than the previously synthesized bicyclic 
triazenes, which contained only two adjacent nitrogen atoms (Stevens et al., 1984). 
Temozolomide represents a new class of second-generation imidazotetrazine prodrug that 
undergoes spontaneous conversion under physiological conditions to the active alkylating 
agent MTIC (Stevens et al., 1987) and does not require hepatic metabolism for 
activation (Clark et al., 1995). TMZ crosses the blood brain barrier due to its small size and 
lipophilic properties (Agarwala, 2000). It works by the  induction of the DNA adduct O6-
methylguanine (O6M-G) which activates the mismatch repair system (MMR), causing 
double strand breaks in the DNA, cell cycle arrest in G2/M phase, and  apoptosis (Roos et 
al., 2007; Caporali et al., 2004; Hickman and Samson, 1999). Preclinical studies showed that 
TMZ demonstrated distribution to all tissues, including penetration into the CNS and low 
toxicity compared to mitozolomide (parent compound), and antitumor activity against a 
broad range of tumour types, including glioma, (Stevens et al., 1984). TMZ was absorbed 
rapidly, exhibited 100% bioavailability within 1–2 h of administration, and also showed 
antineoplastic activity in recurrent high-grade glioma (Newlands et al., 1992). Results 
suggested TMZ is preferably administered once daily for 5 days in a 4-week cycle. Though 
it is the first choice of therapy for gliomas, due to its pro-drug nature, it is not preferred in 
vitro use for control experiments (Friedman et al., 2006).  
 
 
22 
 
 
1.6.2 Cisplatin  
Cisplatin is also used in some cases of glioma (Cancer Research UK, 2014). Cisplatin, 
cisplatinum, or otherwise cis-diamminedichloridoplatinum (II) (CDDP) is a chemotherapy 
drug, used in various cancer treatments, such as sarcoma, small cell lung cancer, germ cell 
tumours, lymphoma testicular cancer, breast cancer, bladder cancer, and ovarian cancer. It is 
often given as a combination chemotherapy regimen with other drugs, but can be used on its 
own. It is an alkylating-like drug, even though it has no alkyl groups, is platinum based and 
the first designed in that class of drugs. Cisplatin, often called the “penicillin of cancer” 
because it is used so widely, was the first blockbuster chemotherapy drug (Tanida et al., 
2012).  It has a simple molecule of only 11 atoms, a chemical formula of Pt(NH3)2Cl2, 
molecular weight of 300.045, and solubility in water allowing delivery in aqueous form 
(Chemical and Engineering News, 2005). Cisplatin was first described by Michel Peyrone in 
1845, and was known for a long time as Peyrone's salt or chloride, and by 1893 the structure 
was deduced by Alfred Werner.  
 
In the 1960s scientists started testing the drugs biological effects, and it was first tested by 
Barnett Rosenberg, a professor of biophysics and chemistry at Michigan State University, on 
bacteria, where it was found that it prevented the cell division, but not the other growth 
processes. The researchers were able to deduce that this effect was due not to the electrical 
fields, but to a compound that was formed in a reaction between the "inert" platinum 
electrodes and components of the solution containing the bacteria (Rosenberg et al., 1965). 
Rosenberg then tested cisplatin on mice with cancerous tumours in 1968, and there were 
significant effects on tumour growth (Rosenberg et al., 1969). Consequently, cisplatin went 
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into clinical trials for cancer therapy in 1971, and has been widely used under the brand name 
Platinol® following its approval in 1978 by the FDA for cancer treatment (Chemical and 
Engineering News, 2005). It is now known that cisplatin forms a platinum complex inside of a 
cell which binds to and cross-links DNA. When DNA is cross-linked this way, it causes cells 
to undergo apoptosis, following damage to the DNA so that the repair mechanisms are 
activated and the cells are found to not be salvageable.  
 
The shape of the cisplatin molecule is square and flat. Its covalent bonds readily exchange 
with other ligands, for example water, so in the aqueous body environment, the chlorine atom 
in the cisplatin molecule is replaced by a hydroxyl group, and later by part of the DNA 
(Tanida et al., 2012). The name “alkylating” comes from cisplatin mechanism of action; an 
alkyl group signifying a single, covalently bonded carbon atom. Alkylating agents are 
capable of forming from strong electrophiles usually via a carbonium ion or carbon radical. 
These electrophilic compounds naturally seek out nucleophilic atoms and functional groups 
to form their covalent bonds, and one atom that is particularly susceptible to alkylation is the 
nitrogen 7 in the guanine nucleotide of DNA. The cisplatin molecule binds with a protein on 
one side and the DNA molecule on the other with the nitrogen atom at position 7 of guanine 
being highly susceptible to alkylation. This protein is critical as it protects the cisplatin 
molecule from being removed by DNA repair mechanisms in the cell (Tanida et al., 2012). 
 
 
 
 
 
 
24 
 
1.7 Aspirin 
1.7.1 History of Aspirin 
Aspirin was first synthesized by Felix Hoffman in 1897 when he acetylated the hydroxyl 
group on the benzene ring of salicylic acid to form acetylsalicylic acid (Vane and Botting, 
2003). By 1899 aspirin powder had been used to treat patients, rapidly becoming the number 
one selling drug worldwide. Only a year later was available in a water-soluble tablet form 
and in 1915 it was made available without prescription (Mahdi, 2006). This revolutionary 
medication was used widely in the flu pandemic in Europe (1918), despite nothing being 
known about its mechanism of action (Schror, 2009). By 1924, its use as a medication 
included the treatment of flu (3 tablets a day- 75mg each), rheumatism, lumbago and 
neuralgia, and aspirin was well known by the general public (Bayer HealthCare LLC, 2009; 
Mahdi, 2006).  
 
Despite its widespread use, it wasn’t until 1971 that Sir John Vane published an article in 
Nature suggesting a mechanism of action for aspirin involving the inhibition of prostaglandin 
synthesis, explaining the pain-relief and anti-inflammatory effects (Vane, 1971). For the first 
time, a mechanism of action of aspirin explained the multiple biological activities of the 
compound by one pharmacological effect, and this discovery resulted in him being awarded 
the Nobel Prize in Physiology or Medicine in 1982 (Bayer HealthCare LLC, 2009; Schror, 
2009).  
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1.7.2 Aspirin and Colorectal Cancer 
The first epidemiological evidence to support the use of aspirin in cancer treatment was 
published by Kune and colleagues in 1988, who reported a decreased risk of developing 
colorectal cancer with aspirin use (Kune et al., 1998). Their study examined a total of 715 
colorectal cancer patients and 727 age and sex-matched controls and found a statistically 
significant decrease in both colon and colorectal cancer development in control patients 
taking aspirin, an effect found in both males and females.  The decrease was dramatic, with 
a 40% reduction in colorectal cancer development in participants regularly taking aspirin 
(Kune et al., 1988). 
 
Subsequently, a link between aspirin and cancer prevention was demonstrated. Case-control 
studies established that the risk of colorectal cancer may be reduced in regular aspirin users 
(Kuneet al., 1988; Rosenberg et al., 1991; Suhet al., 1993; Muscat et al., 1994; Peleg et al., 
1994). Supporting studies showed a protection of between 20% - 40% in regular aspirin users 
(Thun et al., 1991, 1993; Schreinemachers and Everson, 1994; Giovannucci et al., 1994, 
1995). Other trials such as the American Nurses' Health Study, suggest the protection was 
only evident for frequent use (four times per week) and after 20 years of use (Giovannucci et 
al., 1995).  These individual trial findings have been confirmed by more recent studies, where 
meta-analysis of clinical trials and epidemiological studies originally performed to examine 
the cardiovascular effects of aspirin, have demonstrated conclusively that regular aspirin 
(daily), reduces the risk of cancer development in the general population and genetically 
susceptible individuals (Smith et al., 2000; Menter et al., 2010; Dibra et al., 2011; Rothwell 
et al., 2012).  
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A hospital based case control study of 1326 colorectal cancer and 4891 control patients (both 
cancer and non-cancer) examined the effect of aspirin use on the risk of developing large-
bowel cancer (Rosenberg et al., 1991). In addition to finding a reduced risk of cancer with 
continued aspirin use that was proportional to the period of time that aspirin was taken for, 
the study established that if aspirin was discontinued for a period of a year, there was no 
associated decrease in risk, suggesting that sustained use is required. The relationship 
between the frequency of aspirin use and its protective effect has also been examined (Suh 
et al., 1993; Muscat et al., 1994; Peleg et al., 1994). The studies found that the risk of 
colorectal cancers declined progressively as the frequency of aspirin use increased compared 
with control groups, with patients taking aspirin two to three times daily, having a greater 
decrease in risk than those taking aspirin once a day, compared to those taking no aspirin. 
The studies also found a dose related decrease in the incidence of polyps, a predictive marker 
for colorectal cancer development.  
 
1.7.3 Aspirin and Other Cancer 
In addition to the accepted protective effect of aspirin in colorectal cancer, there is emerging 
evidence that NSAID use is protective in a wide range of cancers, an effect that is closely 
linked with inflammation (Ulrich et al., 2006). Epidemiological evidence suggests that 
aspirin or other NSAID use produces risk reductions of 39% for breast and prostate, 36% for 
lung, 73% oesophageal, 62% stomach, 63% in colon and 47% in ovarian cancer, after five or 
more years of daily intake (Harris et al., 2005; Corley et al., 2003; Terry et al., 2004). 
However, this reduction does not apply to cancer in general, with results published on 
pancreatic, urinary bladder and renal cancers showing that incidence did not decrease 
significantly (Ulrich et al., 2006). Other work has investigated the effect of aspirin on cancer 
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in general through retrospective analysis of trials designed to test vascular protective effects 
of aspirin (Elwood et al., 2009). The results showed that taking 500mg of aspirin daily for a 
period of 6 years reduced overall cancer deaths by 18%. 
 
Meta-analysis of published clinical trial data from 51 studies involving over 77,000 
participants has shown that aspirin reduces cancer risk following just 3-5 years of daily use, 
much sooner than the previously suggested 10 years (Rothwell et al., 2012). The study also 
showed that the protective effect was produced with a low daily dose (75-300mg) reducing 
cancer incidence by one quarter in just three years (9 cancer patients in 1000 compared to 12 
in 1000 patient in the placebo group). This reduction in cancer rates increased with time, 
falling to 37% after five years. It was also noted in the results that while the risk of heart 
attacks and strokes were reduced, there was an increase in major bleeding incidences in the 
high dose patients leading to the conclusion that aspirin treatment should be favoured in 
individuals with family history of cancers. 
 
There is an on-going debate amongst clinicians over whether or not aspirin should be 
prescribed as a chemopreventative agent, in particular, to individuals at high risk of cancer 
development. The exact mechanism of cancer prevention or treatment remains today 
unknown although there are some proposed involving apoptosis, angiogenesis, growth 
factors etc. (Langley et al., 2011). A recent study published in the Lancet argued that there 
is still not enough proof to support aspirin use in cancer prevention, but that its side effects 
are well known, and severe (Rothwell et al., 2012), supporting the development of aspirin 
analogues (Dibra et al., 2011) .  
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1.7.4 Aspirin and Glioma  
The association between use of aspirin and other NSAIDs and risk of adult glioblastoma 
multiforme (GBM) was evaluated by the San Francisco Bay Area Adult Glioma Study which 
included 236 incident GBM cases and 401 population-based controls frequency-matched on 
age and gender. Cases with self-reported GBM reported less use of all types of NSAIDs 
combined during the 10-year prediagnostic period than did controls (aspirin (OR = 0.51, 95% 
CI: 0.3, 0.8), ibuprofen (OR = 0.41, 95% CI: 0.2, 0.8), and naproxen/other NSAIDs (OR = 
0.34, 95% CI: 0.1, 0.8)). Their findings showed an inverse association between NSAID use 
and GBM (Sivak-Sears et al., 2004).  
 
The Columbia University and the University of California San Francisco study with 517 
glioma cases and 400 controls compared the intake of NSAIDs for more than six months 
establishing two comparator groups of at least twice weekly use, versus a lower or no use. 
NSAIDs showed significant inverse trends between duration of drug use and glioma risks 
(OR = 0.68, 95% CI 0.49, 0.96) (Ferris et al., 2012).  However, some studies have found no 
association between NSAIDs and brain cancer (Daugherty et al., 2011).  
 
1.7.5 Aspirin and Metastases 
The beneficial effect of aspirin is not just restricted to primary tumours; it also decreases 
metastases (Chan, 2012; Rothwell et al., 2012). Meta-analysis of five randomized placebo 
controlled trials involving over 17,000 participants taking 75 mg of aspirin daily over a period 
of 6.5 years, results showed a reduction in metastasis (Chan, 2012). Aspirin reduced the risk 
for cancer with distant metastasis by 36% and the risk for adenocarcinoma with metastasis 
by 46%. A reduction in death due to cancer by 50% was found in patients who developed 
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adenocarcinoma without metastasis at diagnosis, and an overall 35% decrease in risk for fatal 
adenocarcinoma among participants taking aspirin. Rothwell and colleagues also found a 
decrease in metastasis, concluding that with aspirin treatment, one in five cancers would be 
prevented (Rothwell et al., 2012) 
 
1.8 Aspirin Mechanism of Action 
Before 1971, little was known about the mechanism of action of aspirin-like drugs (Vane and 
Botting, 2003). Guzman et al., 1964 and Lim et al., 1964 provided the first definitive 
evidence of the peripheral analgesic activity of aspirin-like drugs, and Piper and Vane in 
1969 used isolated lungs perfused with Krebs’ solution from sensitised guinea pigs in order 
to detect substances released during the anaphylactic reaction, including histamine and SRS-
A (anaphylaxis mediators). They also found the previously unreported substances PGE2, 
PGF2a, and the ‘‘rabbit aorta contracting substance’’ (RCS) which was later identified by 
Hamberg et al., 1975 as thromboxane A2. Vane published in 1971 that there was a dose-
dependent inhibition of PG formation by aspirin, and in addition Smith and Willis (1971) 
investigated the effects of aspirin on platelet behaviour. They obtained blood samples one 
hour after taking 600 mg of aspirin orally, isolated the platelets, washed and incubated them 
with thrombin and tested the supernatant for the presence of various substances including 
PGs and found that there was only a change in the release of PGs. Collier and Flower (1971), 
also reported that administration of aspirin inhibited human seminal PG production, detecting 
PGs in inflammatory exudates (Di Rosa et al., 1971).  
 
Aspirin selectively acetylates the hydroxyl group of serine residue (Ser 530) located 70 amino 
acids from the C terminus of the COX enzyme (Roth et al., 1975), leading to irreversible 
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COX inhibition. Acetylation of the enzyme by aspirin places a bulky substituent on the Ser 
530 oxygen that inhibits binding of arachidonic acid (De Witt et al., 1990). Cyclooxygenases 
have two main isoforms COX-1 and COX-2. COX-1 is responsible for the synthesis of 
prostaglandin and thromboxane while COX-2 plays a major role in prostaglandin 
biosynthesis in inflammatory cells and in the central nervous system, thus COX-2 has 
analgesic and anti-inflammatory activity by blocking the transformation of arachidonic acid 
into prostaglandin H2 selectively (Figure 2) (Vane and Botting, 2003). Aspirin binds to Ser 
516 in the active site of COX-2 in the same way as it binds to Ser 530 in the active site of 
COX-1, but it has been shown that the active site of COX-2 is slightly larger than that of 
COX-1 (Vane et al., 1998).  
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Figure 1.2 Aspirin inhibition of COX-1 and COX-2 activity.COX-1 is expressed in many tissues and 
PGs produced by COX-1 mediate the normal functions such as platelet aggregation, unlike COX-2 
which is not detected in most normal tissues, but its expression is rapidly induced by both 
inflammatory and mitogenic stimuli resulting in increased synthesis of PGs in inflamed and neoplastic 
tissue (Adapted from Konturek et al., 2005).  
 
1.9 COX Expression in Brain Tumours 
As stated previously, COX enzymes catalyze arachidonate metabolism, resulting in PG 
production (Figure 1.2). Two isoforms of the enzyme have been identified, COX-1 and COX-
2; COX-1 is expressed in several cell types of normal mammalian tissues and is involved in 
the maintenance of tissue homeostasis, while COX-2 is responsible for PG production at sites 
of inflammation (Eberhar et al., 1995). The expression of COX-1 and COX-2 has been linked 
with a variety of diseases of the brain, and colorectal tumourigenesis (Sano et al., 1995; 
Sairanen et al., 1998; Joki et al., 2000). Joki et al., 2000 demonstrated the expression of 
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COX-2 protein in the tumour cells of gliomas and normal brain tissue including, neurons. 
The same study also showed that high-grade glioma tissues expressed higher levels of COX-
2 protein when compared with low-grade glioma. Since overexpression of COX-2 results in 
PG production in colon and human brain tumour tissue (Kokoglu et al., 1998; Maxwell et 
al., 1990), it has been suggested that PGs play a role in tumour development. Interestingly, 
growth factors, tumour promoters, cytokines, and other inflammatory mediators have been 
found to induce COX-2 expression (Smith et al., 1995, Eberhar et al., 1995). 
 
In a study on childhood brain tumours, COX-2 has been shown to induce resistance in 
neoplastically transformed cells to chemotherapeutic agents or radiation (Bodey et al., 2006). 
In vitro experimental systems showed that selective COX-2 inhibitors caused a decrease in 
cell proliferation, an increase in apoptosis and modulated cell cycle regulation at gene levels. 
Elevated COX-2 expression has been linked to a broad range of human cancers, including 
80% of cancers of the breast, colon, oesophagus, liver, lung, pancreas, prostate, cervix, and 
head and neck (Choy and Milas, 2003). Although there is a variation in COX-2 expression 
among tumours, it is generally associated with a more malignant phenotype, aggressive 
tumour behaviour, worse prognosis and the development of metastatic disease (Choy and 
Milas, 2003). COX-2 derived prostaglandins have also shown to stimulate production of 
angiogenic growth factors (Liu et al., 1999; Tsujii et al., 1998).  
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1.10 EGFR and Brain Tumours 
As discussed previously, increased COX-2 expression directly correlates with glioma grade 
and is associated with shorter survival rate in glioblastoma patients. COX-2 is also regulated 
by epidermal growth factor receptor (EGFR) signalling which is important in the 
pathogenesis of GBMs (Figure 2) (Joki et al., 2000).  EGFR is expressed at high levels in 
various types of cancer, suggesting a role in the pathogenesis of multiple cancer types 
(Gullick et al., 1991), and there is substantial experimental evidence supporting a role for 
aberrant EGFR signalling in cancer pathogenesis and resistance to treatment (Huang et al., 
2009). EGFR amplification is found in 40–50% of primary GBM, with approximately half 
of these amplification events involving a variant of the receptor termed EGFRvIII. The most 
common EGFR mutant is EGFRvIII (EGFR type III, EGFRvIII, de2-7, ΔEGFR) (Ekstrand 
et al., 1991; Wond et al., 1992), which results from a deletion of exons 2 to 7 of the EGFR 
gene, which results in an in-frame deletion of 267 amino acids from the extracellular domain 
of the receptor (Mishima et al., 1998). Reports suggest that EGFRvIII expression in cells 
lead to activation of PI3K/Akt pathways, which results in downregulation of p27 and 
inhibition of proapoptotic factors such as procaspase 9 (Choe et al., 2003; Narita et al,. 2002). 
A more specific study showed the expression of EGFR mutant in U87MG cells leads to 
increased Bcl-XL, and result in resistance in apoptosis (Moscatello et al., 1998). EGFR 
activation triggers a diverse array of signals EGFR stimulation is found to activate STAT-3 
and triggers signalling cascades like MAPK which trigger NF-κB activation (Indranil et al., 
2013), as well cyclin D1 expression stimulation, resulting in increased proliferation and 
invasion, and a reduction in apoptosis (Wang, 2011). There is substantial evidence suggesting 
that EGFRvIII signalling plays a key role in gliomagenesis (Nicholas et al., 2006), and 
increased EGFRvIII expression has suggested to influence multiple aspects of tumour 
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biology, including survival, proliferation of cells, motility and invasiveness, and resistance 
to treatment (Nagane et al., 1996). EGFR gene amplification and overexpression are a 
striking feature of glioblastoma but are rare in low-grade gliomas, suggesting a causal role 
for aberrant EGFR signalling in the pathogenesis of GBM (Hatanpaa et al., 2010).  
 
VEGF expression is upregulated in tumor cells by NF-κB and STAT3 signaling. VEGF 
signalling also plays an important role in GBM biology and its expression is upregulated in 
GBM. Activation of its receptor, VEGFR-2, which is found on brain endothelial cells, 
promotes tumor growth by increasing blood supply to the highly metabolic tumour (Atkinson 
et al., 2010).  
 
1.11 NF-κB and Brain Tumours  
The transcription factor NF-κB has been shown to be important in inflammation, suppression 
of apoptosis, and in cell proliferation (Poligone and Baldwin, 2001). Reports indicate that 
NF-κB can function upstream of COX-2 and that the cyclopentenone prostaglandins can 
inhibit NF-κB activation via the inhibition of the IκB kinase. Upon stimulation of the cell, 
such as with TNF-α, IκB is phosphorylated, ubiquitinated, and degraded. This allows the free 
NF-κB to accumulate in the nucleus where it can activate transcription. In the nucleus NF-
κB can regulate the expression of many genes involved in inflammation such as ICAM-1, 
IL-2, IL-6, IL-8, and complement factors (Figure 1.3) (Baldwin, 1996). Strong evidence 
indicates that chronic dysregulation of NF-κB may underlie most inflammatory diseases and 
contribute to oncogenesis (Tak and Firestein, 2001). Levels of NF-κB activity, assessed by 
serine phosphorylation, are much higher in GBM tissue compared with non-GBM tissue 
(Wang et al., 2004; Nozell et al., 2008), and correspond with increasing grade in astrocytic 
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tumors (Korkolopoulou et al., 2008; Angileri et al., 2008). A number of proteins and 
pathways may be dysregulated in GBMs that may cause NF-κB activation. TNF-α for 
instance is produced in the CNS by microglia, astrocytes, endothelial cells and some neurons 
(McCoy and Tansey, 2008). TNF-α and other proinflammatory soluble factors, such as IL-6 
and IL-1β, are important regulators of paracrine signaling in brain tumor cells. TNF-α 
signaling through TNFR1 promotes NF-κB activation and subsequent anti-apoptotic 
responses (Otsuka et al., 1999; Koul et al., 2006). Moreover, the levels of TNFR1 expression 
are elevated in GBM as compared with low-grade gliomas (Hayashi et al., 2001). NF-kB is 
activated by EGF and EGFR and PDGF via a PI3K–Akt–IKK-dependent mechanism 
(Downward, 1998; Romashkova and Makarov, 1999). Literature has shown that inhibition 
of NF-κB activity or NF-κB-regulated genes, reduce brain tumor growth, invasion and 
angiogenesis (Xie et al., 2008). Thus, there is a strong correlation between constitutive NF-
κB activation and gliomagenesis.  
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Figure 1.3 Role of NF-κB in cancer development. Upon stimulation TNFα leads to the activation of 
IKK and subsequently, IKB phosphorylation occurs. NF-κB translocates to the nucleus and activates 
gene transcription. NF- B activation can result in upregulation of genes that are involved in cell 
proliferation, cell invasion and cell death (anti-apoptotic genes) (Adapted from Dey et al., 2008). 
 
1.12 Wnt/-catenin and Brain Tumours 
Canonical Wnt signalling (β-catenin dependent) regulates a wide set of genes that in turn 
orchestrate diverse cellular functions such as morphogenesis, differentiation, and 
proliferation. Consequently, aberrant activation of the canonical Wnt pathway has been 
found to be the driver of several human cancers including glioma.  Early evidences for the 
involvement of Wnt signalling in brain tumours came when similar germline mutations of 
APC were found in gliomas and medulloblastomas (Lowenstein et al., 1992).  EGFR and 
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Wnt/β-catenin pathways are known to interact under malignant conditions. Silencing of 
EGFRvIII reduced the expression of factor β-catenin, with a decrease in cell cycle 
progression which was shown on U87MG cells (Yamoutpour et al., 2008). Small-molecule 
inhibitors of PI3K/Akt signalling pathway result in degradation of β-catenin and reduced 
expression of its target genes Cyclin D1 and c-Myc (Baryawno et al., 2010). β-catenin is 
overexpressed in human glioblastoma and knockdown of β-catenin inhibits glioblastoma cell 
proliferation and invasive ability, and induces apoptotic cell death. Furthermore, intratumoral 
introduction of siRNA targeting β-catenin into established subcutaneous gliomas also 
delayed the tumour growth. Both in vitro and in vivo studies have confirmed that 
downregulation of β-catenin leads to reduced expression of EGFR, STAT3, Cyclin D1, 
MMP2, MMP9, and Akt1 mRNA as well as protein with a concomitant decrease of their 
active forms (Indranil et al., 2013). 
 
1.13 Aspirin Analogues 
With any medicine, there is a balance between the risks and benefits of treatment, and the 
benefits need to outweigh the potential harms (NHS Choices, 2011). As a result, it has been 
widely suggested that significant effort should be directed into producing novel NSAID 
derivatives that do not produce the adverse gastrointestinal and cardiovascular effects 
associated with long term aspirin use, but retain the multiple and potent protective actions 
that are involved in suppressing cancer formation (Baron et al., 2003; Chan et al., 2009; Thun 
et al., 2002; Dibra et al., 2011). Various aspirin derivatives have been made and tested on 
cancer to this day. Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-
NSAIDs) have shown promising effects in colorectal and ovarian cancer cells (McIlhatton et 
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al., 2007; Selvendiran et al., 2008, Bed et al., 2011). In vitro studies also used the primary 
aspirin compound, salicylic acid, which inhibits the growth of rat glioma cells (Aas et al., 
1995). Sulindac, another NSAID, which inhibits both COX-1 and COX-2, has been found to 
inhibit glioblastoma cell growth, proliferation and invasion in a number of studies, a result 
previously observed in gastric carcinoma cell lines and colon cancer cells (Fujiwara et al., 
1993; Yamamoto et al., 1999; Kambe et al., 2009; White et al., 2013; Bernardi et al., 2006).  
 
However, most emphasis has been given to COX-2 selective inhibitors (e.g. NS-398, 
celecoxib, meloxicam, rofecoxib or etoricoxib) which have all shown inhibition of 
proliferation in glioma cell lines (Kuipers et al., 2007). However findings also suggest that 
celecoxib was able to exert pronounced pro-apoptotic effects in vitro and in vivo in the 
absence of any apparent involvement of COX-2 (Schönthal, 2010). Joki et al., 2000 has 
described the effect of COX-2 inhibitor NS-398 on monolayer cell cultures and three-
dimensional glioma spheroids was investigated using U-87MG and U-251MG human 
glioblastoma cell lines. NS-398 was found to reduce the proliferation and induce apoptosis 
of monolayer cell cultures, as well as the growth of spheroids and tumour cell migration in a 
dose-dependent manner. Matsuo et al., 2004 also used the same COX-2 inhibitor in vivo 
using KMG4 tumour xenografts on SCID mice, which slowed tumour growth.  
 
To this end, aspirin analogues have been synthesized and tested successfully on colorectal 
cancer cells (Deb et al., 2011, Claudius et al., 2014). It was shown that in comparison to 
aspirin, which reduced SW480 cell viability by 20%, an analogue called di-aspirin (PN508) 
had a significantly larger effect, reducing viability by approximately 50%. Di-aspirin as its 
name suggests has a structure that compromises two aspirin molecules. The work also 
 
 
39 
 
described other aspirin analogues, such as PN517, that reduced SW480 viability by a greater 
degree (Deb et al., 2011). The analogues described in this study are PN508 (di-aspirin 
biscarbxylyphenol succinate), PN517 (fymaroyl di-aspirin), PN526 (2-carboxyphenyl 
carbonate) and PN529 (isopropyl m-bromobenzoylsalicylate), with a focus on PN508 and 
PN517 with molecular weights of 358and 356 respectively (Fig 1.4). These two analogues 
are structurally two aspirin molecules bound together with a single (PN508) or a double bond 
(PN517). The presence of the double bond restricts rotation around the C=C bond, and cannot 
occur at room temperature, because pi bonds should be broken and thus more energy is 
required. Double bonds, also known as alkenes, are more stable, stronger and shorter 
than single bonds, and are also electron-rich making them reactive. However the double bond 
means that PN517 is in the trans isoform, while PN508 which can rotate, can be both cis and 
trans forms.  
 
 
 
 
 
 
 
Fig 1.4 Chemical structure of aspirin, PN517 and PN 508 
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1.14 Cell Culture Model Systems 
1.14.1 Established Cell Lines 
Established cancer cell lines are the main stay of much research and the development of new 
therapies, with each passage the population becomes more homogenous allowing for the 
replication of experiments between researchers and laboratories. Three glioma cell lines were 
used in this study; a grade I astrocytoma (1321N1), grade II/III astrocytoma/ 
oligodendroglioma (GOS-3), and grade IV glioblastoma (U87 MG). The U87 MG cell line 
was harvested from 44 year old male patient and is an adherent cell with an epithelial like 
morphology and the cell line is classified as a grade IV glioblastoma using the 2007 WHO 
grading. The GOS-3 cell line was harvested from a 55 year old male patient, is an adherent 
monolayer, and has fibroblast morphology, whereas the 1321N1 cell line is also an adherent 
cell but with a glial morphology classed as grade I astrocytoma according to 2007 WHO 
grading. An embryonic cell line served as control (SVG-p12), which are adherent brain cells 
from foetus, in the first trimester, with a fibroblast morphology.   
 
1.14.2 Primary Cell Lines 
In addition to the established cell lines, primary short term cell cultures were obtained from 
the Royal Preston Hospital (BTNW911 and BTNW914). Primary cultures are established 
directly from patient tissue and contain a heterogeneous population of cells including both 
cancer cells and those of surrounding tissue. Both primary cell lines utilised in this project 
were prepared from high grade glioma; the BTNW911 cells came from a male patient in his 
60s and the BTNW914 cells came from a male patient in his 30s.  
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1.15 Summary 
Glioma is a type of aggressive insocranial tumours with extremely narrow window for 
operative approaches, which is mostly palliative and rarely curative, and has a poor long term 
survival rate from diagnosis. Currently, the most common drug used in treatment is the 
prodrug TMZ, however a range of other chemotherapeutics are used including cisplatin. 
Increasing evidence from the meta-analysis of randomised controlled clinical trials supports 
aspirin for the treatment or prevention of cancer, with other trials involving aspirin currently 
still in progress. However, due to aspirins side effects, a need for derivatives with efficacy in 
the treatment of cancer that reduce the side effect profile are required.  
 
1.16 Hypothesis 
Aspirin analogues will show increased efficacy over aspirin and represent a potential 
therapeutic for the prevention or treatment of glioma. 
 
1.17 Specific Aims 
The overall aim of this project is to characterise the effects of aspirin and its analogues on 
both established and primary cell cultures in vitro. The specific aims are: 
1. To use cell viability as a screen to assess aspirin analogue efficacy in both established 
and primary cells 
2. To establish any cell type or tumour stage specific efficacy of aspirin analogues. 
3. To subsequently select an efficacious analogue and further characterise its effects on 
proliferation, cell cycle regulation, apoptosis and migration/invasion 
4. To identify mechanism(s) involved in the action of aspirin analogues 
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Chapter 2: Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
2.1 Materials 
The aspirin analogues used in this study PN508, PN517, PN526 and PN529 were supplied 
by Dr Iain Nicholl (Wolverhampton University, UK).  
 
All other reagents used were of the highest quality commercially available and were obtained 
from the following suppliers: 
 
ATCC (Manassas, VA, USA) 
SVG P12 human foetal astroglial cell line 
 
BD Biosciences (Plymouth, UK) 
FACS Tubes, BD FACSTM Shutdown Solution, BD FACSTM Clean Solution, BD 
FACSFlow Sheath Fluid, BD FACSRinse Solution 
 
BTNW (Brain Tumour North West) 
BTNW911, BTNW914 
 
Cayman Chemical (Michigan, USA) 
COX Fluorescent inhibitor screening assay kit 
 
Cell Signalling, New England Biolabs (Hitchin, UK) 
Caspase-3 control cell Extracts, Caspase-8 (1C12) Mouse mAb, Cleaved Caspase-3 
(Asp175) (5A1E) Rabbit mAb, Caspase-9 Antibody (Human Specific), Cyclin D1 Rabbit 
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mAb, Phospho-Cyclin D1 XP Rabbit mAb, EGF Receptor XP Rabbit mAb, Phospho- EGF 
Receptor XP Rabbit mAb, Anti-rabbit IgG HRP-linked Antibody 
 
ECACC (Porton Down, UK) 
U-87 MG Grade IV Human Glioblastoma Cell Line, 1321N1 Cell Line human Glial cells 
from brain astrocytoma, GOS-3 Cell Line human Glioblastoma (derivative of U-343-MG) 
 
Fisher Scientific (Loughborough, UK) 
Phosphate buffered saline tablets, Foetal Bovine Serum, 8-well LabTek Chamber slide, 
Amersham ECL Prime, Tris Hydrochloride (HCl), Glycine, Sodium dodecyl sulphate (SDS), 
Glycerol, Bromophenol Blue, Dithiothreitol (DTT), Triton X-100, Sodium Phosphate, 
Sodium Chloride, HEPES, Protran nitrocellulose transfer membrane 
 
Life Technologies (Paisley, UK) 
PrestoBlue™ Cell Viability Reagent, Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis 
Kit, Vybrant® CFDA-SE Cell Tracer Kit, MagicMark XP Western Protein Standard, 
SimplyBlue™ SafeStain, GFAP Mouse Monoclonal Antibody (clone 131-17719) Alexa 
Fluor® 594 Conjugate, CD34 Mouse Anti-Human mAb (clone 581) Fluorescein (FITC) 
Conjugate, β-Actin Mouse Monoclonal Antibody AC-15, Goat Anti-Mouse IgG (H+L) 
Horseradish Peroxidase Conjugate, Foetal Bovine Serum Qualified Australia Origin 
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Lonza (Slough, UK) 
EMEM (2.2 g/l sodium bicarbonate 1 g/l glucose Earle’s salt 0.0053 g/l phenol red), DMEM 
(25 mM Hepes  1.0 g/l glucose 1.0 mM sodium bicarbonate 0.011 g/l phenol red), NEAA 
(100x), L-Glutamine 200mM, Trypsin/EDTA 10x, Sodium Pyruvate Solution 100mM 
 
Millipore 
QCM 96-Well Cell Invasion Assay, Guava Mitochondrial Depolarization Kit for Flow 
Cytometry, Milli-Mark™ Anti-CD90-FITC Antibody clone 5E10, Millicell 12 mm 8.0 µm 
polycarbonate Cell Culture Insert  
 
Promega (Southampton, UK) 
Caspase-Glo(R) 8 Assay, Caspase-Glo(R) 9 Assay 
 
Sigma-Aldrich (Poole, UK) 
Cisplatin, Aspirin, Dimethyl Sulfoxide (DMSO),  Trypan blue, Bovine Serum Albumin 
(BSA), sucrose, ColorBurst Electrophoresis Marker, RNAse, Paraformaldehyde (PFA), 
Mounting media, Phosphatase Inhibitor Cocktail 2, Protease Inhibitor Cocktail, 
Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), Copper Sulphate, Sodium 
pyrophosphate decahydrate, Sodium Deoxycholate, Sodium Fluoride, Ponceau-S, Nutrient 
Mixture F-10 Ham, Trizma Base, Salicylic Acid, Acrylamide/Bis-acrylamide, 30% solution, 
ColorBurst™ Electrophoresis Marker, Phenylmethanesulfonyl fluoride, Thiazolyl Blue 
Tetrazolium Bromide, N,N,N′,N′-Tetramethylethylenediamine 
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Thermo Scientific (Paisley, Scotland) 
BCA Protein Assay Reagent A, Western Blotting Filter Paper, Restore Western Blot 
Stripping Buffer 
 
Vector Laboratories (Peterborough, UK) 
Vectashield Mounting Medium with DAPI, ImmEdge Hydrophobic Barrier Pen 
 
The glioma cell lines purchased from the European Collection of Cell Cultures (ECACC) 
and the American Type Culture Collection (ATCC) were of human origin with no evidence 
of the presence of infectious viruses or toxic products. ECACC stated that they should be 
handled as recommend by the Advisory Committee on Dangerous Pathogens (ACDP) for 
Category 2 containment.  
 
Drugs were prepared as 100mM stock solutions in a maximum of 10% DMSO. Untreated 
and appropriate vehicle controls were added in all experiments in addition to aspirin and 
cisplatin treated samples.   
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2.2 Methods 
2.2.1 Cell Maintenance 
U-87 MG and SVG-p12 cells were maintained in Eagles Minimum Essential Media 
(EMEM), supplemented with 10 % Foetal Bovine Serum (FBS), L-glutamine (2 mM), 1 % 
Non-Essential Amino Acids (NEAA), sodium pyruvate (1 mM). 1321N1 and GOS-3 cells 
were maintained in Dulbecco's Modified Eagle's Medium with 10 % Foetal Bovine Serum 
(FBS) and L-glutamine (2 mM). The cell lines were cultured in a 37oC humidified 
atmosphere containing 5% CO2.The BTNW911 and BTNW914 primary cultures were 
maintained in HEPES buffered Ham F-10 nutrient mixture supplemented with 10% FBS 
(Australian Origin) and L-glutamine (2 mM) and were cultured in a 37oC humidified 
atmosphere. When a maximum confluence of 80% was reached, cell monolayers were 
washed with phosphate buffered saline (PBS) solution, 3 ml of 1 x trypsin was added, the 
flasks were returned to the incubator to allow cells to detach, and 7 ml of media was added 
to deactivate trypsin and resuspend the cells to achieve a single cell suspension. Cells were 
passaged 1:4 into flasks to maintain the cell line or seeded into dishes for experimental 
analysis. 
 
2.2.2 Growth Curve 
To determine cell growth rates, growth curve analysis was performed over a period of seven 
days for cell lines. One million cells were seeded in 25 cm2 flasks, harvested by trypsinisation 
daily and cell number determined using a haemocytometer.  
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2.2.3 Cell Characterization:  
Immunofluorescence 
The U87 MG, 1321N1, GOS-3 and SVGp12 cell lines were seeded at a density of 20, 000 
cells per well and cultured overnight on glass slides where 8 chambers had been drawn with 
a PAP Pen HT™ Slide Marker. After 24 hours incubation, the media was removed and the 
cells washed three times with PBS before being fixed with 4% paraformaldehyde in 4% 
sucrose for 15 minutes. The cells were washed three times and permeabelised with 0.4% 
triton X-100 in PBS for 5 minutes. The cells were again washed three times with PBS, and 
the appropriate antibody was added, (GFAP, CD34, CD90) in 1:100 dilution for 1 hour. 
Following a further three washes in PBS, mounting media containing DAPI (2.5 μl per well) 
was added and the coverslip was secured in place with clear nail varnish. DAPI is a blue-
fluorescent nucleic acid stain preferentially staining double stranded DNA but also binds 
RNA (Tanious et al., 1992). It is a popular nuclear specific counterstain for use in multicolour 
fluorescent techniques as its blue fluorescence stands out in vivid contrast to green, yellow, 
or red fluorescent probes of other structures (Life Technologies UK, 2014).   
 
Cells were observed using a Zeiss LSM 510 laser scanning confocal microscope (Zeiss, 
Oberkochen, Germany) using a Zeiss Plan-Neofluar 40 x 1.3 oil immersion objective and 
pinhole of 1. The images were processed with Zeiss LSM Image Browser. 
 
2.2.4 COX Inhibition Assay 
Inhibition of isolated COX-1 and COX-2 enzymes was determined using a COX Fluorescent 
Inhibitor screening Assay Kit (Cayman Chemical (USA) as per manufacturer’s instructions. 
The COX Fluorescent Inhibitor Screening Assay, screens both COX-1 (ovine) and COX-2 
 
 
49 
 
(human recombinant) for isozyme-specific inhibitors, by the peroxidise component of COX, 
PGG2, which when exposed to ADHP produces resorufin, a highly fluorescent compound 
(Cayman Chemical, USA, 2014). Briefly, using black 96-well plates 75 μl of assay buffer, 5 
μl of HEME, 5 μl of the enzyme being assayed (COX-1 or COX-2) and 5 μl of each drug 
(cisplatin, aspirin, PN508, PN517, PN526 & PN529) was added at three final concentrations 
(10, 1 and 0.1 mM). Following incubation at room temperature for 5 minutes, ADHP (5 μl) 
was added to all wells followed by 5 μl Arachidonic Acid. After a further 2 minute incubation 
at room temperature fluorescence was read using an excitation wavelength of 530 nm and an 
emission wavelength of 585 nm.  
 
2.2.5 Cell Viability:  
Thiazolyl Blue Tetrazolium Blue (MTT) Assay 
Cells were seeded in 96-well plates at a density of 1x105/ml in a final volume of 90 μl/well. 
After 24 h incubation, where required drug treatments were added in a 10 μl volume per well  
and after 24 h treatment, 10 μl of MTT (5mg/ml stock solution in media) was added to each 
well and the plate returned for 1 h to the incubator. The media was removed, 100 μl of 10% 
SDS solution was added to each well and the plate was incubated at room temperature 
overnight, wrapped in foil. Absorbance at 570 nm was determined using a spectrophotometer. 
 
PrestoBlue™ Assay 
Cells were seeded in 96-well plates at a density of 1x104/ml in a final volume of 90 μl/well. 
After 24 h incubation, where required drug treatments were added in a 10 μl volume per well 
and after 24 and48 hour treatment, 10 μl PrestoBlue™ was added to each well and incubated 
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for 2 h. Fluorescence was measured with excitation at 535nm and emission at 610nm using 
a spectrophotometer. 
 
Linearity Assay 
The greatest variable in viability assays is cell number, thus linearity of fluorescence versus 
cell number was determined. Cells were seeded at 0, 50, 100, 250, 500, 750, 1000, 1500, 
2500, 5000, 10,000 and 20, 000 cells/well in a 100μl volume of media and cultured for 24 
and 48 hours before incubating with PrestoBlue® or MTT as above and the fluorescence or 
absorbance of each sample being determined. 
 
Drug Concentration Response Assay 
Concentration response assays were performed to determine the IC50 values for each of the 
aspirin analogues in comparison to the commercially available drugs salicylic acid, aspirin 
and cisplatin on U-87 MG, 1321N1, GOS-3 and SVP-p12 cell lines. Cells were treated with 
a range of drug concentrations for 24 or 48 hours unless otherwise stated, and viability 
determined by PrestoBlue® assay. Appropriate media and vehicle controls were also added 
in a 10 μl volume.  
 
Spheroid Viability Assay 
Spheroid cultures were established for the U87 M cell line using the method described by 
Vinci M.et al., 2012. Briefly, cells were seeded at 4x104/ml density per well in round 
bottomed low adherence plates and typically cultured for x time until the formation of 
spheroids was observed. Following spheroid formation, drug treatment and cell viability 
assays were performed as described above using both MTT and PrestoBlue® methods.  
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2.2.6 CFDA-SE Cell Proliferation Assay 
Proliferation was determined by 5[6] Carboxyfluoresceindiacetate, succinimidyl ester 
(CFDA-SE) labelling of cells. Cells were seeded at different densities to take into account 
individual doubling times (Table 2.1) determined by the growth curve assay. 
 
 
Table 2.1 Seeding density and assay period for cell proliferation assay 
Cell line/culture Cell Density Assay Length (days) 
SVG P12 1.5x105 cells/ml 4 
GOS-3 1x105 cells/ml 4 
1321N1 1x105 cells/ml 4 
U87 MG 1.5x105 cells/ml 4 
BTNW911 1.5x105 cells/ml 10 
BTNW914 1.5x105 cells/ml 10 
 
Cells were harvested when 70-80% confluent, and seeded in 6-well plates at the density stated 
in table 2.1 in a final volume of 1 ml/well. After 24 h incubation, cell monolayers were 
washed with PBS and 1 ml of PBS-CFDA-SE (5μM) was added to each well and returned to 
the incubator for 30 min.  The PBS-CFDA-SE solution was discarded and the appropriate 
media was added to each well and incubated for 4 h prior to drug treatment with aspirin, 
double dose aspirin, cisplatin, PN508 andPN517 at a final concentration of 0.1 mM in 1.5ml 
of media.  Prior to flow cytometric analysis, cells were harvested by trypsinisation and 
centrifugation and washed with PBS before resuspension in 100 μl of PBS-0.1% BSA in 
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FACS tubes. If required cells were fixed using a 70% ethanol solution and stored at -20oC 
before washing with PBS and resuspension in 100 μl of PBS-0.1% BSA in FACS tubes. 
 
Cells were analysed using a FACS-Aria flow cytometer (BD Bioscience, Franklin Lakes, 
New Jersey, USA) equipped with an air-cooled 15 mW argon laser emitting at a fixed 
wavelength of 488 nm. The fluorescence filters and detectors used were all standard with 
green fluorescence collected in the FL1 channel (530 ± 30 nm). Samples were gated on 
forward scatter (FS) versus side scatter (SS) to exclude debris and clumps. The cells were 
analysed using algorithmic amplifier to determine the percentage of stained cells and their 
mean fluorescence intensity. During data acquisition, a “live gate” was set on the 
appropriately stained cell population and a total of 10,000 gated events were acquired for 
each treatment.  
 
2.2.7 Cell Cycle Analysis  
Cell cycle distribution was determined by propidium iodide staining. Cells were harvested 
when 70-80% confluent, and seeded in 6-well plates at the density stated in table 2.1 in a 
final volume of 1 ml/well. After 24 h incubation the cells were drug treated with aspirin, 
double dose aspirin, cisplatin, PN508 and PN517 at a final concentration of 0.1 mM in 1.5ml 
of media. After a further 24 and 48 h incubation cells were harvested by trypsinisation, 
washed with 0.5ml of 1% BSA in PBS and centrifuged at 224 G for 5 minutes.  The wash 
solution was discarded and the cells were fixed in 500μl of ice cold 70% EtOH-PBS while 
vortexing before being stored at -20oC.Prior to labelling with PI, the cells were centrifuged 
at 1000rpm for 5 minutes and resuspended in 300μl total volume of RNAse (10mg/ml) and 
PI (50μg/ml), and incubated in room temperature for 30 minutes.  
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Cells were analysed using a FACS-Aria flow cytometer as previously described (2.2.6). The 
DNA profile was optimized to adjust the G0/G1 peak to appear around channel50. Cell-cycle 
software used algorithms that correctly modelled the four cell-cycle compartments to 
determine the percentage of cells in each of the cell cycle phases G0/G1, S, and G2/M phases. 
A total cell population of 10,000 gated events were acquired for each treatment.  
 
2.2.8 SDS-PAGE and Western Blotting 
Sample Preparation 
Following drug treatment cells were harvested by scraping in ice cold PBS and pelleted by 
centrifugation. Lysates were prepared using a standard RIPA buffer in the presence of 
protease and phosphatase inhibitors by shaking at 4oC for 1 h. The resulting lysate was 
centrifuged at 224 G for 5 minutes and the resulting supernatant retained. 
 
Bicinchoninic Acid (BCA) Protein Assay 
BCA working reagent is prepared fresh by mixing CuSO4 and the BCA reagent A (1:50).  
Standards (0 to 2.0 mg/ml BSA) and unknown lysate samples (diluted 1:5 and 1:10
were incubated with 0.2ml of the working reagent for 1 h at 37oC and absorbance measured 
at 562 nm. Calculation of unknown lysate protein concentration was by comparison to the 
BSA standard curve fitted using linear regression. Lysates were mixed with 4x loading buffer 
(2% SDS, 2mM beta-mercapto-ethanol, 4% glycerol, 0.04 M Tris-HCL and 0.01% 
Bromophenol blue) sample buffer lysis buffer) to give a final volume of 40μl containing 
100μg of protein and heated at 95oC for 5 min prior to analysis. 
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SDS-PAGE 
Samples were separated using either 10% (EGFR, Cyclin D1) or 15% (caspases 3, 8 & 9) 
mini gels using a standard protocol. Briefly, the separating gel mix was prepared and poured 
upon the addition of TEMED, overlaid with 0.5ml of 0.1% SDS solution, and left to 
polymerise for 45 min. The SDS solution was discarded and the stacking gel was added and 
again allowed 45 min for polymerization. The comb and excess un-polymerized stacker were 
removed, and 40 μl samples were wet-loaded, and samples separated using a 100V constant 
current through the stacker raised to 200V constant current in the resolving gel. Prior to semi-
dry transfer, the gel, nitrocellulose membrane and filter paper were placed in transfer buffer 
for 20 minutes. Transfer was performed using the  Bio-Rad Trans-Blot Semi-Dry kit 
assembled as described in kit guide with a constant 30 volts applied for 25 minutes.  
 
Table 2.2 SDS-PAGE gel constituents 
 10% Separating Gel 15% Separating Gel 
H20 2.2 ml 3.8 ml 
Acrylamide 5 ml 3.4 ml 
1.5 Tris 2.6 ml 2.6 ml 
10% SDS 0.1 ml 0.1 ml 
10% ammonium Persulfate 0.1 ml 0.1 ml 
TEMED 0.01 ml 0.01 ml 
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Western Blotting 
The membrane was blocked with TBS-T solution containing 5% skimmed milk powder for 
2 hours before being exposed to diluted primary antibody (1:1000 unless otherwise stated) in 
TBS-T containing 5% BSA and 0.1% tween-20 at 4oC with gentle shaking overnight. 
Following three 10 minute washes with TBS-T solution containing 5% skimmed milk 
powder the membrane was incubated for 2 hours with the appropriate HRP conjugated 
secondary antibody (1:5000 unless otherwise stated) in 5% milk TBS-T. Finally, the 
membrane was washed three times for 5 minutes with TBS-T and exposed to ECL solutions 
for 5min prior to visualisation using a BioRad ChemiDoc system. Membranes were typically 
re-probed after stripping with Restore Western Blot Stripping Buffer as per manufacturer’s 
instructions and confirmation of the strip using ECL solution. 
 
Stacking Gel 
H20 2.975 ml 
Acrylamide 0.67 ml 
0.5 Tris-HCL 1.25 ml 
10% SDS 0.05 ml 
10% ammonium Persulfate 0.05 ml 
TEMED 0.005 ml 
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2.2.9 Apoptosis Assay, Annexin-V/Propidium Iodide 
Induction of apoptosis was examined in the U-87 MG,1321N1, GOS-3 and SVG-p12 cell 
lines following drug treatment for 4, 8, 12 24 and 48 hours. Cells were seeded at a density 
described in table 2.1, cultured for 24 hours and drug treated with cisplatin, aspirin, PN517 
and PN508 at 0.1 and 1 mM. Subsequently, the cells were washed with PBS and harvested 
by trypsinisation and centrifugation. A further 100μl of binding buffer was added and the 
samples transferred to FACs tubes.  
 
Cells were analysed using a FACSAria as described previously (section 2.2.7) with green 
fluorescence collected in the FL1 channel (530 ± 30 nm) and red in the FL2 channel (615 ± 
25 nm).  
 
2.2.10 Caspase- Glo 8 & 9 Assay (Promega, UK) 
Caspase-Glo® are luminescent assays that determined caspase activity based on the 
production of a luminogenic substrate following cell lysis. As per manufacturer’s 
instructions, cells were seeded at a density of 10,000 cells per well in 90 μl of media in white 
walled opaque clear bottomed 96 well plates and incubated overnight. Following drug 
treatment with cisplatin, aspirin or PN517 (10μl addition) at 1mM for 12, 24 and 48 hours 
100 μl of Caspase-Glo 8 or 9 was added to each well, the plate protected from light using 
foil, shaken at 500 rpm for 30 seconds using an orbital shaker, and incubated at room 
temperature for 1 hour. The luciferase based luminescent signal, proportional to the amount 
of caspase activity, was detected using a TECAN plate reader. 
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2.2.11 Migration  
2.2.11.1 Migration 
Complete media (300 μl) was added to each well of a 24-well plate, where appropriate 
containing either drug treatments (cisplatin, aspirin, PN517) at 0.1 mM or vehicle control 
(0.1% DMSO). Millicell 8.0 µm polycarbonate cell culture inserts were places in each well 
and following a brief equilibration period cells were seeded in serum free media in the inserts 
at a density of 1.5x105/ml in a final volume of 100 μl/chamber also containing drug treatment 
or vehicle control where appropriate. After 6 hours incubation, the inserts were transferred 
to a fresh 24-well plate containing 200 μl PBS and following a brief wash placed into another 
fresh plate, this time containing 200 μl trypsin to allow cells to be detach. Following 5 
minutes incubation at 37oC, the optimum time determined for trypsinisation, 200 μl media 
was added, and cell density calculated using Trypan blue staining and counting on a 
haemocytometer.  
 
2.2.11.2 Migration Scratch Assay  
Cells were plated in a 24-well plate for 24 hours at a density of 250,000 cells per well. Prior 
to drug treatment, a sterile cocktail stick was used to make a scratch in the middle of the well, 
and media was replaced and drugs treatments added. Each well was imaged every two hours 
over an 18 hour period and the scratch size measured using Zeiss ZEN imaging software.  
 
2.2.12 QCM 96-Well Cell Invasion Assay (Millipore, UK) 
The cell invasion assay was performed as per manufacturer’s instructions. Briefly, prior to 
seeding for the invasion assay, the cells were placed in serum free media for 24 hours. Before 
addition of cells, the plate was rehydrated/equilibrated with 100 μl of serum free media for 2 
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hours at room temperature. The equilibration media was removed, and 150 μl of complete 
media (chemo attractant) added to the lower chamber.  Following standard trypsinisation, the 
cells were seeded at 2x104 cells per well in the 96 well plate in a 100 μl volume of serum free 
media containing where appropriate either drug treatment, aspirin, cisplatin or PN517 at 
0.1mM, or vehicle control, 0.1% DMSO. The plate was then incubated for 12 hours at 37oC. 
Following incubation, the media was discarded from the upper chamber and the inserts were 
placed in a fresh 96-well plate containing 150 μl PBS and incubated for 1 minute. The PBS 
was replaced with 150 μl of pre-warmed cell detachment solution and incubated for 30 
minutes at 37oC. Following gentle tilting of the plate to ensure complete detachment, lysis 
buffer and dye solution (50 μl) were added to each well of the 96-well plate and incubated 
for 15 minutes at room temperature. 150 μl of the resulting mixture was transferred to a 
fresh96 well plate and fluorescence was read using 480 nm excitation and 520 nm emission 
filters.  
 
2.2.13 Statistical Analysis 
Results of cell viability and proliferation assays were expressed as a percentage of control 
untreated cell populations and are expressed as means ± SEM of at least three independent 
experiments with consecutive cell passages. Comparison between experimental groups was 
performed using two-way ANOVA with Tukey's post-hoc text. P-values ≤ 0.05 were 
considered as statistically significant and indicated in the figures as follows: *** p ≤ 0.001, 
** p ≤ 0.01, * p ≤ 0.05. 
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Chapter 3: Cell and Drug Characterization and Cell Viability  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
3.1 Introduction 
The project aims to characterise the effects of a number of aspirin analogues initially in 
glioma cell lines. To confirm the validity of these results a standard approach is to first 
characterise the cell lines using immunohistochemistry. This method combines anatomical, 
immunological and biochemical techniques to identify discrete tissue components by target 
antigens with antibody tagged labels to visualize the distribution and localization of specific 
cellular components within cells and in the proper tissue context. IHC is used in diagnosis, 
prognostication, therapeutic decisions to individual of patients, and investigations into the 
pathogenesis of a disease (Ramos-Vara and Miller, 2014).  
 
In the characterisation of glioma cells, a range of markers are commonly used including Glial 
Fibrillary Acidic Protein (GFAP), CD34 and CD90. GFAP is a protein that is expressed in 
the central nervous system in astrocyte cells (Halliday et al., 1996). GFAP is important in 
astrocyte motility and shape by providing structural stability to astrocytic processes. If brain 
or spinal cord cells are injured through trauma or disease, astroglial cells react by rapidly 
producing more glial fibrillary acidic protein (Eng et al., 2000). As such, the filament protein 
GFAP is used as a specific astrocytic cell marker (Jacque et al., 1978). CD34 a cell surface 
glycoprotein and functions as a cell-cell adhesion factor and has been widely used as a 
marker to assist in the identification of hematopoietic stem cells (HSCs) and progenitors in 
preparation for bone-marrow transplantation (Nielsen and McNagny 2008). It functions as 
an angiogenesis marker, as prognostic marker of recurrence for prostate cancer (Bettencourt 
et al., 1998), and to identify endothelium in glioblastoma tissue (Charalambous et al., 2006).  
CD90, also known as the Thy-1 antigen, is a glycosyl phosphatidylinositol-linked cell surface 
protein (Buccisano et al., 2004) that is part of the immunoglobulin supergene family 
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(Mansour Haeryfar et al., 2005). CD90 is expressed on primitive hematopoietic stem cells in 
normal bone marrow, cord blood, and foetal liver cells and has been identified as a stem cell 
marker in glioma (He et al., 2012).  
 
While it is known that the aspirin analogues act against colorectal cancer cells, the 
mechanisms involved have not been fully elucidated, and nothing is known about their effects 
in glioma. The cyclooxygenase (COX) enzymes, COX-1 and COX-2, convert arachidonic 
acid to prostaglandins resulting in pain and inflammation in vivo. Cyclooxygenase converts 
arachidonic acid to a hydroperoxyendoperoxide (PGG2), and the peroxidase component 
reduces the endoperoxide to the corresponding alcohol (PGH2), the precursor of PGs, 
thromboxanes, and prostacyclins (Vane and Botting, 2003). Traditional NSAIDs are 
considered nonselective because they inhibit both COX-1 and COX-2, but the inhibition of 
COX-2 accounts for the anti-inflammatory effect of the drugs while the inhibition of COX-
1 can lead to toxicity and associated side effects including ulcers, prolonged bleeding time, 
kidney problems (Schror, 2009). Aspirin produces greater inhibition of COX-1 than COX-2 
and thus it has been suggested that there is a need to synthesise analogues that show greater 
selectivity for COX-2 to undesirable side effects (Deb et al., 2011).  
 
Cell viability testing gives an overview of the effects of drug treatment on the general health 
of a population of cells and is the primary method of drug screening for characterisation of 
new compounds. A wide variety of assays are available including the MTT, or (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and PrestoBlue assays, each with 
their advantages and disadvantages (Mosmann, 1983; Lu et al., 2012). 
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The first in vitro chemo-sensitivity test was the colony forming (clonogenic) assay, 
established in the 70s-80s which examines the ability of a treatment to alter colony formation 
(Rosenblum et al., 1975). However, as the clonogenic assay is time consuming, a wide range 
of colorimetric assays were developed, one of which that is still widely used in research being 
the MTT assay. MTT, or (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole first described by Tim Mosmann in 1983, is based on the ability of a mitochondrial 
dehydrogenase enzyme to reduce the yellow coloured substrate to purple formazan product 
in the mitochondria of living cells (Mosmann, 1983). A major disadvantage of this assay is 
that the MTT formazan product is a crystalline precipitate that requires solubilisation before 
readings can be taken. In addition to requiring the use of an appropriate solvent, the 
solubilisation causes cell lysis and death preventing the use of samples for further assay. An 
additional limitation of the MTT assay is the amount of time needed to accurately measure a 
treatment effect. Cultured cells that are undergoing apoptosis in vitro undergo secondary 
necrosis as well. For instance, extended incubation would cause apoptotic cells shut down 
metabolism, lose membrane integrity and release their cytoplasmic contents into the culture 
medium. Therefore if apoptosis is the primary mechanism of cell death, understanding the 
kinetics of the cell death process is critical (Cory et al., 1991). Bearing this in mind, an assay 
that requires only a few minutes to produce a measurable signal would give information 
representing a snapshot in the specific time, rather than after several hour incubation 
generated signal (Dawson et al., 2011).  
 
In response to these disadvantages, the PrestoBlueTM cell viability reagent was developed to 
offer highly reproducible cell viability results and instant time savings (Fejerskov and 
Zelikin, 2012). The PrestoBlueTM reagent is a resazurin-based solution that functions as a cell 
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viability indicator by using the reducing power of living cells to quantitatively measure the 
proliferation of cells (Lu et al., 2012). 
 
Hypothesis 
GFAP staining, as an astrocytic cell marker, should stain the higher grade glioma cell line 
more intensely than the control cell line, (SVG-p12 < 1321N1 < GOS-3 < U87 MG). Also, 
the cell lines should not contain stem cell like cells, and therefore staining with CD34 and 
CD90 should not be present at all, working as negative controls.  
 
Aspirin is known to inhibit both COX-1 and COX-2 enzymes, affecting COX-1 to a greater 
degree, and was used as a positive control in comparison to the aspirin analogues. The aspirin 
analogues will inhibit COX enzyme activity, but with differing efficacies. Cisplatin, not a 
known inhibitor of COX, will serve as a negative control. 
 
The MTT and PrestoBlue assays differ in mechanism, but largely reflect changes in 
proliferation and apoptosis, so the results of the two assays will be very similar, and justify 
the use of the latter assay for subsequent screening. Aspirin reduces glioma cell viability in 
a concentration and time dependent manner, thus it is expected that the analogues will display 
similar activity, but with differing efficacies.   
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3.2 Results 
3.2.1 Immunohistochemistry 
Each of the established cell lines were probed with directly labelled fluorescent antibodies to 
glial fibrillary protein and CD34 with a DAPI nuclear counterstain (Fig 3.1; Table 3.1). The 
four cell lines labelled positively for GFAP, although the degree of staining varied, with the 
SVG-p12 cell line displaying the lowest level of GFAP staining. Unexpectedly, the 1321N1 
cell line also showed specific labelling of the endothelial cell marker CD34.  
 
As each of the short term cultures were probed with the CD90 antibody to identify cancer 
stem cells, although these would not be present in the cell lines it was decided to test them as 
a negative control (Fig 3.2; Table 3.1). Interestingly, both the 1321N1 and GOS-3 cell lines 
displayed a high level of CD90 antibody staining in a pattern consistent with other published 
results (He et al., 2012). Neither the SVG-p12 nor U87 MG cell lines showed any specific 
CD90 binding. 
 
GFAP, as expected, stained more intensively in the higher grade glioma cell line, (SVG P12, 
1321N1, GOS-3 and then U87 MG). Unexpectedly, there was CD34 binding in the 1321N1 
cell line, and CD90 binding in 1321N1 and GOS-3. As a series of antibody dilutions were 
performed and a lack of binding was observed in some cell types, the staining is not due to 
non-specific binding, but could be as a result of binding to an unknown protein that contains 
a similar antigenic sequence.  
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Figure 3.1 Immunofluorescent staining of the SVG-p12, 1321N1, GOS-3 and U87 MG cell lines for glial fibrillary protein (GFAP) and CD34 
with a DAPI nuclear counterstain. GFAP was labelled with an alexa flour 594 conjugated mouse monoclonal antibody (clone 131-17719) and 
CD34 with FITC conjugated mouse anti-human monoclonal antibody (clone 581). Row A represents SVG-p12 cells, row B 1321N1, row C GOS-
3, and row D U87 MG. 
A
B
C
D
DIC GFAP CD34 DAPI Merged
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Figure 3.2 Immunofluorescent staining of the SVG-p12, 1321N1, GOS-3 and U87 MG cell lines for CD90 with a DAPI nuclear counterstain. 
CD90 was labelled with a FITC conjugated mouse monoclonal antibody (clone 5E10). Row A represents SVG-p12 cells, row B 1321N1, row C 
GOS-3, and row D U87 MG. 
 
A
B
C
D
DIC CD90 DAPI Merged
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Table 3.1 Fluorescence intensity quantification of CD34, CD90 and GFAP staining in cell lines. CD34, CD90 and GFAP expression were 
detected using diretly labelled immunoflurescent antibodies in sequential cell passages, 1321N1, GOS-3, U87-MG glioma and SVG-p12 astrocyte 
cell lines. Fluorescence was quantified using Zeiss Zen software and median values determined from three independent experiments.  
 
 1321N1 GOS-3 U87 MG SVG p12 
 Median Min Max Median Min Max Median Min Max Median Min Max 
CD34 322 266 1510 284 226 1334 282 225 1311 306 247 1138 
  334 270 1117 317 242 1490 370 293 1440 320 248 1129 
  406 316 1208 332 264 1618 353 284 1407 320 251 1128 
Mean 354 284 1278 311 244 1481 335 267 1386 315 249 1132 
 
CD90 
 
767 
 
352 
 
3425 
 
434 
 
294 
 
1511 
 
406 
 
332 
 
1487 
 
319 
 
256 
 
1542 
  643 322 3256 538 334 2575 344 271 1443 340 271 1264 
  453 280 2670 383 259 1400 299 239 1354 339 271 1310 
Mean 621 318 3117 452 296 1829 350 281 1428 333 266 1372 
 
GFAP 
 
357 
 
284 
 
2042 
 
358 
 
278 
 
1102 
 
329 
 
261 
 
1847 
 
925 
 
784 
 
2134 
  366 294 1272 375 281 1090 394 304 1910 822 706 1987 
  357 274 1133 347 283 3261 414 328 2063 730 632 1928 
Mean 360 284 1482 360 281 1818 379 298 1940 826 707 2016 
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3.2.2 COX Inhibition 
There are two distinct isoforms of COX, COX-1 and COX-2, and the inhibition of both by 
the aspirin analogues used in this study (PN508, PN517, PN526 and PN529) in addition to 
the control drugs were tested. As expected, in comparison to a non-treated control, the 
selective inhibitors SC-560 and DuP-697 significantly reduced COX-1 and COX-2 activity. 
The control drug SC-560 reduced COX-1 activity to 8% of control, while DuP-697 reduced 
COX-2 activity to 38% of control (p < 0.01). 
 
COX inhibition by aspirin and the analogues was found to be concentration dependent over 
the range used 0.1, 1 and 10mM (p < 0.05). COX-1 (28.5% of control) was inhibited more 
than COX-2 (85% of control) by 10 mM aspirin (p < 0.001) (Fig 3.3, panel A and B). 
Cisplatin showed a greater inhibition of COX-2. The analogues showed a range of effect with 
PN529 producing the greatest effect in COX-1, reducing activity to 25.6% of control (p < 
0.0001), and PN526 producing the smallest effect for COX-1, reducing activity to 80% of 
control (panel C) (p < 0.05). In all cases, the lowest concentration did not significantly reduce 
COX-1 activity compared to control. At 10mM, PN508 reduced COX-1 activity to 76% of 
control, and PN517 to 61.5% (p < 0.001). With respect to COX-2 activity, aspirin was found 
to inhibit activity to 85% of control at 10mM (panel B), and each analogue showed a 
concentration dependent inhibition of activity (panel D). Again, PN529 showed the greatest 
inhibition of enzyme activity, reducing it to 51% of control at 10mM, followed by PN526 
(57.6%), PN517 (73%) and PN508 (76.6%) (p < 0.05).   
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In summary, COX-1 activity was reduced most by aspirin and PN529 followed by PN517, 
PN508, PN526 and then cisplatin. The aspirin analogues produced the largest inhibition of 
COX-2 activity (PN529 > PN526 > PN517 >PN508), greater than that of aspirin.  
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Figure 3.3 Inhibition of COX-1 and 2 enzymes by the aspirin analogues using the COX 
Fluoresent Inhibitor Screening Assay Kit by Cayman Chemical. The data illustrate COX 
inhibition by the aspirin analogues PN508, PN517, PN526 and PN529 and the control drugs aspirin 
and cisplatin at three concentrations (0.1 mM black bar, 1 mM grey bar and 10 mM white bar) for 7 
minutes. Panels A and C illustrate COX-1 inhibition (SC-560 standard inhibitor) and panels B and D 
COX-2 inhibition (DuP-697 standard inhibitor). Enzyme inhibition is expressed as a percent of 
control with significance (p < 0.05) calculated by ANOVA. Data are representative of mean ± SEM 
of three independent experiments.   
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3.2.3 Growth Curves 
Growth curves can provide vital information, doubling time, lag time, and saturation density. 
This is normally the time needed for recovery after subculturing and the time needed to attach 
and spread, the phase where the number of cells increase, and plateau phase where the growth 
rate slows because the cells are confluent (Mather et al., 1998). As a number of cell lines 
were used, growth curves were performed to identify the doubling times of each cell line and 
any significant difference between them (Fig 3.4). Cells were plated at 1x104/ml, and were 
counted using a hemocytometer.  SVG-p12 cell line showed a doubling time of 48 hours, 
U87 MG doubled every 36 hours, and both GOS-3 and 1321N1 cell lines doubled every 24 
hours. There was no significant difference in proliferation between the 1321N1 and GOS-3 
cell lines over the period of the assay, with both proliferating significantly more rapidly than 
the U87MG and SVG-p12 cell lines (p < 0.001). A difference in doubling time between U87 
MG and SVG-p12 cells was only significant after day 5 (p < 0.001).  
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Figure 3.4 Growth curves over six days for the SVG-p12, 1321N1, GOS-3 and U87 MG cell 
lines. Growth curves for SVG-p12 (circle), U87 MG (square), GOS-3 (triangle) and 1321N1 (inverted 
triangle) are blotted over 6 days, showing the growth and plateau phase. Data are representative of 
mean ± SEM of three independent experiments.   
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3.2.4 Cell Viability 
MTT versus PrestoBlue 
As the PrestoBlue assay has only recently been developed, it was decided to perform a 
comparison between it and the established MTT assay. MTT is reduced to a formazan product 
when mitochondrial reductase enzymes are active; consequently the conversion is related to 
the number of viable cells. The amount of purple formazan product produced by untreated 
control cells is quantified by absorbance spectroscopy and compared to the levels in treated 
cells. Using this simple comparison the effect of drug treatment on cell viability can be 
deduced by constructing a concentration-response curve.  The MTT method has been used 
to measure cell viability in response to mitogens, antigenic stimuli, growth factors and other 
cell growth promoting reagents, and forms the basis of cytotoxicity studies, and in the 
derivation of cell growth curves. In the PrestoBlue assay the blue cell-permeant substrate, 
risazurin, is non-florescent when added to the cells, but when modified by the reducing 
environment of viable cells is converted into resorufin, a red and highly fluorescent product.  
As a result, cell viability can be rapidly detected with either fluorescence or absorbance 
measurements. Additionally, as neither the risazurin substrate nor the resorufin product are 
cytotoxic, the PrestoBlueTM reagent allows the development of live-cell assays for real-time 
monitoring of cell metabolism and viability and the recovery of cells following assay for 
further culturing or use in a subsequent experiments.   
 
This comparison examined both the relative sensitivity of the assay, in terms of its ability to 
detect changes in cell number (Fig 3.5 and 3.6, panels C and D), and also in terms of IC50 
value determined for the control drug cisplatin (Fig 3.5 and 3.6, panels C and D). Using the 
primary cells, a direct comparison of the PrestoBlue and MTT assays showed an equal ability 
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to detect large cell numbers (p < 0.0001) (Fig 3.5 and 3.6, panel C) but that the sensitivity of 
the PrestoBlue assay was greater at low cell numbers (Panel D) and was in fact able to detect 
as few as 10 cells (data not shown). In terms of drug induced reductions in cell viability, in 
the BTNW911 cells, no difference was found in the IC50 values for aspirin or cisplatin (Fig 
3.5), however, in the BTNW914 cells, the PrestoBlue assay appeared more sensitive to drug 
induced changes in viability for both drug treatments, with a significant difference in aspirin 
treatment between the two assays (p < 0.0001) (Fig 3.6). This demonstrates that the results 
of standard MTT were confirmed with PrestoBlue, and therefore is appropriate to use the 
latter assay for subsequent testing.  
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Figure 3.5 Comparison of MTT and PrestoBlue cell viability assays following 24 hours 
drug treatment in the BTNW 911 primary culture. The data illustrate cell viability 
expressed as a percent of control determined using the PrestoBlue™ (squares) and MTT 
(triangles) assays in the BTNW 911 primary culture following drug treatment for 24 hours 
(aspirin in panel A & cisplatin in B) using 1000 cells per well, and with increasing cell 
numbers (50 – 20,000 cells per well - panel C; 50 – 1000 cells per well – panel D). ANOVA 
analysis of results, show an overall significant effect of treatment in comparison with control 
(p < 0.0001), and no significant difference between MTT and PrestoBlue IC50 values, with 
data representing results from 3 independent experiments. 
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Figure 3.6 Comparison of MTT versus PrestoBlue assay for the detection of cell viability 
following 24 hours drug treatment in the BTNW 914 primary cell culture. The data illustrate cell 
viability determined using the PrestoBlue™ and MTT assay on BTNW 914 cell culture following 
drug treatment for 24 hours. Viability of MTT (triangles and dashed line) and PB (squares and solid 
line) assay to detect effects on cell viability following aspirin (panel A) and cisplatin (panel B) drug 
treatment for 24 hours. The lower panels illustrate the relationship between cell number and viability 
for both the MTT and PB assays, up to 1000 cells per well (panel D) and 20 000 cells per well (panel 
C). ANOVA analysis of results, show an overall significant effect of treatment in comparison with 
control (p < 0.0001), and significant differences in IC50 values for cisplatin (panel A) and aspirin 
(panel B), data representing results from 3 independent experiments. 
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Aspirin Analogue Characterisation 
Initial investigations aimed to characterise the effect of aspirin and its analogues on cell 
viability using established cell lines for grade II – IV glioma, specifically 1321N1 - a grade 
II astrocytoma, GOS-3 - a grade II/III mixed astro-oligodendroglioma, and U-87 MG - a 
grade IV glioblastoma. Experimental controls included the SVG P12 foetal glial cell line and 
the standard chemotherapeutic drug cisplatin.  
 
SVG P12 Viability 
All compounds tested decreased the viability of the SVG P12 cell line in a concentration 
dependent manner following both 24 (Fig 3.7) and 48 hours of drug treatment (Fig 3.8). The 
aspirin analogue PN517 showed the greatest inhibition of cell viability with an IC50 value of 
1.2 mM at 24 hours (p < 0.001), approximately half that of cisplatin (Fig 3.7, panel A) (p < 
0.05). The IC50 values for aspirin and aspirin analogues remain similar at 48 hours, but as 
expected given its mechanism of action, the IC50 for cisplatin decreased to 0.6 mM (Fig 3.8 
and 3.9) (p < 0.0001). 
 
1321N1 Viability 
In a similar manner to the control cell line, each of the compounds tested decreased the 
viability of 1321N1 cell line in a time and dose response manner (Fig 3.10). Following 24 
hours of treatment, with the exception of PN508 which only reduced cell viability to 
approximately 60% at its highest concentration, the aspirin analogues PN517, 526 and 529 
displayed similar potency. Following 48 hours of incubation, the IC50 value for PN517 of 2 
mM (p < 0.001) was similar to the value observed with the control cell line (Fig 3.11, panel 
A). The control drug cisplatin produced a consistent large decrease in cell viability, with an 
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IC50 value of 0.5 mM at 24 hours, dropping to 0.2 mM at 48 hours (p<0.001) (Fig 3.11,C and 
3.12, C).  
 
GOS-3 Viability 
The GOS-3 cell line represents a grade II/III mixed astro-oligodendroglioma. As with the 
previous cell lines, each of the compounds reduced cell viability in a concentration dependent 
manner following 24 hours of treatment (Fig 3.13), however, the analogue PN529 only 
reduced viability by approximately 50%. Interestingly, at 48 hours the same analogue had 
only a marginal effect on cell viability (Fig 3.14). As with the previous cell lines, PN517 
displayed the greatest effect on cell viability, with an IC50 value at 24 hours of 0.6 mM (p < 
0.001), very similar to cisplatin with an IC50 value of 0.5 mM (p < 0.001) (Fig 3.13 panel C). 
In addition to using aspirin and salicylic acid as controls, a treatment that represented a 
double dose of aspirin was used and its effect on cell viability assessed following 24 and 48 
hours (Fig 3.14 and 3.15, panel B). Following 24 hours the three treatments produced very 
similar results with IC50 values of approximately 3 mM (p < 0.001) (Fig 3.13, panel B). 
However, after 48 hours, while salicylic acid had only a marginal effect on cell viability, 
aspirin had an IC50 of 3.1 mM (p < 0.001) and the double dose 1.7 mM (p < 0.001)  (Fig 3.14, 
panel B). 
 
U87 MG Viability 
The most common primary brain tumour in adults is glioblastoma multiforme (GBM), a 
tumour represented by the U87 MG cell line. Following both 24 (Fig 3.16) and 48 (Fig 3.17) 
hours of treatment, all the compounds tested decreased cell viability. In line with results from 
the previous cell lines, the most potent analogue at both 24 and 48 hours was PN517 with an 
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IC50 value of 1.5 mM and 1.8 mM respectively (p < 0.001) (Fig 3.16 and 3.17). Interestingly, 
PN517 appeared to be more potent in this cell line at reducing viability than the control drug 
cisplatin which had IC50 values of 3.1 mM and 2.5 mM in 24 and 48 hours respectively. 
However, this apparent effect was not statistically significant. As with the GOS-3 cell line 
the PN529 analogue had the least effect on viability producing a maximum reduction at 24 
hours of only 40% (p < 0.001) (Fig 3.16). 
 
To summarise, based on glioma grade, the treatment with the greatest efficacy in comparison 
to control was cisplatin in 1321N1, PN517 in GOS-3, PN517 in U87 MG and also PN517 in 
the SVG-p12 embryonic cell line. This shows that PN517 is the most potent aspirin analogue 
in terms of reduction of cell viability, with comparable results to cisplatin even after 48 hours, 
although the analogues displayed a greater effect in some cases at 24 hours. These results 
have identified the most potent aspirin analogue and identified treatment concentrations for 
subsequent experiments. 
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Figure 3.7 Cell viability following 24 hours drug treatment in SVG-p12 cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on the SVG-p12 cell line following 
drug treatment for 24 hours. Panel A illustrates cell viability following treatment with aspirin 
analogues, PN517, PN508, PN526 and PN529. In panel B, control drugs aspirin and salicylic acid 
decrease cell viability. Panel C illustrates a comparison between PN517, cisplatin and aspirin showing 
that at 24 hours the most potent drug is PN517. Panel D illustrates the IC50 values following 24 hour 
treatment of the aspirin analogues and control drugs. ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments.  
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Figure 3.8 Cell viability following 48 hours drug treatment in SVG-p12 cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on SVG-p12 cell line following drug 
treatment for 48 hours. Panel A illustrates cell viability following treatment with aspirin analogues, 
PN517, PN508, PN526 and PN529, where is it shown than PN517 is the most potent. In panel B, 
control drugs aspirin and salicylic acid show a decrease in a dose dependant manner. Panel C 
compares PN517 with cisplatin and aspirin showing that the most potent drug is cisplatin following 
PN517 and then aspirin. Panel D represents the IC50 values following 48 hour treatment of the aspirin 
analogues and control drugs. ANOVA analysis of results, show an overall significant effect of 
treatment in comparison with control (p < 0.001) with data representing results from 3 independent 
experiments.  
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Figure 3.9 Cell viability following 24 and 48 hours drug treatment in SVG-p12 cell line. The data illustrate cell viability determined using the 
PrestoBlue™ assay on SVG-p12 cell line following drug treatment for 24 and 48 hours. Panel A illustrates cell viability following treatment with 
cisplatin at 24 and 48 hours. Panel B shows the decrease in cell viability over 24 and 48 hour treatment with aspirin. Panel C demonstrates cell 
viability decrease following drug treatment with PN517, panel D shows cell viability decrease with PN508, panel E, F and G show the effect on cell 
viability following drug treatment with PN526, PN529 and SA. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 3.10 Cell viability following 24 hours drug treatment in 1321N1 cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on 1321N1 cell line following drug 
treatment for 24 hours. Panel A illustrates cell viability following treatment with aspirin analogues, 
PN517, PN508, PN526 and PN529, where is it shown than PN526 is the most potent. In panel B, 
control drugs aspirin and salicylic acid show a decrease in a dose dependant manner. Panel C 
compares PN517 with cisplatin and aspirin. Panel D represents the IC50 values following 24 hour 
treatment of the aspirin analogues and control drugs. ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments. 
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Figure 3.11 Cell viability following 48 hours drug treatment in 1321N1 cell line. The data 
illustrates cell viability determined using the PrestoBlue™ assay on 1321N1 cell line following 
drug treatment for 48 hours. Panel A illustrates cell viability following treatment with aspirin 
analogues, PN517, PN508, PN526 and PN529, were PN517 is the most potent. In panel B, control 
drugs aspirin and salicylic acid show a decrease in a dose dependant manner. Panel C compares 
PN517 with cisplatin and aspirin. Panel D represents the IC50 values following 48 hour treatment 
of the aspirin analogues and control drugs. ANOVA analysis of results, show an overall significant 
effect of treatment in comparison with control (p < 0.0001) with data representing results from 3 
independent experiments. 
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Figure 3.12 Cell viability following 24 and 48 hours drug treatment in 1321N1 cell line. The data illustrate cell viability determined using the 
PrestoBlue™ assay on 1321N1 cell line following drug treatment for 24 and 48 hours. Panel A-G illustrate the effect on cell viability following drug 
treatment of cisplatin, aspirin, PN517, PN508, PN526, PN529 and SA respectively over 24 and 48 hours. Cisplatin has shown a large decrease in 
cell viability compared to the rest of the drugs.  ANOVA analysis of results, show an overall significant effect of treatment in comparison with 
control (p < 0.0001) with data representing results from 3 independent experiments.  
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Figure 3.13 Cell viability following 24 hours drug treatment in GOS-3 cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on GOS-3 cell line following drug 
treatment for 24 hours. Panel A illustrates cell viability following treatment with aspirin analogues, 
PN517, PN508, PN526 and PN529, were PN517 shows a large effect in cell viability. Panel B, 
compares control drugs aspirin, double aspirin and salicylic acid. Panel C compares PN517 with 
cisplatin and aspirin. Panel D represents the IC50 values following 24 hour treatment of the aspirin 
analogues and control drugs. ANOVA analysis of results, show an overall significant effect of 
treatment in comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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Figure 3.14 Cell viability following 48 hours drug treatment in GOS-3 cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on GOS-3 cell line following drug 
treatment for 48 hours. Panel A illustrates cell viability following treatment with aspirin analogues, 
PN517, PN508, PN526 and PN529. In panel B, there is a comparison of aspirin, double aspirin and 
SA. Panel C compares PN517 with cisplatin and aspirin. Panel D represents the IC50 values 
following 24 hour treatment of the aspirin analogues and control drugs. Salicylic acid and PN529 
had no recorded IC50 value in the range of drug concentrations used, so were left blank. ANOVA 
analysis of results, show an overall significant effect of treatment in comparison with control (p < 
0.0001) with data representing results from 3 independent experiments. 
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Figure 3.15 Cell viability following 24 and 48 hours drug treatment in GOS-3 cell line. The data illustrate cell viability determined using the 
PrestoBlue™ assay on GOS-3 cell line following drug treatment for 24 and 48 hours. Panel A-H illustrate the effect on cell viability following drug 
treatment of cisplatin, aspirin, PN517, PN508, PN526, PN529, SA and double aspirin respectively over 24 and 48 hours. It is shown that the drugs 
decrease cell viability in both dose and time dependant manner. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.0001) with data representing results from 3 independent experiments.  
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Figure 3.16 Cell viability following 24 hours drug treatment in U87 MG cell line. The data 
illustrate cell viability determined using the PrestoBlue™ assay on U87 MG cell line following 
drug treatment for 24 h. The results for the aspirin analogues are illustrated in panel A and aspirin 
with salicylic acid in panel B. The data for the most potent analogue, PN517 is illustrated with the 
control drugs cisplatin and aspirin (panel C). The final panel (D) illustrates the individual IC50 
values for each treatment with the exception of PN529 where no IC50 value could be determined. 
ANOVA analysis of results, show an overall significant effect of treatment in comparison with 
control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 3.17 Cell viability following 48 hours drug treatment in U87 MG cell line. The data 
illustrate cell viability determined using PrestoBlue™ assay on U87 MG cell line following drug 
treatment of 48 hours. Panel A illustrates the effect of the aspirin analogues, and the control graph 
(panel B) shows the effect of aspirin and salicylic acid. Panel C shows that PN517 has similar 
potency to cisplatin, with a significant difference to aspirin.  IC50 values are shown individually 
showing that PN517 is the most potent and PN529 non-reactive. ANOVA analysis of results, show 
an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 3.18 Cell viability following 24 and 48 hours drug treatment in U87 MG cell line. The data illustrate cell viability determined using the 
PrestoBlue™ assay on U87 MG cell line following drug treatment for 24 and 48 hours. Panel A-G illustrate the effect on cell viability following 
drug treatment of cisplatin, aspirin, PN517, PN508, PN526, PN529 and SA respectively over 24 and 48 hours. The decrease in cell viability is similar 
in both 24 and 48 h. ANOVA analysis of results show an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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3.2.5 Comparison of Drug Effects on Viability across Cell Lines 
The purpose of the data illustrated in figures 3.19 to 3.25 is to allow the assessment of 
individual drug effects across the different cell lines utilised in the study, meaning that any 
cell specific effects can be identified. 
 
Control Drugs 
The effect of cisplatin on cell viability over 24 and 48 hours was compared in the three 
glioma, and the control embryonic cell line (Fig 3.19). At both time points, the IC50 value 
for the 1321N1 and GOS-3 cell lines was significantly lower than in the U87 MG and SVG-
p12 cell lines. Although aspirin did not show any significant difference in IC50 value 
between the cell lines at either the 24 or 48 hour time points, the values following 24 hours 
of incubation were lower than those following 48 hours (Fig 3.20). Interestingly, the 
primary metabolite of aspirin, salicylic acid may show some cell selective differences in 
viability following 24 hours of incubation with an IC50 value of approximately 5 mM for 
both the 1321N1 and GOS-3, and an IC50 closer to 10 mM for the U87 MG and SVG-p12 
cell lines (Fig 3.21). 
 
Aspirin Analogues 
Unlike aspirin which did not show any cell type selectivity, the analogue PN517 was 
significantly more potent in its ability to reduce cell viability in GOS-3 cells than in either 
the U87 MG or the 1321N1 cells (Fig 3.22). Significantly, it was least potent in the control 
cell line, SVG-p12, suggesting selectivity for cancer cells. Neither PN508, nor PN526 
displayed such selectivity, with no significant difference in IC50 value between cell types 
(Fig 3.23 and 3.24 respectively). The aspirin analogue PN529 was consistently the least 
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efficacious treatment and additionally reduced viability in SVP-p12 cells at least as well as 
the cancer cell types and in fact better following 48 hours of treatment (Fig 3.25). 
 
In conclusion, the data identify PN517 as the most potent aspirin analogue in the cell 
viability assays, displaying greater efficacy that aspirin. PN517 demonstrates glioma cell 
line selectivity, with the highest efficacy in the GOS-3 cell line, followed by the U87 MG 
and then 1321N1. However, as viability is a combination of many factors including 
proliferation and apoptosis, the mechanism by which PN517 is producing this effect has 
not been established by these results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
Figure 3.19 Cell viability following drug treatment with Cisplatin at 24 and 48 hours in cell 
lines SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using 
the PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 following drug treatment for 
24 and 48 hours. In panel A the data for 24 hours show the cell line effect is significantly different 
between them. Panel B illustrates the effect following cisplatin drug treatment at 48 hours. The cell 
lines affected the most are 1321N1 and GOS-3 however only the 1321N1 remain consistent at 48 
hours. The drug seems to have little effect on U87 MG cell line. ANOVA analysis of results, show 
an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 3.20 Cell viability following drug treatment with Aspirin at 24 and 48 hours in cell 
lines SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using 
the PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 following drug treatment for 
24 and 48 hours. In panel A the data for 24 hours are shown. Panel B illustrates the effect following 
aspirin drug treatment at 48 hours. ANOVA analysis of results, show an overall significant effect 
of treatment in comparison with control (p < 0.0001) with data representing results from 3 
independent experiments. 
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Figure 3.21 Cell viability following drug treatment with Salicylic acid at 24 and 48 hours in 
cell lines SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined 
using the PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 cell lines following drug 
treatment for 24 and 48 hours, panel A and B respectively. In 24 hours SA shows a large effect on 
GOS-3 cell line which recovers at 48 hours. SA shows no effect after 48 hours of treatment in any 
of the cell lines. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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Figure 3.22 Cell viability following drug treatment with PN517 at 24 and 48 hours in cell lines 
SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using the 
PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 following drug treatment with 
aspirin for 24 and 48 hours. GOS-3 shows the biggest effect in cell viability in both 24 (panel A) 
and 48 hours (panel B) while the less effected cell line is 1321N1. ANOVA analysis of results, 
show an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 3.23 Cell viability following drug treatment with PN508 at 24 and 48 hours in cell lines 
SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using the 
PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 cell lines following drug treatment 
for 24 hours (panel A) and 48 hours (panel B). The results show that GOS-3 shows the largest effect 
at 24 hours and 1321N1 non effective; however at 48 hours 1321N1 show an increase in cell death. 
ANOVA analysis of results, show an overall significant effect of treatment in comparison with 
control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 3.24 Cell viability following drug treatment with PN526 at 24 and 48 hours in cell lines 
SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using the 
PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 cell lines following drug treatment 
with PN 526 for 24 hours (panel A) and 48 hours (panel B). Data show that at 24 hours the drug is 
more effective on 1321N1 following GOS-3 then U87 MG and SVG-p12, in 48 hours the drug does 
not affect GOS-3 cell line, but is more effective on U87 MG.. ANOVA analysis of results, show 
an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 3.25 Cell viability following drug treatment with PN529 at 24 and 48 hours in cell lines 
SVG-p12, GOS-3, 1321N1 and U87 MG. The data illustrate cell viability determined using the 
PrestoBlue™ assay on U87 MG, SVG-p12, 1321N1 and GOS-3 cell lines following drug treatment 
for 24 hours (panel A) and 48 hours (panel B). In this case PN529 at 24 hours is more toxic to SVG-
p12 cell line and least potent on U87 MG. In 48 hours PN529 affects 1321N1 cell line more. 
ANOVA analysis of results, show an overall significant effect of treatment in comparison with 
control (p < 0.0001) with data representing results from 3 independent experiments. 
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3.2.6 Spheroid cell viability 
Spheroids are more representative of in vivo conditions than cell monolayers, and tumour 
cells in these microenvironments typically exhibit several traits including relevant 
morphology, increased cell survival, and a hypoxic core in comparison to traditional 
monolayer cultures (Smith et al., 2012; Godugu et al., 2013; Lee et al., 2013). 
 
Using the U-87 MG cell line it was decided to perform a comparison between PrestoBlue 
and the MTT assay to determine the sensitivity to detect changes in cell number (Fig. 3.26 
panel A), and response to standard drug treatments (Fig. 3.27 panels B to F). A direct 
comparison of the PrestoBlue and MTT assays showed no significance (p > 0.05) (Fig 3.28, 
panel A). In terms of drug induced reductions in cell viability, no difference was found 
comparing the two different methods (panel B and panel C) in the treatments for aspirin 
and PN517 (p > 0.05), but a significant difference was seen in cisplatin treatment (p < 
0.05). Spheroids seem to be more sensitive in cisplatin treated cells (p < 0.05) (panel A). 
IC50 values recorded for monolayer treatment for aspirin was 3 mM, cisplatin 3.1 mM and 
PN517 1.5 mM, in comparison to spheroids with aspirin 1.2 mM, cisplatin 5.1 mM  and 
PN517 1 mM (p < 0.001).  
 
In conclusion, there was no significant differences in results from the two difference cell 
viability methods used (MTT vs. PB), and apart from cisplatin, no difference in efficacy 
was observed between spheroid and monolayer cultures. This suggest that the results from 
the monolayer investigations are representative of a 3D culture environment. 
 102 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 PrestoBlue assay for the detection of cell viability following 24 hours drug treatment in the spheroid U-87 MG cell line. The data 
illustrate growth curve determined using the PrestoBlue™ (circle solid line) and MTT assay (triangles and dashed line) on U-87 MG cell line on 
increase in cell number after 24 hours (panel A) (p > 0.05). Viability of MTT (panel B) and PB assay (Panel C) to detect effects on cell viability 
following aspirin (squares) cisplatin (circles) and PN517 (triangles) drug treatment for 24 hours.   ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 3.27 Comparison of PrestoBlue assay in Spheroid and Monolayer for the detection of cell viability following 24 hours drug treatment 
in the U-87 MG cell line. The data illustrate cell viability determined using the PrestoBlue™ on U-87 MG cell line following 24 hours treatment 
with cisplatin (panel A), aspirin (panel B) and PN517 (panel C) in spheroids (triangles and solid line) and monolayers (squares and dashed line).  
ANOVA analysis of results, show an overall significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments. 
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Figure 3.28 Comparison of PrestoBlue and MTT assay in Spheroids for the detection of cell viability following 24 hours drug treatment in 
the U-87 MG cell line. The data illustrate cell viability determined using the PrestoBlue™ (triangles dotted line) and MTT (circles solid line) on U-
87 MG cell line following 24 hours treatment with cisplatin (panel A), aspirin (panel B) and PN517 (panel C) in spheroids.  ANOVA analysis of 
results, show an overall significant effect of treatment in comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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3.3 Discussion 
The first aim of this project was to characterize the effect of newly synthesized aspirin 
analogues on glioma cell viability to allow identification of the analogue with highest 
efficacy. The initial step was to confirm the cell lines used were glioma cell lines and then 
to identify the inhibition of COX enzyme isoforms on the drugs provided. Results from 
GFAP staining confirmed that the higher the grade of glioma, the more GFAP binding was 
shown. Results of the COX enzyme inhibition assay have suggested the analogues have 
indeed inhibited the enzymes in a concentration dependant manner, while indicating that 
PN529 was the most efficacious, followed by PN517 and PN508, and lastly by aspirin.  
 
Cell viability results provide the first evidence that PN517 might have therapeutic potential 
for the treatment of glioma.  Identifying PN517 as the compound with highest efficacy, 
these initial aims have been met while generating many intriguing results. 
 
To date, the majority of literature examining a role for aspirin, selective COX-2 inhibitors 
or prostaglandin signalling has made use of established cell lines (Xu et al., 2013; Suzuki 
et al., 2013; White et al., 2013; Gomes and Colquhoun, 2012; Lan et al., 2011; Lo et al., 
2010; Kang et al., 2009; Kambe et al., 2009; Annabi et al., 2009; Kim et al., 2009; Lee et 
al., 2005; Amin et al., 2003; Arrieta et al., 2001; Aas et al., 1995). Anti-proliferative effects 
of aspirin or selective COX-2 inhibitors have been discussed in the literature in a range of 
different cell lines. NS398 was demonstrated an effect in glioma (Joki et al., 2000), as well 
as aspirin, acetaminophen and ibuprofen (Casper et al., 2000). NO-ASA, a nitric oxide has 
shown to reduce proliferation in a range of cancer cell lines, including colon, ovarian, 
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pancreas, skin, cervical, oesophageal and breast (Fiorucci et al., 2003; Troyano et al., 2001; 
Chang et al., 2003; Zhi et al., 2006; Gao and Williams, 2012). Both aspirin and 
indomethacin inhibit in vitro glioma cell proliferation in the COX-1 and COX-2 positive 
T98G cell line in a time and concentration dependent manner (Amin et al., 2003). 
 
With respect to the concentrations of aspirin used in studies, these vary in the literature and 
are dependent on assay and cell type. In aspirin experiment with prolonged incubations, 
low concentrations such as 0.001mM have been used (Casper et al., 2000), but studies have 
also utilised treatments with concentrations as high as 10 mM (Pathi et al., 2012).   
 
In this study, as well as using cisplatin as a control treatment, aspirin was also used as any 
developed analogue would at least have to improve on the effects of its parent compound. 
In addition, a treatment equivalent to a double dose of aspirin was also used as a control as 
the structures of two of the analogues, PN508 and PN517, closely resemble two aspirin 
bound together with either a single or double carbon bond (Fig 3.28). The central double 
or single carbon bond either gives the molecule rigidity, or allows for rotational flexibility 
between to the two aspirin groups.  
 
 
 
 
 
 
 
 107 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28 Chemical structures of aspirin, PN508 and PN517 
 
This site may also represent a target for enzyme mediated hydrolysis, yielding two aspirin 
molecules and if this was, then case and any increased efficacy of these compounds would 
be replicated by adding a double dose of aspirin. However, this control treatment seldom 
replicated the potency of PN517 in the cell viability assay (e.g. Fig 3.22), suggesting that 
its efficacy is due to some other structural characteristic and not simply because it 
resembles two aspirin molecules.  
 
Cells are most commonly cultured as monolayers in vitro, but spheroid cell cultures were 
first described in the 1980, focusing on the extracellular matrix and the ability of cultures 
in artificial 3D matrices to produce physiologically relevant multicellular structures 
(Sutherland et al., 1981). The extracellular matrix regulates the cell dynamic behaviour, 
Aspirin 
PN517 
PN508 
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and helps the cells move within their spheroid similar to the way cells would move in living 
tissue (Pampaloni et al., 2007). Spheroids are true representative models for cell 
migration, survival, and growth (Lee et al., 2008), thus are used to evaluate cellular 
responses to pharmaceutical compounds in drug discovery applications.  Unlike classical 
monolayer-based models, spheroids mirror the 3D cellular context and therapeutically 
relevant pathophysiological gradients of in vivo tumours and because of this have the 
potential to either eliminate poor drug candidates before in vivo or clinical testing, or to 
identify promising drugs that would fail in classical 2D cell assays (Hirschhaeuser et al., 
2010).  
 
It is known that 3D structures have a transient G2 delay, apoptosis induction and late onset 
of DNA strand breaks, and thus therapeutic approaches are found to be less effective in 3D 
than in 2D cultures. A major reason for this is that tumour spheroids have been known to 
develop chemical gradients (e.g. of oxygen, nutrients, and catabolites) at diameters 
between 200 and 500 μm with a central secondary necrosis typically established at sizes 
>500 μm (Hirschhaeuser et al., 2010). This, however, cannot be generalized as Frankel et 
al., (2000) tested the activity of PS-341 in a spheroid/solid tumour context using four 
different human ovarian carcinoma and three prostate carcinoma cell lines. PS-341 showed 
equal or greater activity in spheroids than in the respective monolayer cell cultures, 
including the slow growing prostate cancer spheroid model, inducing apoptotic cell death 
in both culture systems. Similarly, the COX-2 selective inhibitor NS-398 was found to 
reduce proliferation rate equally in both monolayer and spheroid cultures (Joki et al., 2000).  
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Here, spheroid cultures were produced using the U87 MG cell line to allow comparison 
with monolayer cell suspension following drug treatments and it was observed that PN517 
showed no significant difference in the effect of the aspirin analogue on cell viability 
between monolayer and spheroid cultures.  
 
These results with COX inbibitors are in contrast to much of the literature, such as to results 
from Li et al., (2008) where they compared the effects of cisplatin and other drugs on cell 
viability using 2D and 3D cell cultures of HepG2 cells. They concluded that the 
multicellular morphology resulted in a differentiated phenotype resulting in increased cell-
cell adhesion and G1 phase cell cycle arrest, enhanced cellular resistance to apoptosis, and 
upregulated angiogenic potential. This altered phenotype resulted in decreased efficacy of 
cisplatin and an increased viability of 3D cultures. A study that developed a multicellular 
spheroid model of malignant mesothelioma to investigate molecular mechanisms of 
acquired apoptotic resistance found that the spheroids developed resistance to a variety of 
apoptotic stimuli, including combinations of tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), ribotoxic stressors, histone deacetylase, and proteasome 
inhibitors that were highly effective against mesothelioma cells when grown as monolayers 
(Barbone et al., 2008). Inhibitors of the phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin (mTOR) pathway, particularly rapamycin, blocked much of the 
acquired resistance of the spheroids, suggesting a key role for mTOR. 
 
The aim of drug discovery is to develop a new compound that improves on the current 
“best in class”. The introduction of temozolomide (TMZ), a prodrug of the alkylating agent 
5-(3 methyltriazen-1-yl) imidazole-4-carboximide (MTIC), has improved glioblastoma 
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patient median survival time by 2.5 months (Stupp et al., 2005). Due to its prodrug nature, 
it does not have reproducible effects in vitro so is commonly replaced in research with 
other standard chemotherapeutic drugs, and as such, throughout this project cisplatin was 
used as a control. Cisplatin has proven to be one of the more effective anticancer 
chemotherapeutic agents due to targeting of multiple intracellular sites to induce death in 
tumour cells (Rosenberg et al., 1965). 
 
The cell viability results for cisplatin typically show a decrease in IC50 value from 24 to 48 
hours of incubation, an effect that is related to its mechanism of action. Platinum based 
compounds damage tumours via induction of apoptosis, which is mediated by the 
activation of various signal transduction pathways (Rosenberg et al., 1965). Cisplatin 
becomes activated intracellularly by aquating one of two chloride-leaving groups and 
covalently binding to DNA, forming DNA adducts. The drug binds with DNA to form 
intrastrand crosslinks and adducts that cause changes in the conformation of the DNA and 
affect DNA replication. Other mechanisms of cisplatin cytotoxicity include mitochondrial 
damage, decreased ATPase activity, and altered cellular transport mechanisms. Although 
cisplatin is cell cycle non-specific, cytotoxicity is increased with exposure during S-phase. 
Cisplatin causes cell cycle arrest in the prolonged G2-phase and deregulation of signal 
transduction pathways involved in growth, differentiation, and stress responses which then 
induces programmed cell death or apoptosis (Florea and Busselberg, 2011). Cisplatin 
affects cells which turn over rapidly (e.g. tumour cells, gastrointestinal cells, bone marrow 
cells), meaning that cell death will occur at a faster rate than in other cells with a slower 
proliferation rate. The mode of cell death has been related to drug concentration, with 
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necrosis occurring with high concentrations and apoptosis with lower concentrations. 
While cisplatin is not selective for cancer cells over normal cells, it will affect rapidly 
growing cells more quickly (Sancho-Martinez et al., 2011). Thus, its mechanism of action 
explains why fast growing cell lines like 1321N1 and GOS-3 showed reduced viability in 
the first 24 hours following treatment with cisplatin giving IC50 values of 0.5 mM for both 
cell lines (Fig 3.19). The slower proliferating cell lines SVG P12 and U87 MG responded 
more slowly to cisplatin treatment with cell viability IC50 values of 0.6 and 2.5 mM at 48 
hours (Fig 3.19) respectively. The fivefold higher IC50 value for the U87 MG cell line could 
indicate that a longer incubation with cisplatin (e.g. 72 hours) would decrease the IC50 
further.  
 
The data have also revealed a number of other cell line selective responses. For example, 
the analogue PN517 displayed greater efficacy to cisplatin in the U87 MG cell line (Fig 
3.16 to 3.18), in contrast to the other lines where cisplatin was more potent. The anti-cancer 
effects of aspirin have largely been linked to its ability to inhibit the cyclooxygenase 
enzymes and a decrease in the production of prostaglandins. Expression of the COX-1 
enzyme plays an important role in platelet aggregation and is largely associated with the 
gastro-intestinal tract and the side effects of chronic aspirin treatment. However, the 
expression of COX-2 protein is more varied, and is found in both normal brain and glioma 
specimens, and is significantly higher in high-grade glioma than low-grade glioma and 
normal brain tissue. Additionally, its expression is higher in more in slower growing cells 
than faster growing (Joki, 2000). The U87 MG cell line is both high grade and relatively 
slow growing with a doubling time of approximately 30 hours, both characteristics 
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associated with high COX-2 expression. COX-1 inhibition is particularly higher compared 
to COX-2 inhibition of all the drugs tested (Fig 3.3) PN529 being the most effective in both 
COX isoform inhibition, however no data has been recorded in decreasing cell viability in 
glioma cell lines U87 MG and GOS-3, although it has been observed that it was toxic in 
SVG P12 cell line in 24 hours (Fig 3.9). Although there is a two-fold difference in COX-1 
inhibition of PN517 compared to that of aspirin, it is the closest to aspirin compared to the 
other drugs, even though it affects COX-2 more too. This provides a potential explanation 
for the high efficacy of PN517 in U87 MG cell line, and warrants further investigation as 
it could contribute to future patient specific treatment based on COX expression. Even 
though COX-2 is associated with growth factors, oncogenes and carcinogens, it is 
suggested that the role of COX-1 in the induction of COX-2 explains in epidemiologic 
studies, why aspirin reduces risk of colorectal cancer at very low doses that could not 
sustain COX-2 inhibition in nucleated cells (Thun et al., 1991, Giovannucci et al., 1995). 
COX-2 expression between cell lines (Elder et al., 2000; Sheng et al., 1998) and is 
correlated with the cell characteristics, but not directly with malignancy. Since reports have 
shown that even non-cancerous cell lines express COX-2, this suggests that prostaglandins 
and lipid metabolites formed by astrocytes may be involved in central nervous system 
pathology and physiology (Pistritto et al., 1998; Koyama et al., 1999).  
 
While the effect of cisplatin on cell viability increased from 24 to 48 hours, little increase 
was observed between time points with either aspirin or its analogues. In fact the IC50 
values for the aspirin analogues typically increased between time points in the 1321N1 and 
GOS-3 cell lines, indicating a recovering in cell viability following 48 hours (Fig 3.14 and 
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3.17 respectively). The only exception to this observation is the most potent analogue, 
PN517 in 1321N1 cells. The simplest explanation for this result is that the drugs are rapidly 
undergoing metabolism to form inactive metabolites.  
 
The chemical stability of a drug is of great importance since it becomes less effective as it 
undergoes degradation. In humans, aspirin is rapidly deacetylated to salicylic acid, which 
is further metabolized by glucuronidation, hydroxylation, and glycine conjugation (Hutt et 
al., 1986; Takanashi et al., 2000). In low concentrations (250 mg) salicylates half-life is 
about 2-5 hours, but higher doses can increase the half-life up to 30 hours, because the 
biotransformation pathways concerned with the formation of salicyluric acid and salicyl 
phenolic glucuronide become saturated (Schror, 2009).  
 
Cytochrome P450 enzymes are essential for the detoxification of foreign chemicals and the 
metabolism of drugs and consist of a family of 50 enzymes, six of which metabolize 90 per 
cent of drugs (Guengerich, 2008). Cytochrome P450 enzymes are called so because they 
are bound to membranes within a cell (cyto) and contain a heme pigment (chrome and P) 
that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. These 
enzymes are largely expressed in the liver, but they also occur in the small intestine, lungs, 
placenta, and kidneys, and in fact throughout all cells of the body at lower levels of 
expression.  
 
Metabolism of NSAIDs involves oxidation by CYP enzymes and conjugation, particularly 
glucuronidation by phase II enzymes (Bigler et al., 2001). Aspirin is rapidly deacetylated 
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to salicylic acid which is further metabolized by glucuronidation, hydroxylation, and 
glycine conjugation with the major enzymes involved being CYP2C9 (Takanashi et al., 
2000; Miners and Birkett, 1998) and UGT1A6 (Ciotti et al., 1997). Both of these enzymes 
are polymorphic and produce slow-metabolizing enzymes, which does affect the quick 
metabolism of aspirin and could affect the metabolism of the aspirin analogues in the 
different cell lines. Significantly, the CYP2C9 enzyme is expressed in glioma and its 
expression increased in higher grade glioma compared to low grade (Knupfer et al., 2006). 
This expression of CYP2C9 provides a potential explanation as to why the cell viability 
IC50 values for aspirin and its analogues did not decrease at 48 hours, and in addition also 
explains why they were least effective against the U87 MG cell line which was derived 
from high grade GBM (Fig 3.16 to 3.18).  
 
Conclusion 
In conclusion, while each of the analogues decreased cell viability and proliferation, PN517 
consistently displayed the greatest efficacy. The effect of PN517 was greater than that of 
aspirin, and in high grade glioma (U87 MG) was greater than that of cisplatin. The results 
from both the cell viability and COX assays suggest that the aspirin analogues will produce 
tumour grade selective effects. Further investigation is needed to determine the mechanism 
of action of the most efficacious drug (PN517) and compare it to that of aspirin because 
cell viability is the measure of the overall health of a population and is affected by a range 
of parameters including cell proliferation, cell death and enzyme activity.  
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Chapter 4: Cell proliferation and Cell cycle analysis 
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4.1 Introduction 
While cell viability is an important screening tool in the characterisation of novel 
compounds, it is a reflection of the overall health of a population and is affected by a range 
of parameters including cell proliferation, cell death, and metabolic activity, and thus, 
accurate characterisation of drug effects requires more specific assays.  
 
Examining the cell cycle status of individual cells of a proliferating population can be 
used to further characterise novel compounds and can be quickly and accurately 
determined using flow cytometry and propidium iodide staining (Cecchini et al., 2012). 
The cell cycle is a highly controlled series of events which has two major phases, 
interphase and the mitotic phase (Nojima, 1997). The first of these, interphase, can be 
further subdivided into three stages, G1 where cells initiate RNA and protein synthesis 
to induce growth, S phase where the cells replicate their DNA, and G2 phase where cells 
continue to prepare for division. The mitotic phase, as the name suggests, is where a 
mother cell divides and produces two identical daughter cells. Propidium iodide (PI) is 
a red-fluorescent dye agent that intercalates between DNA bases with a stoichiometry 
of one dye molecule per 4-5 base pairs, and following a maximum excitation at 535 nm, 
PI emits at a maximum wavelength of 617 nm (Life Technologies UK, 2014). This 
property of PI can be exploited to determine the cell cycle phase distribution of a 
population, because as the cell progresses through S-phase, the DNA content ultimately 
doubles, and consequently PI intercalation increases proportionally, as does the resulting 
fluorescence meaning the fluorescence of cells in the G2/M phase will be twice as high as that 
of cells in the G0/G1 phase.  
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As already mentioned, the cell cycle is a highly regulated process where, following DNA 
replication, identical chromosomal copies are distributed to two daughter cells. An 
important regulator of this process is the cyclins, with progression between phases initiated 
after cyclins are phosphorylated by an activating kinase (Israels and Israels, 2000). Cyclin 
dependent kinases form complexes with partner cyclins and regulate specific protein 
substrates through phosphorylation to control progression through the cell cycle. The 
expression of cyclins D 1, 2 and 3 is associated with G1 phase of the cell cycle where DNA 
replication initiates (Sherr and Roberts, 2004). Their accumulation reaches a maximum 
before S-phase and the formation of complexes with CDK4 and CDK6 regulates the 
phosphorylation of retinoblastoma (RB) protein which controls G1 progression (Baldin et 
al., 1993; Israels and Israels, 2000).  
 
While cyclin D1 expression is observed in normal brain tissue, it is overexpressed in glioma 
(Zhang, 2005), and this overexpression increases proliferation and invasion, while 
reducing apoptosis (Wang, 2011). Increasing evidence has shown that cyclin D1 
overexpression in the tumour cells is partly dependent on the mitogenic effects of EGF 
signalling through the EGFR in a number of cancers (Rieber and Rieber, 2006; Poch et al., 
2001; Perry et al., 1998). Thus, downregulation of cyclin D1 expression may provide a 
new gene therapy approach for patients with malignant glioma.  
 
Epidermal growth factor receptor (EGFR) and its ligands are frequently upregulated in 
cancer including GBM and typically is a hallmark for high grade tumours resistant to 
therapy (Lo et al., 2006; Yarden, 2001), however, is not always a marker for survival 
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(Faulkner et al., 2014). EGFR is involved in DNA synthesis, enhanced cell growth, 
invasion, and metastasis and specific abrogation of EGFR results in cell cycle arrest, 
apoptosis, or differentiation of cancer cells (Lui and Grandis, 2002). It has also been 
demonstrated that PGE2 enhances cell proliferation through EGFR transactivation 
(Fernández-Martínez and Cazaña, 2013; McCarty, 2014). Establishing EGFR expression 
and the impact of drug treatment on its activation is important in the development of novel 
therapies in glioma. 
 
Thus, having established that the aspirin analogues decreased cell viability, it was 
subsequently decided to determine if cell proliferation was affected using the fluorescent 
proliferation marker CFDA-SE and flow cytometry. Additionally, cell cycle analysis was 
performed to assess the status of the cells following drug treatment, and finally, due to the 
association of EGFR with cyclin D1, the effect of drug treatment on Cyclin D 
phosphorylation in EGFR treated cells was determined.  
 
Hypothesis  
It known that NSAID treatment effects cell cycle in many cell lines, with reports of G0/G1 
phase arrest and changes cell cycle distribution, including in M/G1 phase, as well as G2/M 
and S/G2 phases. As a result, it is expected that the analogues PN517 and PN508 will have 
an effect on both proliferation and cell cycle and regulatory proteins including cyclin D1. 
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4.2 Results 
Cell proliferation is regularly assayed using CFDA-SE (carboxyfluoresceindiacetate, 
succinimidyl ester), a colourless and non-fluorescent dye that passively diffuses into cells 
where its acetate groups are cleaved by intracellular esterases producing an amine-reactive 
carboxyfluoresceinsuccinimidyl ester with a green fluorescence (Weston, 1990). 
Importantly, the succinimidyl ester group reacts with intracellular amines, forming 
fluorescent conjugates, and these dye–protein adducts are retained by cells throughout 
development, mitosis, and in vivo tracing and is not transferred to adjacent cells in a 
population. Importantly for proliferation, the label is inherited by daughter cells after cell 
division, resulting in a 50% reduction in fluorescence following each cell division (Weston 
and Parish, 1990). Initial studies examined the effect of drug treatment on the established 
glioma cell lines where a rightward shift in the data indicates an increase in the average 
fluorescence of the population and thus a decrease in proliferation compared to control (Fig 
4.1 to 4.9).  
 
The results from the 1321N1 cell line indicate that while both aspirin analogues 
significantly decrease proliferation compared to control (PN517, p < 0.001; PN508, p < 
0.001), there wasn’t a significant difference between the analogues. While both aspirin and 
the double dose of aspirin decreased the rate of proliferation (aspirin, p < 0.0001; 2x 
aspirin, p < 0.001), there was no significant difference between them. Interestingly, 
cisplatin had no effect on proliferation at 24 hours, but significantly reduced proliferation 
at 48 hours (p < 0.001). The treatment that reduced proliferation to the greatest extent 
compared to control in the GOS-3 cell line was cisplatin (p < 0.001). The aspirin analogues 
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PN517 also significantly reduced cell proliferation (p < 0.0001), with PN508 not having 
any effect (p > 0.05). The effect of PN517 was significantly greater than that of aspirin (p 
< 0.001). Results from the U87 MG cell line found that the treatment with the greatest 
effect on proliferation compared to control was cisplatin (p < 0.001), with aspirin having 
no effect. PN517 and PN508 both significantly reduced proliferation (p < 0.001 and p < 
0.05 respectively), but were not significantly different from each other. Interestingly, while 
aspirin did not affect proliferation, 2x aspirin significantly reduced proliferation, producing 
a similar effect to the aspirin analogues. Finally, in the 1321N1 cell line there was the 
greatest effect on proliferation (p < 0.001), in cisplatin, aspirin and PN517. There was no 
significant effect between U87 MG and 1321N1 cell lines effect in aspirin and PN517. 
GOS-3 showed a similar effect to that of SVG-p12 in cisplatin, aspirin and PN517 (p < 
0.05).  
 
The effect of each treatment was also compared across the cell lines (Fig 4.5). In each case, 
treatments were most effective against the GOS-3 cell line with the exception of the aspirin 
analogues (panels D and E) which were most effective against the SVG-p12 cell line. A 
general trend of all treatments was displayed towards a greater effect on proliferation of 
the SVG-p12 and GOS-3 cell lines than U87 MG and 1321N1.  
 
Figures 4.6 to 4.9 illustrate sample raw data as generated using the flow cytometer. In each 
case a leftward shift in the peaks indicates cell proliferation as the intensity of fluorescent 
signal decreases. 
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To summarise, proliferation was significantly reduced by treatment with PN517 when 
compared to control in the SVG-p12 cell line. This effect was not significantly different to 
that of treatment with double the concentration of aspirin. In the glioma cell lines, all 
treatments significantly reduced proliferation in the low grade 1321N1 cells, but were not 
significantly different from each other. In GOS-3 cells, PN517 also significantly reduced 
proliferation, however, in the high grade glioma U87 MG cells, the only significant 
reduction in proliferation was observed following cisplatin treatment.  
  
Consistent with the cell viability results, the most effective analogue in the SVG-p12 and 
GOS-3 cell lines was PN517. However, in the 1321N1 and U87 MG cell lines the pattern 
was not repeated, potentially suggesting that other signalling pathways are involved.   
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Figure 4.1 Cell proliferation measured by flow cytometry following drug treatment in 1321N1 
cell line. The data illustrate cell proliferation determined using CFDA-SE staining of the 1321N1 
cell line, following drug treatment (0.1mM) over a period of 3 days. Panel A shows the effect 
on all treatments on cell proliferation, where a rightward shift indicates a reduction in 
proliferation; panel B compares PN508 to PN517; panel C compares the most potent analogue 
PN517 with control, aspirin and cisplatin treatments; panel D illustrates the effect of aspirin and 
double aspirin in comparison to control and PN517 treatments. ANOVA analysis of results, show 
an overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 4.2 Cell proliferation measured by flow cytometry following drug treatment in GOS-
3 cell line. The data illustrate cell proliferation determined using CFDA-SE staining of the GOS-3 
cell line, following drug treatment (0.1mM) over a period of 3 days. Panel A shows the effect on 
all treatments on cell proliferation, where a rightward shift indicates a reduction in proliferation; 
panel B compares PN508 to PN517; panel C compares the most potent analogue PN517 with 
control, aspirin and cisplatin treatments; panel D illustrates the effect of aspirin and double aspirin 
in comparison to control and PN517 treatments. ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments. 
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Figure 4.3 Cell proliferation measured by flow cytometry following drug treatment in U87 
MG cell line. The data illustrate cell proliferation determined using CFDA-SE staining of theU87 
MG cell line, following drug treatment (0.1mM) over a period of 3 days. Panel A shows the effect 
on all treatments on cell proliferation, where a rightward shift indicates a reduction in proliferation; 
panel B compares PN508 to PN517; panel C compares the most potent analogue PN517 with 
control, aspirin and cisplatin treatments; panel D illustrates the effect of aspirin and double aspirin 
in comparison to control and PN517 treatments. ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments. 
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Figure 4.4 Cell proliferation measured by flow cytometry following drug treatment in SVG-
p12 cell line. The data illustrate cell proliferation determined using CFDA-SE staining of the SVG-
p12 cell line, following drug treatment (0.1mM) over a period of 3 days. Panel A shows the effect 
on all treatments on cell proliferation, where a rightward shift indicates a reduction in proliferation; 
panel B compares PN508 to PN517; panel C compares the most potent analogue PN517 with 
control, aspirin and cisplatin treatments; panel D illustrates the effect of aspirin and double aspirin 
in comparison to control and PN517 treatments. ANOVA analysis of results, show an overall 
significant effect of treatment in comparison with control (p < 0.0001) with data representing results 
from 3 independent experiments. 
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Figure 4.5 Comparison of proliferation measured by flow cytometry following drug treatment of the SVG-p12, GOS-3, 1321N1 and U87 
MG cell lines. The figure illustrates the effect of each drug treatment (0.1mM) on proliferation of U87 MG (parallelogram), SVG-p12 (triangle), 
1321N1 (square), and GOS-3 (inverted triangle) cell lines as measured by CFDA-SE staining. Panel A shows proliferation following treatment with 
cisplatin; panel B with aspirin; and panel C with PN517. ANOVA analysis of results, show an overall significant effect of treatment in comparison 
with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Cell Cycle Analysis 
Cell cycle analysis by flow cytometry was performed following PI staining and drug 
treatment of each of the cell lines over a 48 hour period (Figures 4.6 to 4.13).  
 
In the SVG-p12 control cell line, treatment with cisplatin, aspirin or PN517 at 0.1mM did 
not significantly alter cell cycle populations following 4, 8 and 12 hours of treatment (Fig 
4.6, panels A-C). Also, there was no significant change in the control population 
distribution over 48 hours. However, following 24 and 48 hours of treatment (Fig 4.6, 
panels D & E respectively), all three drug treatments produced significant changes in cell 
cycle distribution. Cisplatin produced overall the largest effect by 48 hours with the sub 
G1 population indicating apoptosis increasing from 1.3% to 24% (p < 0.0001), G1 
decreasing from 88.3% to 35%, (p < 0.0001) with a large increase in the S phase population, 
increasing from 3.3% to 34.4%, (p < 0.0001). A small but significant increase in the M 
phase population was also observed (6% to 8%), (p < 0.0001). No significant difference 
was observed between aspirin and PN517 treatments, both producing small increases in the 
apoptotic population (0.5 and 3% respectively), with a significant decrease in the G1 phase 
(88.3% and 64% respectively) (p < 0.0001), and increases in both the S (1 and 13% 
respectively) and M phases (9.6 and 20% respectively) (p < 0.0001). A similar trend was 
observed following treatment at 1mM (Fig 4.7), however a greater increase in the S phase 
population was observed for each of the drug treatments (cisplatin 30%, aspirin 14%, 
PN517 12%) (p < 0.0001). 
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The 1321N1 cells produced some unexpected results. The control population in both the 
0.1mM (Fig 4.8) and 1mM (Fig 4.9) treatment groups displayed an unusually high M phase 
population, in addition to a larger than expected S phase population at some time points. 
However, it can be seen that cisplatin treatment (0.1mM, Fig 4.10) significantly increased 
the apoptotic and S phase populations compared to control at each time point (p < 
0.0001and p < 0.0001, respectively). Aspirin treatment (0.1mM) also increased the 
apoptotic population significantly (p < 0.0001) apart from at 8 hours, with an increase in 
the S phase population found at each time point (p < 0.0001). PN517 treatment resulted in 
a gradual but significant increase in the S phase population (8% p < 0.0001 at 8 hrs; 26% 
p < 0.0001 at 12 hrs; 42% p < 0.0001 at 24 hrs; 65% p < 0.0001 at 48 hours). Treatment at 
1mM produced similar results, with cisplatin significantly increasing the apoptotic and S 
phase populations at all time points compared to control (p < 0.0001), aspirin significantly 
increasing the S phase population at all time points (p < 0.0001) and apoptotic population 
at 12 (23 %, p < 0.0001), 24 (17 %, p < 0.0001) and 48 (6 %, p < 0.0001) hours. PN517 
treatment significantly increased the S phase population at all time points compared to 
control (p < 0.0001).  
 
A different pattern of drug effects was observed for the GOS-3 cell line. While the control 
population displayed a normal distribution at 4, 24 and 48 hour time points, a large increase 
in the M phase population can be seen at both 8 and 12 hours (Fig 4.10). Additionally, 
cisplatin (0.1mM) produced a significant increase in the apoptotic population at each time 
point compared to control (p < 0.0001) with particularly large increases in the S phase 
population (p < 0.0001). While treatment with aspirin initially produced a significant 
 129 
 
increase in the apoptotic population (17% at 12 hours, p < 0.0001), this effect was lost by 
24 and 48 hours when a significant increase in the M phase population can be seen (53.4%, 
p < 0.0001, and 54% p < 0.0001, respectively). PN517 treatment resulted in a significant 
increase in the apoptotic population at 12 (23 %, p < 0.0001) and 48 (28%, p < 0.0001) 
hours with significant increase in the S and M phase populations compared to control (p < 
0.0001) at all time points apart from 48 hours. While the control populations display a 
normal distribution over each time point in the 1mM treatment group (Fig 4.11), cisplatin 
again produced significant increases in the apoptotic population (p < 0.0001) at all time 
points, and a similar increase in the S phase population (p < 0.0001). At all time points, 
PN517 produced a significant decrease in the G1 phase population compared to control (p 
< 0.0001), with an increase in the M phase population at 4, 8 and 48 hours treatment (p < 
0.0001), with aspirin producing a similar pattern of results.  
 
A similar pattern of cell cycle distribution was observed between the SVGP12 and U87 
MG cell line, where treatment at 0.1mM had little effect at up to 12 hours (Fig 4.12, panels 
A – C), with a decrease in the G1 phase population and corresponding increases in the 
apoptotic and S and M phase populations following 24 hours of treatment with all three 
drugs (Fig 4.12, panel D). A further increase in the S and M phase populations can be 
observed following 48 hours of cisplatin treatment (Fig 4.12, panel E), however, while no 
greater effect of aspirin was observed, the apoptotic population further increased with 
PN517 treatment. At 1mM, cisplatin significantly increased the apoptotic population 
following 24 (17%) and 48 hours (37%) of treatment compared to control (p < 0.0001). A 
significant increase in the S phase population was also observed at both time points (47 
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and 27% respectively, p < 0.0001). Again, while an increase in the apoptotic population 
(8%, p < 0.0001) and decrease in G1 phase population (79%, p < 0.0001) following aspirin 
treatment for at 24 hours, no enhancement of this effect was found at 48 hours. Treatment 
with the aspirin analogue PN517 decreased the G1 phase population significantly at both 
24 and 48 hour time points (52%, p < 0.0001, and 36%, p < 0.0001, respectively), with 
corresponding increases in both S (24%, p < 0.0001, and 29%, p < 0.0001, respectively) 
and M (16.5%, p < 0.0001, and 30%, p < 0.0001, respectively) phase populations. One 
unexpected result was an increase in the M phase population following both 0.1 and 1mM 
treatments at 8 hours. 
 
To summarise, a similar effect of treatment was observed in the SVG-p12 and U87 MG 
cell lines with the greatest effects observed following cisplatin treatment for 48 hours. In 
the lower grade glioma cell lines, 1321N1 and GOS-3, again the most potent treatment was 
cisplatin, but all drugs altered cell cycle distribution even at early timepoints, with phase 
distribution changing over time.  
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Figure 4.6 Cell cycle distribution of the SVG P12 cell line following drug treatment 0.1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 4.7 Cell cycle distribution of the SVG P12 cell line following drug treatment 1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments.
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Figure 4.8 Cell cycle distribution of the 1321N1 cell line following drug treatment 0.1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 4.9 Cell cycle distribution of the 1321N1 cell line following drug treatment 1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 4.10 Cell cycle distribution of the GOS-3 cell line following drug treatment 0.1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 4.11 Cell cycle distribution of the GOS-3 cell line following drug treatment 1 mM. Cell cycle distribution was determined by PI staining 
and flow cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The 
proportion of the sub G1 apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, 
show an overall significant effect of treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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Figure 4.12 Cell cycle distribution of the U87 MG cell line following drug treatment 0.1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Figure 4.13 Cell cycle distribution of the U87 MG cell line following drug treatment 1 mM. Cell cycle distribution was determined by PI staining and flow 
cytometry following drug treatment for 4 (panel A), 8 (panel B), 12 (panel C), 24 (panel D) and 48 (panel E) hours respectively. The proportion of the sub G1 
apoptotic, G1, S and M phase populations is displayed as a percentage of the total population. ANOVA analysis of results, show an overall significant effect of 
treatment, in comparison with control (p < 0.0001) with data representing results from 3 independent experiments. 
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Cyclin D 
The effect drug treatment on cyclin D1 activation in the U87 MG cell line was examined 
after 24 hour treatment at 1 mM, following EGF activation for 0, 5, 15 and 60 minutes (Fig 
4.14). Using densitometry, cyclin D1 activation, indicated by phosphorylation (pCyclin 
D1), was expressed as a percentage of the phosphorylation found in cells that were not drug 
treated, but activated with EGF. The total expression of cyclin D1 was also determined for 
each sample and used to correct for any loading differences between lanes. Cisplatin and 
PN517 treatments produced the greatest reduction in phosphorylation following 5 and 15 
minutes of activation, with no significant difference between respective time points. 
Aspirin treatment did not significantly reduce phosphorylation at any of the time points 
tested.   
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Figure 4.14 Phosphorylation of Cyclin D following drug treatment for 24 hr at 1 mM and 
EFG activation in the U87 MG cell line. The data illustrate cyclin D phosphorylation in U87 MG 
cell line after 24 hour drug treatment and EGF stimulation for 0, 5, 15 and 60 minutes as determined 
by densitometry. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.05) with data representing results from 3 independent experiments. 
  
Cisplatin  
Total Cyclin D - cisplatin  
ToAspirin  
Phospho Cyclin D – cisplatin 
 
 
* 
* 
* 
* 
* 
Phospho Cyclin D - aspirin  
Total Cyclin D - aspirin  
ToAspirin  Phospho Cyclin D - PN517  
Total Cyclin D - PN517  
ToAspirin  
* 
* * 
* 
**   
** 
** 
** 
** 
* 
 141 
 
EGFR Activation  
Initial western blotting examined EGFR expression in the cell lines (Fig 4.15). It was 
observed that EGFR expression was lowest in the SVG-p12 cell line with a similar level 
of expression in GOS-3, and highest in the 1321N1 cells with a similar level of expression 
in U87 MG. 
 
EGFR activation following EGF stimulation was examined in the U87 MG cell line (Fig 
4.16) and phosphorylation compared to non-treated control following EGF stimulation. 
Total EGFR expression and EGFR phosphorylation were determined by densitometry, with 
any differences in sample loading corrected using the total EGFR results. EGFR 
phosphorylation was subsequently expressed as a percentage of non-treated control 
phosphorylation following 60 minutes of EGF activation. Both aspirin and PN517 
significantly reduced the levels of phosphorylation following 60 minutes of EGF 
stimulation in comparison to control, but no significant difference was observed in 
phosphorylation between aspirin and cisplatin treatments.  
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Figure. 4.15 Expression of the EGF receptor in the SVG-p12, 1321N1, GOS-3 and U87 MG 
cell lines. The data represents the total EGFR expression determined by western blotting in each 
cell line and expressed as a fold difference from the lowest expressing cell line, the SVG-p12. SVG-
p12 showed the lowest level of expression followed by GOS-3, 1321N1, with U87 MG showing 
the highest. Data are representative of results from 3 independent experiments.  
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Figure 4.16 Phosphorylation of the EGF receptor following drug treatment for 24 hr at 1 mM 
and subsequent EFG activation in the U87 MG cell line.  The data illustrate EGF activated 
phosphorylation of the EGFR at 0, 5, 15 and 60 minutes in the U87 MG cell line after 24 hour drug 
treatment as determined by densitometry. ANOVA analysis of results, show an overall significant 
effect of treatment in comparison with control (p < 0.05) with data representing results from 3 
independent experiments. 
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4.3 Discussion 
As already stated, cell viability is dependent on a range of factors including cell death, 
proliferation and metabolic activity and with this in mind, the aim of this series of 
experiments was to determine the effect of aspirin and the analogues on cell proliferation.  
 
There is a wealth of literature on the anti-proliferative effects of aspirin or selective COX-
2 inhibitors in a range of different cancers and cell lines. Since the analogues short-listed 
have shown an effect of both COX-1 and COX-2 it is fair to relate the enzymes with the 
supporting literature on proliferation. Selective COX-2 inhibition has been shown to inhibit 
proliferation in colon, prostate and pancreatic cell lines (Tucker et al., 1999; Elder et al., 
2000; Tsujii et al., 1998; Liu et al., 2000). Importantly, the COX-2 selective inhibitor 
NS398 was shown to inhibit proliferation in glioma (Joki et al., 2000). Casper and 
colleagues found similar effects with millimolar concentrations of aspirin, acetaminophen 
and ibuprofen using human and rodent glioma cell lines (Casper et al., 2000). The COX-2 
selective inhibitor SC-236 inhibits proliferation in the HT-29 colorectal cancer cell line, 
significantly, an effect that is reversed by co-treatment with PGE2 (Doherty et al., 2009). 
 
In addition, other novel aspirin analogues have demonstrated anti-proliferative effects, 
including NO-ASA, a nitric oxide releasing form of acetylsalicylic acid. This compound 
has been shown to reduce proliferation in a range of cancer cell lines, including colon, 
ovarian, pancreas, skin, cervical, oesophageal and breast (Fiorucci et al., 2003; Troyano et 
al., 2001; Chang et al., 2003; Zhi et al., 2006; Gao and Williams, 2012).  
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Further support for a role of COX-2 in cancer cell proliferation comes from the finding that 
increased prostaglandin levels increase cell proliferation amongst other effects (Maxwell 
et al., 1990; Zimmermann et al., 1999). In human oesophageal squamous cell carcinoma 
cultures, COX-2 is highly overexpressed compared to normal squamous epithelium, and 
expression was positively correlated with tumour progression (Zhi et al., 2006). The 
importance of COX-2 was confirmed using siRNA knockdown which dramatically 
inhibited PGE2 production and cell growth. Li and colleagues also demonstrated a positive 
correlation between COX-2 inhibition, a reduction in PGE2 levels, and the time and 
concentration dependent inhibition of oesophageal squamous carcinoma cells (Li et al., 
2009).  
 
With respect to brain tumours, elevated PGE2 and arachidonic acid levels have been found 
in glioma and meningioma (Kokoglu et al., 1998), a finding that correlates well with the 
long established role for lipoxygenase products of arachidonic acid metabolism as positive 
modulators of glioma cell line division in vitro (Wilson et al., 1989). Additionally, both 
aspirin and indomethacin inhibit in vitro glioma cell proliferation in the T98G cell line in 
a time and concentration dependent manner (Amin et al., 2003). 
 
However, these are not universal findings, because a lack of correlation between COX-2 
expression and proliferation and apoptosis has been observed in human colorectal 
carcinoma cell lines, where cell lines lacking COX-2 expression responded similarly to 
NS398 treatment to cell lines expressing COX-2 (Elder et al., 1997). In pancreatic 
adenocarcinomas, cell lines negative for COX-2 expression were found to respond 
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similarly to selective COX-2 inhibitor treatment as those expressing the enzyme (Molina 
et al., 1999). Zhi and colleagues also found that the concentration of NS398 required to 
inhibit cell proliferation was ten times higher than the concentration required to inhibit 
PGE2 production, suggesting non-COX-2 dependent pathways (Zhi et al., 2006).  
Similarly, one of the original publications examining the effect of NSAIDs on glioma cell 
proliferation found that while aspirin decreased cell growth in vitro, neither indomethacin, 
nor prioxicam had any effect, suggesting a prostaglandin independent pathway (Aas et al., 
1995). 
 
The effect of NSAID treatment on cell cycle distribution in a range of cancer cell lines has 
also produced conflicting results. Early publications suggested that treatment of the 
colorectal carcinoma COX-2 positive cell line HT29, and the COX-2 negative cell line 
S/KS with NS398 was reported to have no effect on cell cycle distribution in either cell 
line (Elder et al., 1997), a finding that was in contrast to treatment with non COX-2 
selective NSAIDS where accumulation in the G0/G1 phase was found following sulidac or 
salicylate treatment in a range of colorectal cancer adenoma or carcinoma cell lines (Shiff 
et al., 1995; Elder et al., 1996). 
 
These early findings are in contrast to more recent publications however, where using the 
same colorectal carcinoma cell line, HT29, Doherty and colleagues reported cell cycle 
arrest in the G0/G1 phase following treatment with the COX-2 selective inhibitor SC-236, 
and this effect was reversed by co-treatment with PGE2, confirming the dependence on 
COX activity (Doherty et al., 2009). G0/G1 arrest following aspirin treatment has also been 
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observed in human hepatoma HepG2 cells (Raza et al., 2011) and oesophageal squamous 
carcinoma cells (Li et al., 2009). However, these results are in contrast to results following 
treatment with NO-ASA, where using a wide range of human carcinoma cell lines 
including colon, pancreatic, skin, cervix and breast, consistent cell cycle arrest in the G2/M 
phase was observed (Gao and Williams, 2012). Also, treatment with the COX-2 selective 
inhibitor NS-398 induced G1/S phase arrest in oesophageal carcinoma cell lines (Zhi et al., 
2006), pancreatic tumour cell lines and ovarian carcinoma cells (Yip-Schneider et al., 
2001; Denkert at al., 2003).  
 
The impact of COX expression and subsequent prostaglandin production on regulators of 
the cell cycle has been examined in a range of cell lines. Over 24 and 48 hours, aspirin 
treatment of human pancreatic endocrine BON1 and human bronchopulmonary NCI-H727 
cells reduced expression of the cyclin dependent kinase 4 (CDK4) and cyclin D3 
(Spampatti et al., 2014). A more common finding is that NSAID treatment decreases the 
expression of cyclin D1. Treatment with the aspirin analogue NO-ASA results in a decrease 
in the expression of cyclin D1, and an increase in the expression of cyclin B1 in the SW480 
colon cancer cell line (Gao and Williams, 2012), the former change decreasing progression 
from M to G1 phase, and the latter combining with changes in Cdk1 activity to result in 
G2/M arrest. Yip-Schneider and colleagues determined the effect of a number of COX 
inhibitors on cyclins and reported that sulindac, indomethacin and NS-398 all decreased 
cyclin D1 expression in PaCa-2 and BxPC-3 pancreatic carcinoma cells (G1/S phase) (Yip-
Schneider et al., 2001). In the same study, NS-398 was also found to decrease the 
expression of cyclin A in both cell lines (S/G2 phase). Pathi and colleagues examined the 
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effect of aspirin treatment for 24 or 48 hours on cyclin D1 expression in a range of colon 
cancer cell lines, including RKO, SW480, HT29 and HCT116, finding a significant 
decrease in all cases at 10mM (Pathi et al., 2012). In contrast to observing decreased cyclin 
expression following COX inhibition, hepatocyte treatment with PGE2 amplifies 
subsequent epidermal growth factor stimulation of cyclin D1 expression (Dajani et al., 
2007).  
 
Taken together, these reports suggest that there is a great deal of variation in cell specific 
responses to NSAID treatment, that each NSAID may possess a unique efficacy profile, 
and that COX expression is not always a requirement for NSAID activity might support 
the range of effects on proliferation and the cell cycle observed in the different glioma cell 
lines.  
 
For example, while PN517 displayed greater efficacy than cisplatin in reducing cell 
viability in the U87 MG cell line, this was not replicated in the proliferation assay, where 
cisplatin decreased proliferation to a much greater degree (Fig 4.12), suggesting a 
difference in the signalling pathways altered by analogue treatment in cell viability and 
proliferation. As mentioned already, one pathway known to be targeted by aspirin in it’s 
the regulation of cell proliferation is the epidermal growth factor receptor (EGFR) 
signalling. EGFR stimulation results in activation of signalling cascades like MAPK which 
result in changes in NF-B and c-Myc, and regulation of proliferation, migration and 
differentiation (Indranil. et al, 2013). EGFR gene amplification and over-expression has 
been reported in glioblastoma (e.g. U87 MG) but is rare in low-grade glioma (e.g. 1321N1 
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and GOS-3) (Hatanpaa et al., 2010; Mestre et al, 1995).This cell type specific expression 
of EGFR could provide an explanation for the effects of aspirin and its analogues, where 
EGFR expression would correlate with analogue reduction of cell proliferation. It is 
important to note that there are no data in the literature describing EGFR expression in the 
control cell line, SVG-p12, and thus it is not currently possible to relate growth factor 
receptor expression to drug efficacy in this cell line.  
 
In the U87 MG cell line it was observed that treatment with aspirin or PN517 significantly 
decreased EGFR expression over 24 hours (Fig 4.5), and additionally, the same drug 
treatment decreased subsequent EGF activation of cyclin D1. Coupled with the known 
overexpression of COX-2 and subsequent increase in PGE2 levels, these results correlate 
well with the finding that PGE2 amplifies subsequent epidermal growth factor stimulation 
of cyclin D1 expression (Dajani et al., 2007), and that COX-2 inhibition and reduced PGE2 
levels result in an inhibition of proliferation (Li et al., 2009). 
 
Goel et al., (2003) tested the effect of aspirin on COX-independent mechanisms in HCT116 
and SW480 human colon cancer cell lines at 1, 2.5 and 5 mM concentrations, and showed 
a significant decrease in cell growth, induction of apoptosis, and arrest in G0/G1 phase at 
48 and 72 hours.  In another study HT29, HCT116 and HCT116p53−/− were cultured in the 
presence of 2.5, 5, and 10 mM aspirin for 48 h. HCT116 cells arrested in G1 almost 
completely HCT116p53−/− and HT29 cells showed a less complete arrest (REF). The results 
suggested that p53 had only a partial role in the G1 arrest, although cell cycle arrest was 
seen in all cell lines at G1/G2 phase, and to a lower extent, in apoptosis. There was no 
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significant effect on the cell cycle parameters when SW480 and Caco-2 cells were treated 
with NS-398, although aspirin treatment resulted in an increase in the proportion of cells 
in the S phase (Lin et al., 1998).  
 
Another important factor that has recently emerged to be a significant determinant of 
glioma initiation and progression is the canonical Wnt/β-catenin signalling pathway. 
Additionally, studies have linked prostaglandin E2 (PGE2) to tumour growth by activating 
EGFR (Pai et al., 2002) and β-catenin (Castellone et al, 2005). In breast cancer it has been 
shown that Wnt overexpression activates signalling via EGFR (Faivre and Lange 2007; 
Musgrove.2004), and that EGFR activation induces nuclear accumulation of β-catenin via 
PI3K/Akt pathway in prostate cells (Figure 4.3.1) (Sharma et al, 2002). 
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Figure 4.3.1. PGE activation of EGFR to stimulate tumour growth. EGFR stimulation results 
in activation of signalling cascade including MAPK which results in changes in NF-κB levels and 
regulation of proliferation (cyclin D1), migration and differentiation. Wnt overexpression activates 
signalling via EGFR activation, which induces accumulation of β-catenin via the PI3K/Akt 
pathway.  
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Aspirin has been shown to exert its antineoplastic action by inhibition of the β-catenin/TCF 
signalling pathway in glioma cells (Lan et al., 2011), as well as in colorectal cancer which 
has been linked to decreased transcription and translation of cyclin D1 (Hawcrift et al., 
2002; Dihlmann et al., 2003). Conversely, increased -catenin levels in colon cancer 
results in the activation of the cyclin D1 gene promoter by the heterodimeric complex 
formed between -catenin and LEF-1, which, in turn, results in the elevation of cyclin D1 
gene expression and protein level, and thus increased proliferation (Michael et al, 1999).  
 
Recent findings by Claudius et al., (2014) showed that treatment of the SW480 colorectal 
cancer cell line with aspirin results in degradation of IB, nuclear translocation of NF-
κB/ReIA complexes and suppression of NF-κB activity. However, they reported that the 
analogues PN517 and PN508 failed to induce nucleolar translocation of ReIA or cell cycle 
arrest. They suggested that these differences could be explained by the aspirin analogues 
retaining the salicylate part of the aspirin molecule, but losing the acetyl component. This 
could mean that NF-κB stimulation is directly linked with the salicylate component, and 
the nucleolar translocation of ReIA and cell cycle arrest with the acetylating potential. 
These findings are in contrast with the results reported here using glioma cell lines treated 
with the aspirin analogue PN517, as an effect on cell cycle was observed with a decrease 
in G1 and increase in the S cell populations, an effect linked to changes in cyclin D1, and 
a prolonged M phase which could potentially be linked to cyclin B, although this has not 
been investigated. A change in cyclin B1 has been previously reported following treatment 
of a colon cancer cell line with the aspirin analogue NO-ASA, which showed an increase 
in the expression of cyclin B1 (Gao and Williams, 2012).  
 153 
 
 
It has been reported that selective COX-2 inhibitors cause G1/S cell cycle arrest in the U87 
MG cell line in vitro (Kang et al., 2009), an effect that was p53 dependent and accompanied 
by p21 activation. In addition to p21 activation, it has also been reported that COX-2 
inhibition results in activation of the tumour suppressor p27 (Han et al., 2004; Maier et al., 
2004; Narayanan et al., 2003). COX dependent activation of p53 is not unique to glioma, 
with similar finding in colon and oral cancer (Grosch et al., 2005; Ho et al., 2003; Swamy 
et al., 2003). The report of Kang and colleagues is in contrast to our results with PN517, 
aspirin and the U87 MG cell line, where a decrease in G0/1 population was observed with 
a corresponding increase in S/M phase populations.  However, PN517 and aspirin were 
used at concentrations 10-fold higher with celecoxib where G1/S phase arrest was 
observed, providing two possible explanations for this difference. Additionally, mutational 
activation of p53 is only found in approximately 60% of high grade glioma (Newcomb et 
al., 1993), thus this COX-2 effect is dependent on expression of functional p53 and thus is 
not a universal mechanism.  
 
It has also been observed, that while COX-2 expression correlates with increasing 
histological grade in glioma, COX-2 expression does not correlate with p53 expression or 
loss of p16 or retinoblastoma protein (Shono et al., 2001), although COX-2 tended to 
correlate with p16 expression (p < 0.05), providing another potential mechanism for G1 
phase cell cycle arrest as p16 is a tumour suppressor protein that inhibits progression 
from G1 to S phase. p16 is an inhibitor of cyclin dependent kinases such 
as CDK4 and CDK6 which mediate the progression from G1 phase to S phase through 
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their interaction with cyclin D1 (Hara. et al, 1996). Immunohistochemistry has found a 
correlation between high grade glioma and the expression of p53 and p21, with p14 and 
p16 more frequently present in low grade tumours (Zolota et al, 2008).These differences 
in expression could provide some explanation for why PN517 alters the cell cycle 
distribution and proliferation of the 1321N1 and GOS-3 (grade 2-3) cell lines at an earlier 
time point and at the lower drug concentration than was found in the U87 MG (grade 4) 
cell line.  
 
There is also a link between p53 and COX-2 expression, as wild type p53 has been shown 
to inhibit COX-2 expression in vitro (Subbaramaiah et al, 1999). So in addition to a loss 
of p53 causing a disruption in cell cycle regulation, it may also result in an increase in the 
expression of COX-2 in glioma. Increased COX expression and the resulting production 
of PGE2 provide a further potential mechanism for changes in proliferation. Its known that 
PGE1 and PGE2 increase cell number and incorporation in the T98G human glioma cell 
line in vitro with PGE2 producing consistently larger effects than PGE1 (Gomes and 
Colquhoun 2012). Activation of the EP4 receptor by PGE2 has been shown to correlate 
with proliferation, with COX inhibitors suppressing expression of the receptor (Kambe et 
al., 2008; Kambe et al., 2009).  
 
Conclusion 
We have observed both a decrease in proliferation and inhibition of cell cycle progression 
following treatment with the novel aspirin analogue PN517. Additionally, PN517 both 
decreased EGFR expression and inhibited EGF stimulation of cyclin D1 activation. While 
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it is clear from the literature that COX enzymes play a significant role in the regulation of 
proliferation and cell cycle in glioma, the pathways are complex with evidence suggesting 
that decreases in cell proliferation following treatment with COX inhibitors might be 
mediated by both COX-2 and by COX independent pathways; cell cycle arrest may occur 
in each stage of the cell cycle, an effect that may be concentration dependent; and 
expression of a range of cyclins and tumour suppressor proteins may be involved. In 
summary, PN517 has shown an effect in proliferation, mostly in GOS-3 cell line, a results 
replicated by aspirin, and a G1 arrest was observed, followed by an increase in S/M phase. 
An effect on phosphorylated Cyclin D1 has supported cell cycle data, as well as EGFR. 
The results support the therapeutic potential of PN517 for the treatment of glioma. 
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Chapter 5: Apoptosis 
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5.1 Introduction 
The cells in a multicellular organism are members of a highly organized community which 
are tightly regulated from the rate of cell division and cell death where in general cells die 
through either of two distinct processes, cell apoptosis and cell necrosis. Apoptosis is the 
process of programmed cell death that avoids eliciting inflammation (Fink et al, 2005). It 
involves a series of biochemical events that lead to a variety of morphological changes, 
like membrane blebbing, loss of membrane asymmetry, cell shrinkage, nuclear 
fragmentation, chromatin condensation, and chromosomal DNA fragmentation (Elmore, 
2007). Necrosis on the other hand is the premature death of cells and living tissue and is a 
passive process of accidental cell death resulting from environmental perturbations with 
uncontrolled release of inflammatory cellular contents, a process that prevents 
phagocytosis, leading to a build-up of dead tissue and cell debris (Edinger and Thompson 
2004). Thus, the disposal process of cellular debris that does not damage the organism 
differentiates apoptosis from necrosis. Apoptosis often provides beneficial effects to an 
organism, whereas necrosis is almost always detrimental. 
 
The first indication that apoptosis might influence the malignant phenotype was by Kerr 
and colleagues in 1972, where they described how apoptosis contributed to the high rate of 
cell loss in malignant tumours and could promote tumour progression (Kerr et al., 1972). 
Apoptosis has since been separated in three stages, early, intermediate and late-stage 
apoptotic events with methods and reagents developed to identify the various apoptotic 
stages, and to clearly distinguish them from necrotic processes (Wlodkowic et al, 2011).  
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Early to mid-stage apoptosis is characterized by the translocation of phosphatidylserine 
(PS), a lipid located in the cellular membrane. PS in live, intact cells is cytosolic but 
translocates to the extracellular portion of the membrane in early/mid-stage apoptosis 
(Kawasaki Y., et al 2000). Annexin V, a cellular protein of unclear function, can be used 
for PS detection in addition to cell impermeable dyes, such as Propidium Iodide (PI), that 
are used as a counterstain to differentiate early apoptosis from late apoptosis or necrosis 
(Waehrens  2009).Late stage apoptosis is characterised by DNA fragmentation and can be 
detected using PI.  
 
In addition to differentiating apoptosis from necrosis, caspase enzymes can be used to 
determine the apoptotic pathway activated following a drug treatment, either the 
intrinsic/mitochondrial pathway, or the extrinsic pathway (Fig 5.1). The intrinsic pathway 
is often activated in response to signals resulting from DNA damage, loss of cell-survival 
factors, or other types of severe cell stress (Fulda et al, 2010). The intrinsic pathway is 
complex and involves a wide variety of signalling molecules, but can involve p53 induction 
of the expression of PUMA, p53 upregulated modulator of apoptosis (Bai and Wei-Guo 
2006). Upon its activation PUMA interacts with anti-apoptotic members of the Bcl-
2 family of proteins, resulting in their release from apoptotic family members such as Bax, 
which subsequently insert into the mitochondrial membrane causing permeabilisation, 
break down of the membrane potential, and release of cytochrome c (Krakstad 
and Chekenya 2010). Cytochrome C, Apaf-1 and caspase-9, the initiator caspase, form the 
apoptasome and initiate a further cascade of signalling resulting in the activation of the 
caspase-3, the terminal caspase (Baliga and Kumar, 2003).  
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The extrinsic signalling pathway involves the activation of transmembrane death receptors that are 
members of the tumour necrosis factor (TNF) receptor gene superfamily (Wang and El-Deiry 
2003). These receptors bind extrinsic ligands and transduce intracellular signals that induce 
apoptosis with the most well characterized ligands being TNF-alpha, Apo3L, and Apo2L, while 
known receptors include FasR, TNFR1, DR3, and DR4/DR5 (Elmore 2007). Ligand binding leads 
to the formation of a death-inducing signalling complex (DISC), activating procaspase-8 which in 
turn can either directly activate caspase-3 or can regulate the bcl-2 family leading to activation of 
the intrinsic pathway (Elmore 2007).  Having established that the aspirin analogues decreased 
cell viability, one potential factor contributing to this result is the induction of apoptosis, 
and thus it was decided to examine its contribution using a variety of assays including flow 
cytometric analysis of cells stained with annexin V and PI following drug treatment.  
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Fig 5.1 Extrinsic and intrinsic pathways of apoptosis. Diagrammatic representation of signalling 
pathways involved in the induction of apoptosis (Ashkenazi, 2012).  
 
 
Hypothesis  
Aspirin and its analogue PN517, reduced both cell viability and proliferation in each of the 
cell lines tested, but the pattern of results from the assays did not correlate directly, 
suggesting a role for another mechanism. In addition to cell proliferation, cell viability also 
includes apoptotic cell death, thus it is hypothesised that treatment with aspirin and PN517 
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will induce apoptosis, and this effect will be greatest in the GOS-3 cell line, the glioma 
cells most sensitive to treatment in previous assays. There are conflicting results in the 
literature as to which pathway is most important for the induction of apoptosis by NSAIDs 
in glioma, extrinsic or intrinsic, thus it is expected to find effects on both pathways.  
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5.2 Results 
The first assay performed to examine the induction of apoptosis used differential staining 
of cells by annexin V and PI to distinguish between early and late apoptotic cells. As 
already stated, annexin V conjugated to green-fluorescent FITC dye detects the 
externalization of phosphatidylserine in apoptotic cells, and red fluorescent PI staining to 
distinguish early from late apoptotic cells. Additionally, PI can be used to indicate necrotic 
cells, where the cell membrane is no longer intact, but phosphatidylserine staining is not 
observed as translocation has not occurred. In control living populations little or no 
fluorescence was observed, thus in all cases, no apoptosis was recorded at the zero 
timepoint thus these results were not shown on the graphs. The effect of drug treatment 
with aspirin and PN517 at 0.1 and 1mM was examined using the established cell lines for 
grade II – IV glioma, specifically 1321N1 - a grade II astrocytoma, Gos-3 - a grade II/III 
mixed astro-oligodendroglioma, and U-87 MG - a grade IV glioblastoma. Experimental 
controls included the SVG-p12 foetal glial cell line and the standard chemotherapeutic drug 
cisplatin.  
 
Following drug treatment of the SVG-p12 cell line, induction of apoptosis was observed 
in both a time and concentration dependent manner for cisplatin, aspirin and PN517 (Fig 
5.2). A significant increase in both early and late apoptotic cells was observed following 
24 hours of drug treatment with cisplatin at both 0.1 mM (p < 0.0001) and 1mM (p < 
0.0001), an effect that increased further following 48 hours of treatment (p < 0.0001and p 
< 0.0001 respectively). A similar trend was observed with aspirin at 24 (p<  0.0001 for 
0.1mM and p < 0.0001 for 1mM) and 48 hour timepoints (p < 0.0001 for 0.1mM and p < 
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0.0001 for 1mM), and also with PN517 following 24 (p < 0.0001 for 0.1mM and p < 0.0001 
for 1mM) and 48 hours of treatment (p < 0.0001 for 0.1mM and p < 0.0001 for 1mM). Of 
the three treatments, cisplatin produced the largest induction of apoptosis with early and 
late phase apoptosis at 55% and 83% following treatment at 0.1 mM and 1 mM respectively 
at 48 hours. Aspirin and PN517 produced similar results, inducing 35% and 33% apoptosis 
respectively after 48 hour treatment at 1 mM concentration.  
 
In a similar manner to the control cell line, each of the drug treatments induced apoptosis 
in the 1321N1 cell line (Fig 5.3). However, in contrast to the SVG-p12 cell line, an increase 
in apoptosis is observed at an earlier time point following treatment with all three drugs, 
with significant increases in apoptosis observed at either the 4 or 8 hour timepoints. At 
0.1mM, a similar level of apoptosis is observed following treatment with each drug at 48 
hours with cisplatin resulting in 70%, aspirin 60% and PN517 62.5% of apoptotic cells. At 
1mM, cisplatin induces apoptosis at the earliest timepoint and to a greater extent than was 
observed at 0.1mM. However, little difference was observed between 0.1 and 1mM 
treatments for aspirin apart from a greater proportion of apoptotic cells at the 4 hour 
timepoint (13% versus 36% respectively). An increase in the proportion of apoptotic cells 
at the 4 hour timepoint was also observed following PN517 treatment at 1mM (27%), a 
trend that was reproduced at each subsequent timepoint apart from at 48 hours, where the 
proportion of apoptotic (22%) cells dropped unexpectedly.   
 
A similar pattern of apoptosis induction was observed with the GOS-3 cell line (Fig 5.4) 
as was observed in the 1321N1 cell line, with each drug inducing apoptosis at both 
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concentrations and from the earliest timepoints. The largest apoptotic population in the 
GOS-3 cell line was observed following treatment with cisplatin at both 0.1 and 1mM (Fig 
5.4, panels A and B). Interestingly, the proportion of apoptotic cells was greater at 1mM 
following aspirin treatment than PN517 treatment at 24 (60% for aspirin and 83% for 
PN517) and 48 hours (53% for aspirin and 86% for PN517), but at the earlier timepoints, 
PN517 produced a larger effect.  
 
The effect of drug treatment on apoptosis was also examined in the U87 MG grade IV 
GBM cell line with both a concentration and time dependent effect observed for each drug 
(Fig 5.5).  The largest apoptotic population was observed following 1mM cisplatin 
treatment for 24 and 48 hours, 64% and 66% respectively. The size of this population is 
almost three times that observed at the equivalent 0.1mM timepoints (18% and 19% 
respectively). While aspirin generally increased the apoptotic population in a time 
dependent manner, following 48 hours of treatment the population decreased significantly 
in comparison to the 24 hour timepoint at both concentrations (p < 0.0001 at 0.1mM and p 
< 0.0001 at 1mM). PN517 also induced apoptosis in a time dependent manner at both drug 
concentrations, but while little difference was observed in the total apoptotic population at 
48 hours following either 0.1mM (31%) or 1mM (35%) treatments, the proportion of late 
apoptotic cells was greater at the higher drug concentration (10% versus 29%).  
 
Representative sample dot plots for the annexin V/PI apoptotic flow cytometry analysis of 
each of the cell lines can be found in the appendix. A shift from quadrant three (Q3), live 
cells with little or no staining, into quadrant four (Q4 – early apoptosis annexin V positive) 
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and quadrant two (Q2 – late apoptosis, both annexin V and PI positive) is observed where 
treatments induce apoptosis. The cells in quadrant one (Q1 – PI positive) may indicate 
necrotic cells. 
 
To summarise, as expected the effect on all cell lines was greater at 1 mM drug treatment 
as compared to 0.1 mM. The lowest level of apoptosis induction by all treatments was 
found in the control SVG-p12 cell line, although both time and concentration dependent 
effects were observed, with cisplatin producing the largest effect. In the glioma cell lines, 
little difference was seen between the levels of apoptosis induced by PN517 or cisplatin 
across all grades, with aspirin being less efficacious. An inverse correlation was observed 
between apoptosis and glioma grade, with typically the highest levels of apoptosis found 
in the 1321N1 cell line, and the lowest levels of apoptosis in the U87 MG cell line.  
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Figure 5.2 Induction of apoptosis determined by Annexin V/PI staining following drug 
treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM in the SVG-p12 cell line. The data 
represent the proportion of apoptotic cells (white - early apoptotic, black - late apoptotic) in SVG-
p12 cell line as determined by flow cytometry following drug treatment over time. Panel A and B 
illustrate cisplatin treated cells at 0.1 and 1 mM respectively, and similarly C and D aspirin treated 
cells and E and F panel show PN517 treated cells. The data represent results of 3 independent 
experiments with an overall significant effect of treatment in comparison with control (p < 0.0001) 
determined by ANOVA.  
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Figure 5.3 Induction of apoptosis determined by Annexin V/PI staining following drug 
treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM in the 1321N1 cell line. The data 
represent the proportion of apoptotic cells (white - early apoptotic, black - late apoptotic) in 1321N1 
cell line as determined by flow cytometry following drug treatment over time. Panel A and B 
illustrate cisplatin treated cells at 0.1 and 1 mM respectively, and similarly C and D aspirin treated 
cells and E and F panel show PN517 treated cells. The data represent results of 3 independent 
experiments with an overall significant effect of treatment in comparison with control (p < 0.0001) 
determined by ANOVA.  
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Figure 5.4 Induction of apoptosis determined by Annexin V/PI staining following drug 
treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM in the Gos-3 cell line. The data 
represent the proportion of apoptotic cells (white - early apoptotic, black - late apoptotic) in Gos-3 
cell line as determined by flow cytometry following drug treatment over time. Panel A and B 
illustrate cisplatin treated cells at 0.1 and 1 mM respectively, and similarly C and D aspirin treated 
cells and E and F panel show PN517 treated cells. The data represent results of 3 independent 
experiments with an overall significant effect of treatment in comparison with control (p < 0.0001) 
determined by ANOVA.  
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Figure 5.5 Induction of apoptosis determined by Annexin V/PI staining following drug treatment for 
4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM in the U87 MG cell line. The data represent the proportion of 
apoptotic cells (white - early apoptotic, black - late apoptotic) in U87 MG cell line as determined by flow 
cytometry following drug treatment over time. Panel A and B illustrate cisplatin treated cells at 0.1 and 1 
mM respectively, and similarly C and D aspirin treated cells and E and F panel show PN517 treated cells. 
The data represent results of 3 independent experiments with an overall significant effect of treatment in 
comparison with control (p < 0.0001) determined by ANOVA. 
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Caspase 8 & 9 
In parallel to the flow cytometric determination of apoptosis, the luminescent Caspase Glo 
assay was performed to quantify the activation of both caspase 8 and 9 in the U87 MG and 
SVG-p12 cell lines (Fig 5.6 and 5.7).  
 
In the SVG-p12 cell line in the case of both caspase 8 and 9, each drug treatment showed 
a time dependent activation of the enzymes with the exception of PN517 where activity 
dropped between the 24 and 48 hour timepoints. The greatest activation of both caspase 8 
and 9 was observed following aspirin treatment, with PN517 showing a similar efficacy 
for the activation of caspase 9 but peaking at 24 hours, and cisplatin showing the lowest 
degree of activation in both assays.  
 
In the U87 MG cell line, again a time dependent activation of both enzymes was observed 
by each drug treatment with the exception of aspirin activation of caspase 9 where a high 
degree of activation was observed at the 12 hour timepoint. Both PN517 and aspirin 
showed a similar efficacy in the activation of caspase 9, but aspirin produced a greater 
activation of caspase 8. As with the SVG-p12 cell line, the lowest activation in both 
enzymes was observed following cisplatin treatment. 
 
When compared to the results of the annexin V and PI staining, the activation of caspase 8 
and 9 as measured using the caspase glo assay do not always directly correlate. An example 
of this can be observed in the U87 MG cells, where aspirin treatment results in the highest 
level of caspase 8 activity at 48 hours, but the lowest level of apoptosis by flow cytometry. 
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This is not entirely unexpected though, as caspase activation precedes events like 
membrane degradation and PI staining. Overall, both assays demonstrate a time and 
concentration dependent activation of apoptosis by each treatment.  
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Figure 5.6 Activation of caspase 9 and 8 following drug treatment for 12, 24 and 48 hr at 1 
mM in SVG-p12 and U87 MG cell lines. The data illustrate fold change in caspase activity 
determined by the Caspase Glo luminescent assay with results grouped by drug. Activation of 
caspase 9 (panel A and C) and caspase 8 (panel B and D) in SVG-p12 cell line (top panels of graph) 
and U87 MG cell line (bottom panels of graph).  The data shows a time dependant activation of 
both caspases by each drug treatment. An overall significant effect of treatment in comparison with 
control (p < 0.005) was found by ANOVA with data representing results from 3 independent 
experiments. 
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Figure 5.7 Activation of caspase 9 and 8 following drug treatment for 12, 24 and 48 hr at 1 
mM in SVG-p12 and U87 MG cell lines. The data illustrate fold change in caspase activity 
determined by the Caspase Glo luminescent assay with results grouped by timepoint. Activation of 
caspase 9 (panel A and C) and caspase 8 (panel B and D) in SVG-p12 cell line (top panels of graph) 
and U87 MG cell line (bottom panels of graph).  The data shows aspirin producing the greatest 
activation, followed by PN517 and lastly cisplatin. An overall significant effect of treatment in 
comparison with control (p < 0.005) was found by ANOVA with data representing results from 3 
independent experiments.  
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In parallel with the annexin V/PI flow cytometry assay, western blotting was used in an 
attempt to examine the activation of caspases 8, 9 and 3 following drug treatment in the 
various cell lines. However, following difficulty with primary antibodies only provisional 
data were generated for the 1321N1 and U87 MG cell lines (Fig 5.8).  Treatment with 
aspirin and PN517 seemed to indicate cleavage of procaspase 9 and an appearance of 
cleaved caspase 9 over the time course examined, with loss occurring at an earlier timepoint 
in the 1321N1 cell line than in U87-MG cell line, a finding that correlates with the flow 
cytometric apoptosis data. Similarly, a loss of procaspase 8 was apparent in the 1321N1 
cell line following aspirin treatment, and may be observed following PN517 treatment. The 
blots for the U87 MG cell line do not show as big a change in procaspase 8 expression, 
with an obvious decrease following 24 hours of aspirin treatment, but a less obvious effect 
with PN517 treatment. 
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Fig 5.8 Activation of caspase 8 & 9 in the 1321N1 and U87 MG cell lines following drug 
treatment with aspirin and PN517. The data show representative western blots of caspase 8 and 
9 in the 1321N1 and U87 MG cell lines following drug treatment at 1mM with aspirin and PN517 
for 4, 8, 12, 24 and 48 hours. The data are preliminary and are representative of two independent 
experiments.   
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5.3 Discussion 
An important mechanism for the anti-tumour activity of aspirin and other non-steroidal 
anti-inflammatory drugs is the induction of apoptosis. Aspirin has been shown to enhance 
apoptosis in several cancer cell lines including colorectal adenoma and carcinoma cells 
(Elder et al., 1996), mouse Neuro 2a cells (Dikshit et al., 2006) human hepatoma cells 
(Raza et al., 2011), oesophageal squamous carcinoma cells (Li et al., 2009), and myeloma 
cell lines (Ding et al., 2014). COX-2 selective inhibitors have also been demonstrated to 
have similar activity, including ninesulide (Li et al., 2009), NS-398 (Liu et al., 1998; Elder 
et al., 2000; Elder et al., 2002), and SC326 (Doherty et al., 2009). Importantly, an 
enhancement of apoptosis has been demonstrated following aspirin, indomethacin and 
ibuprofen treatment in T98G human glioblastoma cells (Amin et al., 2003; Gomes and 
Colquhoun, 2012) and through COX-2 selective inhibition in U87 MG cells (Kang et al., 
2009).  
 
Our results examining the induction of apoptosis confirm that short term aspirin treatment 
can enhance apoptosis in different glioma cell lines and also demonstrate for the first time 
that the aspirin analogue PN517 increases apoptosis with at least the same, if not greater 
efficacy. In the four cell lines tested, induction of apoptosis correlated with the known 
proliferation rate of the cells, with the greatest induction in the GOS-3 and 1321N1 cell 
lines which have a doubling time of 24 hours, and a lower degree of induction in the SVG-
p12 and U87 MG cell lines which have a doubling time of 36 and 48 hours respectively. 
Using the in vitro luciferase assay we found that both aspirin and PN517 activated caspase 
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8 and caspase 9 in a time and concentration dependent manner, a finding supported by 
western blotting.  
 
The control drug cisplatin enhanced apoptosis to a greater degree than aspirin or PN517 
treatment in all cell lines, again correlating with proliferation rate. This finding is 
unsurprising given that the known mechanism of action for cisplatin induction of apoptosis 
is through the formation of inter and intra crosslinked DNA adducts (Tanida et al., 2012). 
This DNA damage is detected during transcription or replication and activates downstream 
pathways including p53 which ultimately result in the induction of apoptosis. While the 
novel aspirin analogue PN517 enhanced apoptosis to a lesser extent than cisplatin, the 
induction of apoptosis was significant, and importantly in vivo PN517 does not display any 
obvious toxicity related side effects (Caludius et al., 2014). This is in contrast to 
chemotherapeutic drugs like cisplatin whose toxicity limits their use.   
 
Several mechanisms have been reported for aspirin induction of apoptosis including the 
downregulation of anti-apoptotic protein Bcl-2 (Li et al., 2009; Raza et al., 2011; Ding et 
al., 2014), the upregulation of the pro-apoptotic protein Bax (Zhou et al 2001;Gu et al 
2005; Diskshit et al., 2006; Ding et al., 2014), release of cytochrome c (Pique et al. 2000; 
Zimmermann et al. 2000; Diskshit et al., 2006;Raza et al., 2011), activation of caspase 8 
(Ding et al., 2014), caspase 9 (Diskshit et al., 2006; Gomes and Colquhoun, 2012; Ding et 
al., 2014), and caspase 3 (Diskshit et al., 2006; Raza et al., 2011; Gomes and Colquhoun, 
2012; Ding et al., 2014), inhibition of ATP synthesis (Raza et al., 2011), and 
downregulation of VEGF (Ding et al., 2014). The COX-2 selective inhibitor NS398 causes 
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a similar downregulation of Bcl-2 protein expression in the LNCaP prostate cancer cell 
line (Liu et al., 1998), with an activation of poly-(ADP ribose) polymerase in HT29 
colorectal cancer cells (Elder et al., 2002). Interestingly, NSAID upregulation of Bax 
expression was not a universal finding, with Li and colleagues reporting that neither aspirin 
nor nimesulide altered its expression in oesophageal squamous carcinoma cells (Li et al., 
2009). 
 
NF-κB is found as a heterodimer of the ReIA/P50 subunits in the cytoplasm bound to IκB, 
but degradation of the latter allows NF-κB nuclear translocation where it can regulate target 
gene expression. In addiation to aspirin activation of this pathway resulting in the 
degradation of cyclin D1 and apoptosis induction in SW480 colorectal cancer cells (Thoms 
et al., 2010), Claudius et al., (2014) found that the aspirin analogue PN517 decreases IB 
levels leading to activation of NF-B, a reduction in cyclin D1 and induction of apoptosis.  
In contrast to the findings presented here using glioma cells, they did not observe cell cycle 
arrest in SW480 cells following PN517 treatment, and also reported effects using a higher 
concentration of analogue (3mM) than used in these studies. This higher concentration may 
suggest that the SW480 cell line is less sensitive to treatment with aspirin or aspirin 
analogues, and explain some of the differences observed in the timescale of reponses. 
However, it is clear that NF-κB activation is likely to play a role in glioma cell lines, and 
is therefore associated with the  
 
Our results with PN517 and aspirin confirm the previously reported NSAID activation of 
caspase 8 and 9, suggesting the involvement of both the extrinsic and intrinsic pathways of 
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apoptosis induction. The extrinsic pathway involves the activation of death receptors such 
as Fas and TNFR1, leading to clustering and formation of a death-inducing signalling 
complex which includes the adapter protein FADD (Fas-associated death domain) and 
initiator procaspase-8, the latter of which is cleaved and activates downstream effector 
caspases (caspase-3) (Gu et al 2004). The intrinsic pathway is controlled by the Bcl-2 
family. Anti-apoptotic proteins (e.g. Bcl-XL and bcl-2) antagonize the pro-apoptotic 
proteins Bax and Bak by binding to their BH3 domains. This antagonism is relieved by 
BH3-only, pro-apoptotic proteins (BIM, BID, BAD, NOXA, PUMA), which alternately 
bind to anti-apoptotic proteins. This leads to the release of cytochrome c, and apoptosome 
formation with Apaf-1 and caspase-9 which subsequently activates the effector enzyme, 
caspase 3.  
 
While numerous studies have suggested the involvement of COX enzymes in the 
mechanism of apoptosis induction, it has been reported that different doses of aspirin effect 
different pathways (Arrieta et al., 2001), with low aspirin concentrations inhibiting COX 
enzymes and the production of prostaglandins, but high concentrations producing effects 
through COX independent mechanisms such as β-catenin and wnt signalling (Lan et al., 
2011; Bos et al., 2006). COX-1 and COX-2 are prostaglandin H synthetases and catalyses 
the conversion of arachidonic acid into prostaglandins and thromboxanes.  COX-2 
expression is inducible and increases response to various stimuli, including inflammatory 
signals, mitogens, cytokines, tumour promoters and growth factors, while COX-1 is 
expressed in nearly all normal tissues and mediates the synthesis of PGs required for 
physiological tissue homeostasis (Pairet and Engelhardt, 1996). COX-2 has been linked to 
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tumourigenesis in certain cancers, and more recently was shown to be upregulated in high-
grade gliomaresulting in elevated prostaglandin levels (Joki et al., 2000; Shono et al., 2001; 
Kokoglu et al., 1998). These increased PG levels have been linked to increased 
proliferation, decreased apoptosis, promotion of angiogenesis, and inhibition of immune 
surveillance (Maxwell et al., 1990; Zimmermann et al., 1999; Kokoglu et al., 1998). This 
is supported by the concentration of aspirin and nimesulide required to inhibit PGE2 
production correlating with the inhibition of proliferation and induction of apoptosis (Li et 
al., 2009). However, there are other reports which failed to find a correlation between 
COX-2 expression and NSAID induced apoptosis (Elder et al., 2000; Molina et al., 1999). 
Elder and colleagues also found no effect of PGE2 addition on the induction of apoptosis 
(Elder et al., 2000).  
 
A further pathway implicated in the induction of apoptosis by aspirin was described in the 
A172 human glioblastoma cell line A172 where a reduction in the level of phosphorylated 
STAT3 (Tyr705), a transcription factor required for survival of glioblastoma, was found 
(Kim et al., 2009). Aspirin reduced the expression of STAT3 target genes such as Cyclin 
D1, XIAP, and Bcl-2, all contribution to decreased proliferation and apoptosis induction. 
The same study showed that the expression and secretion of interleukin-6 (IL-6), led to 
STAT3 phosphorylation and activation, and this was inhibited by aspirin. When exogenous 
IL-6 was administered to aspirin-treated A172 cells, the phosphorylation of STAT3 and 
cellular apoptosis was reduced compared to aspirin only-treated cells. The description of 
this pathway is highly significant because interleukins such as IL-6 are often found 
expressed in human glioma cells (Sasaki et al. 2001), and phosphorylation and activation 
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of STAT3 has recently been described as an independent prognostic factor in GBM linked 
to poor clinical outcome (Lo et al.,  2008; Lin et al., 2014a, b). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1. Activation of NF-B represents an important step in the regulation of IL-6 gene 
expression. IL-6 expression and secretion leads to STAT3 phosphorylation and activation. Aspirin 
reduces the expression of STAT3 target genes such as cyclin D1, XIAP, and Bcl-2.  
 
As well as the JAK/STAT pathway, another pathway involved in apoptosis in many 
cancersincludingbrain tumours, is the upregulation of NF-B (Noqueira et al., 2011). NF-
B activity is high in GBM tissue and corresponds with increasing grade in astrocytic 
tumours (Korkolopoulou et al., 2008; Angileri et al., 2008). The exact mechanism of NF-
B activation in GBMs is not known, however, a variety of proteins and pathways affecting 
IL-6/IL-2 
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κ
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GBM could be related to NF-B activation. TNF-α, IL-6 and IL-1β, are important 
regulators of paracrine signalling in brain tumour cells which cause changes in gene 
expression in neighbouring cells through direct ligand–receptor interactions, and cause 
inflammation. TNFR1, expression of which correlates positively with glioma grade, 
activates TNF-α signalling which promotes NF-B activation and subsequent anti-
apoptotic responses (Otsuka et al., 1999; Koul et al., 2006).Inhibition of NF-B activation 
has been demonstrated to reduce brain tumour growth, invasion and angiogenesis (Xie et 
al., 2008), and importantly, aspirin is known to inhibit the NF-B pathway by inhibiting 
I(kappa)B kinase-beta activity (IKKβ) (Yin et al., 1998). 
 
Crosstalk between the STAT3 and NF-B pathways has been observed at various points, 
including upregulation of VEGF expression in tumour cells (Wu et al., 2004; Loeffer et 
al., 2005). Additionally, EGF has been shown to activate NF-B in GBM cells (Hayashi et 
al., 2001), and EGFR amplification at the protein level has been described in 60-90% of 
GBMs, with the expression level correlating with poor patient outcome (Shinojima et al., 
2003; Umesh et al, 2009). A downstream effect of EGFR over-activation is stimulation of 
STAT3 activity in GBM cells (Rao et al., 2005). This pathway has been reported to activate 
COX-2 gene expression in GBM (Lo et al., 2010), thus NSAID inhibition of COX and 
subsequently NF-B activation may actually negatively regulate COX-2 expression, a 
finding that emphasises the complexity of the signalling pathways involved in 
tumourigenesis.  
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In conclusion, we have shown that aspirin and PN517 induce early and late apoptosis at 
0.1 and 1 mM concentrations in a time dependent manner, and with an efficacy that 
correlates with proliferation rates. Both drugs activated caspase 8 and 9 in vitro, suggesting 
the involvement of both intrinsic and extrinsic pathways of apoptosis. In conjunction with 
our finding that PN517 and aspirin inhibit EGFR activation in U87 MG cells, the literature 
would suggest that STAT3 and NF-B signalling are involved, however further work is 
required to confirm this hypothesis.   
 185 
 
Chapter 6: Invasion and Migration  
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6.1 Introduction 
Glioma is the most common intracranial tumour with patients undergoing invasive surgery, 
radiotherapy and chemotherapy but despite this having a median survival time of 
approximately 12 months following diagnosis (Cancer Research UK, 2013). It has been 
observed that after surgical removal, tumours recur mainly due to the fact that cells from 
the tumour have already invaded normal brain tissue, making the invasive behaviour of 
glioma cells one of the most important hallmarks, with a median recurrence time of 7 
months (Stupp at el., 2005). GBM invasion occurs along nerve fibre tracts and regularly 
penetrates the glial limiting membrane resulting in cancer spread throughout the spinal 
fluid (Lee et al., 2005). Invasion requires degradation of the local extracellular matrix and 
in GBM, the proteolytic activity of two matrix metalloproteinases (MMP-2 and MMP-9) 
has been identified to play a role, with expression being upregulated in line with tumour 
grade (Rao et al., 1993; Forsyth et al., 1998; Yang et al., 2014). 
 
PGE2, the levels of which are elevated in brain tumours (Kokoglu et al., 1998), plays an 
important role in proliferation, invasion, and metastasis in GBM (Sivak-Sears et al., 2004). 
In primary cultures derived from head and neck tumours, it has been demonstrated that 
invasion, and MMP-2 and MMP-9 activity is reduced by the non-selective COX inhibitor 
sulindac, aspirin, and the COX-2 selective inhibitor NS398 (Koontongkaew et al., 2010). 
The invasiveness of U87 MG cells was shown to be inhibited by sulindac and the COX-2 
selective inhibitor celecoxib, a process unaffected by aspirin, ketoprofen, ketorolac and 
naproxen (Lee et al., 2005). Inhibition of invasiveness was linked to MMP-2 activity. 
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Prior to metastasis, cells must acquire several properties in addition to increased 
invasiveness. These properties include the loss of cell adhesion, intravastation and 
increased survival and proliferation (Chaffer and Weinberg, 2011; Fidler, 2003; Joyce and 
Pollard, 2009). Survival of the cancer cells while circulating is thought to involve platelets 
(Gasic et al., 1968; Gasic et al., 1973 Bambace et al., 2011; Gay and Felding-Habermann, 
2011), a process which is reduced by aspirin (Bambace et al., 2011; Gay and Felding-
Habermann, 2011; Gasic et al., 1972; Henschke et al., 1977; Futakuchi et al., 2002). The 
importance of this has been emphasised by the results of many clinical trials and described 
in a meta analysis of five major randomised controlled trials by Rothwell and colleagues 
who found that aspirin reduced the risk of cancer with distant metastasis in all cancers but 
mainly due to a reduction in metastatic adenocarcinomas (Rothwell et al., 2012). Overall, 
aspirin reduced the risk of fatal adenocarcinoma significantly, an effect independent of age 
and gender. This finding has been demonstrated elsewhere, confirming that regular use of 
aspirin lowers the risk of distant metastasis for several cancers such as breast and biliary 
cancer (Zhang X, Smith-Warner et a.,l 2012). Based on these findings, we decided to 
determine the effect of PN517 on migration and invasion. 
 
Hypothesis  
Invasion is known to be reduced by NSAID treatment in vitro, and meta-analysis of clinical 
data has shown that aspirin reduces metastasis. Thus it is prediceted that aspirin and the 
aspirin analogue PN517 will reduce invasion and migration in glioma cell lines in vitro.  
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6.2 Results 
The effect of drug treatment (0.1mM) on cell migration was examined in each of the cell 
lines over a six hour period with the migrated population expressed as a percentage of 
control migration (Fig 6.1). Briefly, cells were seeded on polycarbonate inserts (8.0 µm) 
and following equilibration the media within the insert was replaced with serum free media, 
with complete media within each well acting as a chemoattactant. Drug treatments were 
placed in both the serum free and complete media. Following 6 hours incubation, cells were 
removed from the underside of the insert by trypsinisation and counted (Fig 6.1A).  
 
An important finding of the migration assay was that in the SVG-p12 foetal astrocyte cell 
line, neither aspirin nor PN517 significantly altered migration, demonstrating a selectivity 
for glioma cancer cell lines (Fig 6.1B).  
 
With the exception of cisplatin treatment in the SVG-p12 cell line, PN517 treatment 
produced the greatest reduction in cell migration with aspirin producing the next largest 
reduction in migration. Cisplatin treatment reduced cell migration in the SVG-p12 and U87 
MG cell lines but did not significantly alter migration in the GOS-3 or 1321N1 cell lines.  
 
The greatest effect of PN517 was in the U87 MG cell line where migration was reduced to 
60% of control, with reductions to 62%, 77% and 90% of control for GOS-3, 1321N1 and 
SVG-p12 cell lines respectively. Aspirin also produced its greatest reduction in migration 
in the U87 MG cell line (73% of control), followed by GOS-3 (82%), 1321N1 (86%), and 
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SVG-p12 (91%). The control drug cisplatin reduced migration in the control cell line, 
SVG-p12, to 71% of control and in the U87 MG cell line to 88% of control. 
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A 
 
B 
 
 
 
 
 
 
 
Fig 6.1 Effect of drug treatment on cell migration in SVG-p12, GOS-3, 1321N1 and U87 MG 
cell lines over 6 hours (A) and a diagramatic representation of the assay (B). The data illustrate 
the effect of drug treatment at 0.1 mM on migration expressed as a percentage of control in the 
SVG-p12, GOS-3, 1321N1 and U87 MG cell lines. With the exception of the SVG-p12 cell line, 
PN517 treatment produced the largest reduction in migration. An overall significant effect of 
treatment (p < 0.005) was found by ANOVA analysis with data representing results from 3 
independent experiments. 
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Migration was also examined in the cell lines using the wound healing/scratch assay (Fig 
6.2). Once cells were confluent, a scratch was created using a sterile cocktail stick so as 
not to scratch the plastic surface and alter migration, and the media replaced (including 
drug treatment where appropriate) to remove any floating cells whose re-attachment might 
influence the results (Fig 6.2).  
 
In control the slowest migration was observed with the SVG-p12 cell line with the scratch 
not completely closing over the 18 hour period (Fig 6.3). This is in contrast to the GOS-3 
cell line where the scratch completely closed.  
 
In each cell line, treatment with PN517 reduced migration with the scratch remaining open 
after 18 hours, with migration being reduced to approximately 60% of control. Aspirin also 
reduced migration, but to a lesser extent, to an average of approximately 80% of control in 
all cell lines.  
 
The control drug cisplatin had the largest effect on migration in the scratch assay, reducing 
overall migration in the 18 hour period to between 40% and 80 % of control, with the 
greatest effect in the U87 MG cell line. 
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Fig 6.2 Diagramatic representation showing a single well of the scratch assay. Following 
scratching with a cocktail stick, cells (indicated in blue) migrate over 18 hours to fill the resulting 
space.  
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Fig 6.3 Effect of drug treatment on U87 MG, GOS-3, 1321N1 and SVG-p12 cell migration using the scratch assay. Migration was expressed 
as fold decrease over 18 hours in scratch width as measured by minimum distance following treatment with PN517, aspirin and cisplatin at 1mM. 
An overall significant effect of treatment (p < 0.01) was found by ANOVA analysis with data representing results from 3 independent experiments. 
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In contrast to migration, invasion of the established cell lines was not consistently reduced 
by drug treatment (Fig 6.4A), where invasion was measured over an 18 hour period with 
cells exposed to drug treatment at 0.1mM. Briefly, invasion was measured as the proportion 
of cells migrating from a serum free environment into complete media over 12 hours with 
quantification by enzyme activated fluorescence (Fig 6.4B) 
 
Cisplatin was the only treatment found to significantly reduce invasion across each of the 
cell lines, reducing invasion to 68% of control in the SVG-p12 cell lines followed by U87 
MG (70%), 1321N1 (76%), and GOS-3 (92%). While aspirin had no effect (SVG-p12 
101%; 1321N1 102%; U87 MG 104%; GOS-3 112%), PN517 appeared to increase 
invasion in some cell lines (SVG-p12 92%; 1321N1 104%; U87 MG 116%; GOS-3 123%). 
 
In control cells, the greatest proportion of invasion was observed in the SVG-p12 cell line, 
followed by U87 MG, 1321N1 and GOS-3 cell lines respectively (data not shown). 
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A 
 
B 
 
 
Fig 6.4 Effect of drug treatment on invasion in the SVG-p12, GOS-3, 1321N1 and U87 MG 
cell lines (A) and a diagramatic representation of the assay (B). The data illustrate the effect of 
drug treatment 0.1 mM) over 18 hours on cell invasion in the SVG-p12, GOS-3, 1321N1 and U87 
MG cell lines expressed as a percentage of control. Cisplatin was the only treatment found to reduce 
invasion, with aspirin and PN517 producing no effect. Statistical significance determined by 
ANOVA with data representing results from 3 independent experiments. 
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6.3 Discussion 
Migration and invasion are two key properties of tumour development and represent an 
important drug target in the development of new therapeutics for cancer treatment. We 
have demonstrated that the novel aspirin analogue PN517 significant reduces migration in 
glioma cell lines, but did not reduce invasion.  
 
A wide range of literature supports a role for aspirin and COX selective inhibitors in the 
inhibition of both migration and invasion. In addition to the previously mentioned clinical 
trial data indicating that aspirin reduces metastasis (Rothwell et al., 2012; Algra and 
Rothwell, 2012), in vivo results using a mouse model examining lung cancer metastasis 
demonstrated that aspirin significantly reduced LLC-GFP cell metastasis following 
injection into regional lymph nodes, an effect accompanied by a significant reduction in 
motality (Ogawa et al., 2014). A vital step in metastasis is invasion, an ability acquired 
after a cell goes through epithelial mesenchymal transition (EMT) (Yu et al., 2012), a 
process inhibited by aspirin (Lou et al., 2014). In addition to in vivo and clinical evidence, 
many in vitro studies have characterised the molecular mechanisms involved, establishing 
that COX-2 expression increases the metastatic potential of Caco-2 colon cancer cells in a 
matrigel invasion assay (Tsujii et al., 1997), an effect replicated in LN229 glioma cells and 
found to be dependent on Id1 expression (Xu et al., 2013). It was also reported that PGE1 
and PGE2 treatment of T98G glioma cells increased migration measured by scratch assay 
and transwell Boyden chambers, with PGE2 producing the greater stimulation (Gomes and 
Colquhoun, 2012). Also using transwell Boyden chambers and scratch assay, Lee and 
colleagues showed an inhibition of invasion in U87 MG cells by sulindac associated with 
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a downregulation of MMP-2 (Lee et al., 2005), a result replicated in HN4, HN12, HT29 
and HCT116 cell lines in addition to demonstrating a downregulation of MMP-9 
(Koontongkaew et al., 2010).  
 
 
 
 
 
 
 
 
Figure 6.5 Growth factors and cytokines affect MMP-9 expression. MMP expression is 
regulated by the transcription factors NF-κB and AP-1 through the Ras/MAPK and PI3K/AKT 
signalling pathways. NF-κB reduces the levels and activities of MMP-2, MMP-9. NF-κB binding 
to the MMP-2 and MMP-9 promoter is involved in the induction of MMP-2 and MMP-9 gene 
expression associated with tumour cell invasion.  
 
Our results with aspirin and PN517 using the transwell migration assay and scratch assay 
support these findings and further confirm the therapeutic potential of PN517 for the 
treatment of glioma. However, the failure of PN517 or aspirin to inhibit invasion is a 
confounding result given the literature, but there are a number of potential explanations. 
Firstly, one difficulty associated with the use of matrigel coated transwell inserts for the 
measurement of invasion is that it is very difficult to establish uniformity of coating, 
meaning that an increase in matrigel volume in a treatment well compared to a control well 
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may provide a false positive result. However, in our case, the invasion assay was provided 
by an independent company where quality control should eliminate such issues. The 
second, and more likely explanation for contradictory results is incubation time. We 
examined invasion over eighteen hours, an incubation time significantly greater than many 
published results where five hours (Koontongkaew et al., 2010), and eight hours (Lee et 
al., 2005) have been previously used. It could simply be that our incubation was too long 
and that any decrease in the rate of invasion by either PN517 or aspirin would have only 
been observed at an earlier timepoint. 
 
One other potentially interesting finding of our results was that the GOS-3 and 1321N1 
cell lines showed the greatest level of migration measured using the transwell chambers. 
This result correlates well with our report of CD90, also known as Thy-1, expression in 
these two cell lines (Fig 3.2), as it has been reported that up-regulation of CD90 is 
associated with increased invasion and metastasis in cancer (Cheng et al., 2012). 
 
In conclusion, the data presented in this chapter demonstrate that PN517 and aspirin reduce 
cell migration, an effect that supports its therapeutic potential for the treatment of glioma. 
This effect was found at micromolar concentrations, significantly lower than the millimolar 
concentrations of aspirin that are found in vivo after administration of a dose for the 
treatment of cardiovascular disease (Stark et al., 2001; Paulus et al., 1971; Tin et al., 1998; 
Borthwick et al., 2006). 
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Chapter 7. Short Term Cultures 
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7.1 Introduction 
In vitro experiments are most often performed with immortalized cell lines because they 
are widely available and are able to expand to a high number of passages without any 
alterations, but they are often criticized because these properties further removes them from 
in vivo data. However, one clinically relevant tumour model system that has gained wide 
acceptance is the primary cell, or short term culture model, a time consuming process with 
a relative high success rate of 60% (Mullin et al., 2013).  Primary cultures are isolated from 
tissue and have a heterogeneous population of cell types but they have a limited life span 
and can lose their phenotype. They are more difficult to work with because of their slower 
proliferation rate, but should be passaged as little as possible to prevent epigenetic or 
genetic alterations. 
 
The main purpose for generating in vitro models of brain tumours is for the identification 
of the mechanisms contributing to oncogenesis or tumour maintenance through analysis of 
distinct molecular patterns, and evaluation of potential therapeutic strategies. This model 
of testing can also provide a patient-individual sample for the use of individualized therapy. 
In this chapter, two very different high grade gliomas were supplied from the Preston Royal 
hospital, BTNW911 and BTNW 914. These two primary cultures have a different doubling 
time (data not shown), a small and simple difference, but one which allows comparison of 
drug efficacy in two cultures with contrasting proliferation.  
 
As the short term cultures have a limited availability, quantification of cell viability was 
performed using PrestoBlue, a reagent with sufficient sensitivity to detect as few as ten 
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cells. Proliferation was also examined using CFDA-SE staining, but over a longer 
timecourse than with the cell lines due to the naturally longer doubling time of short term 
cultures. Finally, cell cycle distribution and apoptosis were examined using flow 
cytometry, a technique that is sensitive to changes in small cell populations. 
 
Hypothesis 
It was anticipated that the effects reported in the previous chapters using standard cell lines 
would be replicated to some degree with primary cultures. However, as it is known that 
differences in protein expression, such as EGFR and COX, are found in primary cultures, 
and that proliferation is much lower, differences in the results would be expected.  
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7.2 Results 
Immunofluorescent staining of the short term cultures was performed to examine GFAP, 
CD34 and CD90 labelling (Fig 7.1, 7.2 and Table 7.1). Both BTNW911 and BTNW914 
showed similar levels of GFAP staining in different passages, but the latter culture had a 
higher degree of labelling with the endothelial cell marker CD34, however this staining 
appeared to co-localise with GFAP. With respect to the stem cell marker CD90, both short 
term cultures displayed a high level of staining across a number of different passages. 
 
   
 
 
 
 
 
 
 203 
 
 
Figure 7.1 Immunofluorescent staining of the BTNW911 and BTNW914 short term cultures for glial fibrillary protein (GFAP) and CD34 
with a DAPI nuclear counterstain. GFAP was labelled with an alexa flour 594 conjugated mouse monoclonal antibody (clone 131-17719) and 
CD34 with FITC conjugated mouse anti-human monoclonal antibody (clone 581). Row A represents BTNW911 passage 7, row B BTNW911 
passage 10, row C BTNW914 passage 6, and row D BTNW914 passage 7. 
A
B
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Figure 7.2 Immunofluorescent staining of the BTNW911 and BTNW914 short term cultures for CD90 with a DAPI nuclear counterstain. 
CD90 was labelled with a FITC conjugated mouse monoclonal antibody (clone 5E10) Row A represents BTNW911 passage 7, row B BTNW911 
passage 10, row C BTNW914 passage 6, and row D BTNW914 passage 7. 
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 205 
 
Table 7.1 Fluorescence intensity quantification of CD34, CD90 and GFAP staining in short term cultures. CD34, CD90 and GFAP expression 
were detected using diretly labelled immunoflurescent antibodies in sequential cell passages of BTNW911 and BTNW914 short term cultures. 
Fluorescence was quantified using Zeiss Zen software and median values determined from three independent experiments.  
 
 BTNW911 BTNW914 
 Mediun Min Max Mediun Min Max 
CD34 467 336 2233 416 335 3471 
  398 323 4095 428 338 3471 
  423 325 3329 405 332 2259 
Mean 429 328 3219 416 335 3067 
 
CD90 
 
333 
 
263 
 
1752 
 
418 
 
318 
 
4013 
  457 287 4095 455 341 3419 
  505 277 4095 397 275 3797 
Mean 432 276 3314 423 311 3743 
 
GFAP 
 
1104 
 
914 
 
2696 
 
961 
 
813 
 
2382 
  1095 935 2742 1891 1649 4070 
  1107 954 2495 1817 1577 4095 
Mean 1102 934 2644 1556 1346 3516 
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A direct comparison of the PrestoBlue and MTT assays showed an equal ability to detect 
large cell numbers (Fig 7.3 and 7.4) but that the sensitivity of the PrestoBlue assay was 
greater at low cell numbers (Panel D) and the ability of the assay to detect ten cells was 
confirmed but required approximately 12 hours of incubation with the reagent (data not 
shown). In terms of drug induced reductions in cell viability, in the BTNW911 cells, no 
difference was found in the IC50 values for aspirin and cisplatin (Fig 7.3), however, in 
BTNW914 cells the PrestoBlue assay appeared more sensitive to drug induced changes in 
viability for both drug treatments (Fig 7.4).  
 
The effect on cell viability by the aspirin analogues was subsequently examined over 24 
and 48 hours (Fig 7.5 – 7.10). In BTNW911 cells, PN517 was the most potent drug tested 
at both timepoints, with an IC50 value of 2.6 mM and 1.2 mM respectively (Fig 7.5 and 
7.6), and as in the cell lines, PN529 failed to reduce cell viability by 50%. Cisplatin was 
the next most potent drug, with an IC50 at of 2.7mM in the PrestoBlue assay and of 3.0mM 
in the MTT assay. Interestingly, salicylic acid produced a greater reduction in cell viability 
at both timepoints than aspirin. In BTNW914 cells cisplatin was the most potent treatment 
at both timepoints with an IC50 value of 0.7mM and 1.9mM at 24 and 48 hours respectively 
(Fig 7.8 and 7.9). The most potent analogue at 24 hours was PN517 with an IC50 value of 
1.7 mM, but PN508 showed greater efficacy at 48 hours with an IC50 value of 4 mM. In 
contrast to the BTNW911 short term culture, aspirin had greater efficacy than salicylic 
acid.  
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Figure 7.3 Comparison of MTT and PrestoBlue cell viability assays following 24 hours drug 
treatment in the BTNW 911 primary culture.  The data illustrate cell viability expressed as a 
percent of control determined using the PrestoBlue™ (squares) and MTT (triangles) assays in the 
BTNW 911 primary culture following drug treatment for 24 hours (aspirin in panel A & cisplatin 
in B) using 1000 cells per well, and with increasing cell numbers (50 – 20,000 cells per well - panel 
C; 50 – 1000 cells per well – panel D). ANOVA analysis of results, show an overall significant 
effect of treatment in comparison with control (p < 0.0001), and no significant difference between 
MTT and PrestoBlue IC50 values, with data representing results from 3 independent experiments. 
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Figure 7.4 Comparison of MTT versus PrestoBlue assay for the detection of cell viability 
following 24 hours drug treatment in the BTNW 914 primary cell culture. The data illustrate 
cell viability determined using the PrestoBlue™ and MTT assay on BTNW 914 cell culture 
following drug treatment for 24 hours. Viability of MTT (triangles and dashed line) and PB 
(squares and solid line) assay to detect effects on cell viability following aspirin (panel A) and 
cisplatin (panel B) drug treatment for 24 hours. The lower panels illustrate the relationship between 
cell number and viability for both the MTT and PB assays, up to 1000 cells per well (panel D) and 
20,000 cells per well (panel C). ANOVA analysis of results, show an overall significant effect of 
treatment in comparison with control (p < 0.0001), data represent results from 3 independent 
experiments. 
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Figure 7.5 Cell viability following 24 hours drug treatment in BTNW911 short term culture. 
The data illustrate cell viability determined using the PrestoBlue™ assay on BTNW911 cells 
following drug treatment for 24 hours. Panel A illustrates the results for the aspirin analogues 
PN517, PN508, PN526 and PN529. In panel B, the control treatments aspirin, salicylic acid and 
double aspirin decrease cell viability. Panel C illustrates a comparison between PN517, cisplatin 
and aspirin showing that at 24 hours PN517 and cisplatin have similar efficacy. Panel D illustrates 
the IC50 values following 24 hour treatment of the aspirin analogues and control drugs. ANOVA 
analysis of results, show an overall significant effect of treatment in comparison with control (p < 
0.0001) with data representing results from 3 independent experiments. 
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Figure 7.6 Cell viability following 48 hours drug treatment in BTNW911 short term culture. 
The data illustrate cell viability determined using the PrestoBlue™ assay on BTNW911 cells 
following drug treatment for 48 hours. Panel A illustrates the results for the aspirin analogues 
PN517, PN508, PN526 and PN529. In panel B, the control treatments aspirin, salicylic acid and 
double aspirin decrease cell viability. Panel C illustrates a comparison between PN517, cisplatin 
and aspirin showing that at 48 hours PN517 and cisplatin have similar efficacy. Panel D illustrates 
the IC50 values following 48 hour treatment of the aspirin analogues and control drugs. ANOVA 
analysis of results, show an overall significant effect of treatment in comparison with control (p < 
0.0001) with data representing results from 3 independent experiments. 
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Figure 7.7 Cell viability following 24 and 48 hours drug treatment in BTNW911 short term culture. The data illustrate cell viability determined 
using the PrestoBlue™ assay in the BTNW911 cells following drug treatment for 24 and 48 hours. Panel A-G illustrate the effect on cell viability 
following drug treatment of cisplatin, aspirin, PN517, PN508, PN526, PN529 and SA respectively over 24 and 48 hours. The decrease in cell viability 
is similar in both 24 and 48 h. ANOVA analysis of results show an overall significant effect of treatment in comparison with control (p < 0.0001) 
with data representing results from 3 independent experiments. 
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Figure 7.8 Cell viability following 24 hours drug treatment in BTNW914 short term culture. 
The data illustrate cell viability determined using the PrestoBlue™ assay on BTNW914 cells 
following drug treatment for 24 hours. Panel A illustrates the results for the aspirin analogues 
PN517, PN508, PN526 and PN529. In panel B, the control treatments aspirin, salicylic acid and 
double aspirin decrease cell viability. Panel C illustrates a comparison between PN517, cisplatin 
and aspirin. Panel D illustrates the IC50 values following 24 hour treatment of the aspirin analogues 
and control drugs. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
 
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
PN 517
PN 529
PN 508
PN 526
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
Aspirin
2xAspirin
SA
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
Aspirin
PN 517
Cisplatin
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
P
N
51
7 
P
N
50
8
P
N
52
9
P
N
52
6  
A
sp
iri
n 
C
is
pl
at
in
 
S
A
2x
A
sp
iri
n
0
2
4
6
8
10
IC
5
0
 (
m
M
)
A B
C
D
***   **** 
** 
** 
** 
*** 
 213 
 
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
PN 517
PN 529
PN 508
PN 526
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
Aspirin
2xAspirin
SA
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
-4.0 -3.5 -3.0 -2.5 -2.0
0
20
40
60
80
100
120
Aspirin
PN 517
Cisplatin
Log Concentration (mM)
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
P
N
51
7 
P
N
50
8
P
N
52
9
P
N
52
6  
A
sp
ir
in
 
C
is
pl
at
in
 
S
A
2x
A
sp
ir
in
0
2
4
6
8
10
IC
5
0
 (
m
M
)
A B
C D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 Cell viability following 48 hours drug treatment in BTNW914 short term culture. 
The data illustrate cell viability determined using the PrestoBlue™ assay on BTNW914 cells 
following drug treatment for 48 hours. Panel A illustrates the results for the aspirin analogues 
PN517, PN508, PN526 and PN529. In panel B, the control treatments aspirin, salicylic acid and 
double aspirin decrease cell viability. Panel C illustrates a comparison between PN517, cisplatin 
and aspirin. Panel D illustrates the IC50 values following 48 hour treatment of the aspirin analogues 
and control drugs. ANOVA analysis of results, show an overall significant effect of treatment in 
comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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Figure 7.10 Cell viability following 24 and 48 hours drug treatment in BTNW911 short term culture. The data illustrate cell viability 
determined using the PrestoBlue™ assay in the BTNW911 cells following drug treatment for 24 and 48 hours. Panel A-G illustrate the effect on cell 
viability following drug treatment of cisplatin, aspirin, PN517, PN508, PN526, PN529 and SA respectively over 24 and 48 hours. ANOVA analysis 
of results show an overall significant effect of treatment in comparison with control (p < 0.0001) with data representing results from 3 independent 
experiments. 
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The effect of drug treatment on proliferation in the BTNW 911 and BTNW914 short term 
cultures was subsequently determined (Fig 7.11 and 7.12). It is important to note that as 
these cells divide at a much slower rate than the established cell lines, the experiment was 
run over 10 days and not 3 days as previously used in chapter four. Each drug treatment 
reduced the proliferation rate of the short term cultures, but most significantly, the largest 
effect was observed with the aspirin analogue PN 517 (Fig 7.11 and 7.12). In BTNW914 
cells, the effect of PN517 on proliferation returned to levels similar to other drug treatments 
by day 6 and to the same level as control by day 10 (Fig 7.12).  
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Figure 7.11 Cell proliferation measured by flow cytometry following drug treatment in the 
BTNW911 short term culture. The data illustrate cell proliferation determined using CFDA-SE 
staining of BTNW911 cells, following drug treatment (0.1mM) over two weeks (days 2, 4, 6, 8 and 
10). Panel A shows the effect on all treatments on cell proliferation, where a rightward shift 
indicates a reduction in proliferation. Panel B compares control to PN517; panel C compares the 
most potent analogue PN517 with control, aspirin and cisplatin treatments; panel D shows a 
comparison of aspirin and PN517. ANOVA analysis of results, show an overall significant effect 
of treatment in comparison with control in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Figure 7.12 Cell proliferation measured by flow cytometry following drug treatment in the 
BTNW914 short term culture. The data illustrate cell proliferation determined using CFDA-SE 
staining of BTNW914 cells, following drug treatment (0.1mM) over two weeks (days 2, 4, 6, 8 and 
10). Panel A shows the effect on all treatments on cell proliferation, where a rightward shift 
indicates a reduction in proliferation. Panel B compares control to PN517 and PN508; panel C 
compares the most potent analogue PN517 with control, aspirin and cisplatin treatments; panel D 
shows a comparison of aspirin, double aspirin and PN517. ANOVA analysis of results, show an 
overall significant effect of treatment in comparison with control (p < 0.0001) with data 
representing results from 3 independent experiments. 
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Cell cycle analysis was performed at 24 and 48 hours with a low (0.1mM) and high (1mM) 
concentration of cisplatin, aspirin and PN517 in the BTNW911 short term culture (Fig 
7.13). PN517 increased the proportion of cells in the sub-G0 apoptotic population at both 
timepoints following treatment at both 0.1 and 1mM, decreased the G0/G1 population, and 
increased the S phase population of cells. While aspirin increased the sub G0 population at 
24 hours with 0.1mM treatment it had little effect on either the S or M phases. At 48 hours 
it produced a similar effect to PN517, an affect replicated at 24 hours with 1mM treatment, 
but not at 48 hours where a larger G0/G1 population was observed. Treatment with 
cisplatin increased the sub-G0 apoptotic population at both concentrations and timepoints, 
with an increase in the S phase population apart from at 48 hours. 
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Figure 7.13 Cell cycle distribution of the BTNW911 short term culture following drug 
treatment. Cell cycle distribution was determined by PI staining and flow cytometry following 
drug treatment for 24 (panel A and C) and 48 hours (panel B and D) at 0.1mM (panel A and B) and 
1mM (panel C and D). The proportion of the sub G1 apoptotic, G1, S and M phase populations is 
displayed as a percentage of the total population. ANOVA analysis of results, show an overall 
significant effect of treatment, in comparison with control (p < 0.0001) with data representing 
results from 3 independent experiments. 
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Apoptosis was examined using flow cytometry (Fig 7.14 and 7.15). PN517 induced 
apoptosis in the BTNW911 short term culture at both timepoints and at both drug 
concentrations, showing a time dependent effect. Interestingly, in contrast to cell viability 
and proliferation assays, aspirin induced apoptosis to a greater degree than PN517. 
Apoptosis in the BTNW914 short term culture was induced in both a concentration and 
time dependent manner by the aspirin analogue PN517 (Fig 7.15). In contrast to BTNW911 
cells, a larger proportion of late apoptotic cells was observed. Aspirin again induced 
apoptosis to a greater degree than PN517, also with a larger proportion of late apoptotic 
cells in the 1mM treatment. 
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Figure 7.14 Induction of apoptosis determined by Annexin V/PI staining following drug 
treatment for 24 and 48 hrs at 0.1 mM and 1 mM in the BTNW911 short term culture. The 
data represent the proportion of apoptotic cells (white - early apoptotic, black - late apoptotic) in 
BTNW911 cells as determined by flow cytometry following drug treatment over time. Panel A and 
B illustrate cisplatin treated cells at 0.1 and 1 mM respectively, and similarly C and D aspirin treated 
cells and E and F panel show PN517 treated cells. The data represent results of 3 independent 
experiments with an overall significant effect of treatment in comparison with control (p < 0.0001) 
determined by ANOVA. 
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Figure 7.15 Induction of apoptosis determined by Annexin V/PI staining following drug 
treatment for 24 and 48 hrs at 0.1 mM and 1 mM in the BTNW914 short term culture. The 
data represent the proportion of apoptotic cells (white - early apoptotic, black - late apoptotic) in 
BTNW914 cells as determined by flow cytometry following drug treatment over time. Panel A and 
B illustrate cisplatin treated cells at 0.1 and 1 mM respectively, and similarly C and D aspirin treated 
cells and E and F panel show PN517 treated cells. The data represent results of 3 independent 
experiments with an overall significant effect of treatment in comparison with control (p < 0.0001) 
determined by ANOVA. 
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Migration was examined in the BTNW911 short term culture using the wound 
healing/scratch assay (Fig 7.16). As with the cell lines, once cells were confluent, a scratch 
was created using a sterile cocktail stick so as not to scratch the plastic surface and alter 
migration, and the media replaced (including drug treatment where appropriate) to remove 
any floating cells whose re-attachment might influence the results. In non-treated cells, 
migration did not completely close the scratch over the 18 hour period of the assay. 
Treatment with PN517 reduced migration to approximately 60% of control with the scratch 
remaining unclosed after 18 hours. In contrast to the cell lines, cisplatin did not reduce 
migration any further, showing similar efficacy to PN517. Aspirin also reduced migration, 
but only reduced it to approximately 80% of control. 
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Fig 7.16 Effect of drug treatment on the BTNW911 short term culture migration using the 
scratch assay. Migration was expressed as fold decrease over 18 hours (panel A control) in scratch 
width as measured by minimum distance following treatment with PN517 (panel B), aspirin (panel 
C) and cisplatin (panel D) at 1mM. An overall significant effect of treatment (p < 0.01) was found 
by ANOVA analysis with data representing results from 3 independent experiments. 
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7.3 Discussion  
In the present chapter the aspirin analogue PN517 was evaluated in comparison to the 
control drugs aspirin and cisplatin in the short term cultures BTNW911 and BTNW914.  
Although the same methodology was used as described in previous chapters, assays were 
adapted to allow for the slow proliferation rate when compared to the commercially 
available cell lines. Both BTNW911 and BTNW914 are high grade glioma, originating 
from male patients of 33 and 66 years of age respectively. Both cultures were passaged 
typically in a 1:2 ratio, in contrast to the normal 1:4 for the cell lines. BTNW911 had a 
doubling time of approximately 7 days, and was used up to passage 10 in the lab without 
any slowing of proliferation or change in IC50 for the control drugs. On the other hand 
BTNW914 initially had a doubling time of approximately 7 days, which increased by about 
2 days at every passage, finally taking up to 3 weeks to double at passage 10.  
 
Immunohistochemical results indicated that both short term cultures display a high level of 
GFAP staining, indicating that they are of an astrocytic cell origin (Jacque et al., 1978; 
Halliday et al., 1996), with CD34 staining found to a lesser extent suggesting only a 
relatively small population of endothelial cells in the culture (Charalambous et al., 2006). 
In both the BTNW911 and 914 cultures, a high degree of CD90 positive cells were 
observed, indicating a large population of cancer stem cells (He et al., 2012). However, 
following our previous observation of CD90 binding in the GOS-3 and 1321N1 cells, this 
conclusion would have to be treated with caution. 
As previously mentioned, the sensitivity of the PrestoBlue assay made it ideal for assessing 
changes in cell viability in short term cultures where cells are in limited supply. However, 
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while we found no difference in IC50 values for either aspirin or cisplatin in the BTNW911 
short term culture, the PrestoBlue assay appeared to be significantly more sensitive to drug 
treatment in BTNW914 cells.  It is possible that given the slow proliferation rate that the 
mitochondrial content of these cells is low, and thus the MTT assay, which is based on the 
ability of a mitochondrial dehydrogenase enzyme to reduce the yellow coloured substrate 
to purple formazan product (Mossman, 1983), is not sensitive to the effects of drug 
treatment. Whereas the PrestoBlue assay, that functions as a cell viability indicator by using 
the reducing power of cells (Lu et al., 2012), might be more sensitive to treatment.  
 
With respect to drug treatment, PN517 showed at least similar if not greater efficacy than 
cisplatin in cell viability, proliferation, apoptosis and migration assays. This is again a 
strong indicator of the therapeutic potential of this novel compound. One unexpected result 
in the apoptosis assay was that aspirin actually produced a greater reduction in cell viability 
when compared to either PN517 or cisplatin. This effect is unlikely to be due to differences 
in inhibition of COX enzymes, as we found both compounds to have similar efficacy in the 
isolated enzyme assay, suggesting a difference in COX independent pathways. These 
pathways may include inhibition of the transcription factor nuclear factor kappa B (NF-
B) however, as earlier stated, this does contribute to activation of other signalling 
pathways which are COX dependant, thus, is not a truly independent pathway.  
 
What is clear from the literature is that COX-2 plays an important role in aspirin mediated 
effects and as a result has been highly studied (Xu et al., 2013; Suzuki et al., 2013; White 
et al., 2013; Gomes and Colquhoun, 2012; Lan et al., 2011; Lo et al., 2010; Kang et al., 
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2009; Kambe et al., 2009; Annabi et al., 2009; Kim et al., 2009; Lee et al., 2005; Amin et 
al., 2003; Arrieta et al., 2001; Aas et al., 1995). However, very few publications have 
examined aspirin effects or looked at COX expression and activity either in vivo or in vitro 
using primary cultures. Kokoglu and colleagues reported that prostaglandin and 
arachidonic acid levels are elevated in brain tumours (Kokoglu et al., 1998). In 2000, it 
was reported that COX-2 expression which is greater in high-grade glioma (Shono et al., 
2001), is most elevated in more slowly growing cultures (Joki et al., 2000). A decrease in 
proliferation and migration in a concentration dependant manner by the COX-2 selective 
inhibitor NS398 was also reported. However, only a small induction of apoptosis was 
found, in contrast to our findings with either aspirin which is relatively COX-1 selective, 
or the novel analogue PN517. This result might suggest that the induction of apoptosis in 
glioma is dependent on the constitutively expressed COX-1 enzyme and not the induced 
COX-2.   
 
As previously mentioned, it is also possible that metabolism of aspirin or the PN517 
analogue is occurring in vitro as the CYP2C9 enzyme is expressed in glioma and correlates 
positively with tumour grade (Knupfer et al., 2006). This expression of CYP2C9 provides 
a potential explanation as to why the cell viability IC50 values for aspirin and its analogues 
did not decrease further at 48 hours. Additionally, in the BTNW 914 short term culture, the 
cells appeared to recover at 48 hours following treatment with PN517, reflected in an 
increase in the IC50 value. As the cells were derived from a high grade glioma, this might 
be a reflection of CYP2C9 expression, but would require confirmation.  
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The epidermal growth factor receptor (EGFR) pathway is probably the most significant 
signalling pathway clinically implicated in glioma, with the EGF polypeptide playing an 
important role in the regulation of growth, proliferation (Lo et al., 2010; Zhang et al., 2013; 
Auf et al., 2013). EGFR expression positively correlates with the glioma grade of cell lines, 
however, it was been reported that primary cells express the receptor at an even higher 
level. The aspirin analogue, NCX-4016, induces cell cycle arrest and apoptosis in cisplatin-
resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signalling 
and modulation of Bcl-2 family proteins (Selvendiran et al., 2008). Aspirin is also known 
to inhibit EGFR activation, with inhibition having been demonstrated in COX-1 expressing 
OVCAR-3 cells, further demonstrating an interaction between EGFR-activated signalling 
pathways and COX (Cho et al., 2013). Since aspirin can affect both COX-1 and COX-2, a 
correlation between both could be the key to activation of different pathways. The Wnt/β-
catenin signalling pathway which regulates proliferation in glioma also cross links with 
EGFR (Chen et al., 2011). Tcf-4 protein expression is significantly increased in high-grade 
glioma when compared to low-grade glioma and is correlated with Akt-1 expression. β-
catenin/Tcf-4 directly regulates Akt-1 in glioma, and these two proteins may cooperate 
with each other in exerting their oncogenic effects (Chen L. et al 2011).   
 
Both BTNW911 and BTNW914 short term cultures show expression of the stem cell 
marker CD90, an important property for the development of new therapies. It has been 
shown that NSAID inhibition of COX-2 reduced the population of cancer stem cells in 
colon cancer (Moon et al., 2014). This may also be related to NF-B signalling, as elevated 
NF-B signalling activates the Wnt pathway and induces de-differentiation of non-stem 
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cells that have acquired a tumour-initiating capacity (Schwitalla et al., 2013). This aspirin 
and its analogues may reduce cancer stem cell populations through an anti-inflammatory 
action on the tumour microenvironment. In addition, the PI3K/Akt/mTOR pathway is 
activated for maintenance and proliferation of cancer stem cells, by AMPK (Kim et al., 
2014). Activation of AMPK induces cell cycle arrest by inhibiting the expression of cyclin 
D1 and activating p21/p27, resulting in apoptosis.  As aspirin activates AMPK it could 
provide one possible explanation for the protective effects of NDAIS against development 
of glioma. 
 
In conclusion, the aspirin analogue PN517 has demonstrated efficacy in primary cultures 
derived from high grade glioma, reducing viability, inhibiting proliferation, inducing 
apoptosis, causing cell cycle arrest and inhibiting cell migration. These results may provide 
a better assessment of therapeutic potential because they contain various tumour derived 
cell types and not just a single cell population which established cell lines contain.  
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Chapter 8 Final Discussion 
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This project characterised the effect of novel aspirin analogues using a range of assays in 
glioma cell lines and primary cultures, to allow identification of the analogue with best 
therapeutic potential. The primary aim examined cell viability and identified the compound 
displaying the greatest efficacy, with the remaining aims of the project focusing on 
characterising the mechanism of action of this lead compound, including the investigation 
of its effect on cell proliferation, apoptosis, and migration/invasion. In identifying PN517 
as the compound with highest efficacy, these initial aims have been met while generating 
many intriguing results. 
 
Currently, the biggest challenges in GBM treatment are the extremely narrow window for 
operative approaches, which is mostly palliative and rarely curative even when in 
combination with radiotherapy. A further issue is the blood brain barrier, which poses a 
major challenge in successful drug delivery, one which many NSAIDs successfully 
overcome (Goncalves et al., 2010). Therefore, most investigators and clinicians believe 
that development of better chemotherapeutic agents targeting multiple pathways in glioma 
stand a better chance of improving patient survival. Many potential targets have been 
identified, including activation of the EGFR and PI3K/Akt pathways, NF-B and Wnt/β-
catenin signalling pathways, as well was cyclin D, STAT3, and interleukins, in addition to 
the common pathogenic pathway of p53/Rb. These pathways contribute to cell survival, 
proliferation, apoptosis, migration, invasion and angiogenesis, and thus are crucial for 
tumourigenesis. Vitally, the COX enzymes have been shown to be involved in most of 
these pathways in various cancer models, and crucially are overexpressed in glioma and 
correlate with tumour grade and poor clinical outcome (Shono et al., 2001). Therefore, 
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while the regulation of COX-2 in glioma is an attractive target, the complex signalling 
pathways and their crosstalk represent a significant challenge in the characterisation of 
novel drugs.  
 
To date, the majority of literature examining a role for aspirin, selective COX-2 inhibitors 
or prostaglandin signalling has made use of established cell lines (Xu et al., 2013; Suzuki 
et al., 2013; White et al., 2013; Gomes and Colquhoun, 2012; Lan et al., 2011; Lo et al., 
2010; Kang et al., 2009; Kambe et al., 2009; Annabi et al., 2009; Kim et al., 2009; Lee et 
al., 2005; Amin et al., 2003; Arrieta et al., 2001; Aas et al., 1995), with few publications 
using either clinical tissue or primary cultures (Kokoglu et al., 1998; Joki et al., 2000; 
Shono et al., 2001). The results of Joki and colleagues provides the best in vitro insight 
into the role of COX-2 inhibition in glioma. They characterised the specific COX-2 
inhibitor NS-398 using both monolayer cell cultures and three-dimensional glioma 
spheroids using U-87MG and U-251MG human glioblastoma cell lines in addition to 
immunohistochemical analysis of glioma and normal brain tissue. They reported that 
proliferation rate was reduced in both monolayer and spheroid cultures. The effects of NS-
398 were concentration dependant, suggesting the regulation of specific pathways as 
opposed to non-specific effects. Interestingly though, they only reported a moderate 
increase in the number of apoptotic cells in the treated spheroids, and NS-398 did not have 
an inhibitory effect on tumour invasion in the co-culture spheroid system.  
 
The aspirin analogue PN517 has been investigated previously in colorectal cancer cell 
models (Deb et al., 2011; Claudius et al., 2014). It was reported to decrease cell viability, 
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activate NF-B signalling, decrease cyclin D1 expression, but unlike aspirin did not affect 
cell cycle in vitro. Importantly, in an in vivo tumour model, PN517 eliminated tumours but 
had no side effects in control animals (Claudius et al., 2014). In characterising PN517, our 
results have supported the findings of Joki and colleagues but at times contradicted 
Claudius, emphasising the therapeutic potential for aspirin analogues in the treatment of 
glioma, but indicating that tumour specific differences may be impact efficacy.  
 
In many assays throughout the project, the effect of aspirin or its analogues reached a 
maximum at the twenty four hour timepoint, and in fact the IC50 values for the aspirin 
analogues typically decreased between twenty four and forty eight hour time points in the 
1321N1 and GOS-3 cell lines, suggesting a recovery in cell viability. The only exception 
to this observation was the most potent analogue, PN517 in 1321N1 cells. The simplest 
explanation for this result is that the drugs are rapidly undergoing metabolism to form 
inactive metabolites.  
 
The chemical stability of a drug is of great importance since it typically becomes less 
effective as it undergoes degradation. In humans, aspirin is rapidly deacetylated to salicylic 
acid, which is further metabolized by glucuronidation, hydroxylation, and glycine 
conjugation (Hutt et al., 1986; Takanashi et al., 2000). The cytochrome p450 enzymes that 
are largely responsible for drug metabolism and detoxification of foreign chemicals are 
found at their highest concentrations in the liver, but are also distributed throughout the 
body (Guengerich, 2008). In the case of aspirin metabolism, the major enzyme involved is 
CYP2C9 (Takanashi et al., 2000; Miners and Birkett, 1998), an enzyme that is 
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polymorphic, with fast and slow metabolising forms. While it is known that CYP2C9 is 
expressed in glioma, expression that correlates positively with grade (Knupfer et al., 2006), 
it is not know whether there is any heterogeneity in the expression of the polymorphic 
forms. This provides not only an explanation for why IC50 values do not decrease further 
with longer incubations, for example in the U87 MG cell line where high expression would 
be expected, but also a potential explanation for why aspirin or its analogues have greater 
efficacy in one cell culture versus another. 
 
In this study, aspirin was included as a control because any developed analogue would at 
least have to improve on the effects of its parent compound. Throughout the results, with 
few exceptions this was true of PN517 in comparison to aspirin, identifying it as the lead 
analogue of interest. In addition, a treatment equivalent to a double dose of aspirin was also 
used as a control as the structures of two of the analogues, PN508 and PN517, closely 
resemble two aspirin bound together with either a single or double carbon bond (Fig 8.1). 
It has been suggested that the central double or single carbon bond either gives the molecule 
rigidity, or allows for rotational flexibility between to the two aspirin groups and that the 
site might also be a target for hydrolysis, the result of which would essentially be two 
aspirin molecules. 
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Figure 8.1 Chemical structures of aspirin, PN508 and PN517 
 
If this was the truly the mechanism of action of PN517, then any increased efficacy of these 
compounds observed in comparison to aspirin would simply be replicated by adding a 
double dose of aspirin. However, this control treatment seldom replicated the potency of 
PN517 in any assay, suggesting that its efficacy is due to some other structural 
characteristic and not simply because it resembles two aspirin molecules. This fact supports 
its development as a unique chemical entity and not simply as an increased dose of aspirin. 
 
In addition to CYP2C9 expression, a further explanation for variations in PN517 responses 
between the cell lines or short term cultures might simply be linked to COX expression and 
prostaglandin production. COX-2 protein expression is inducible and found in both normal 
brain and glioma specimens, and is significantly higher in high-grade glioma than low-
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grade glioma and normal brain tissue. Additionally, its expression is higher in slow 
growing cells than fast growing (Joki, 2000). The U87 MG cell line is both high grade and 
relatively slow growing with a doubling time of approximately 36 hours, both 
characteristics associated with high COX-2 expression. This provides a potential 
explanation for the high efficacy of PN517 in this cell type and warrants further 
investigation as it could contribute to future patient specific treatment based on COX 
expression.  
 
Interestingly, the cell viability efficacy of PN517 in the U87 MG cell line was not replicated 
in the proliferation assay, where cisplatin decreased proliferation to a much greater degree, 
suggesting a difference in the signalling pathways altered by analogue treatment in cell 
viability and proliferation. This may be related to EGFR, the expression of which is 
elevated in glioblastoma (e.g. U87 MG) but the literature would suggest is rare in low-
grade glioma such as 1321N1 and GOS-3 (Hatanpaa et al., 2010). However, while we did 
find that U87 MG expressed EGFR at the highest level, the expression in the GOS-3 and 
1312N1 cell lines was still significantly elevated in comparison to the control SVG-p12 
cell line. While the variation in expression may provide some explanation for cell specific 
proliferation responses it is unlikely to be the whole story. Also, it has been reported that 
primary culture show significantly elevated levels of EGFR compared to established cell 
lines (Tong, 1998), but as both the BTNW911 and BTNW914 cultures were slow 
proliferating, this would suggest that the receptor is unlikely to be linked to proliferation.  
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While many therapeutic approaches to cancer treatment promise patient individualised 
therapies, the cost of such developments are typically prohibitive and mean that the 
treatments which are developed are not widely available. With the development of a low 
cost and widely applicable therapy in mind, this in vitro project characterised the aspirin 
analogues in a range of glioma cell lines derived from tumours of differing grades, in 
addition to the short term cultures established from surgical tissue from Royal Preston 
Hospital. The primary cultures more closely mimic the true tumour environment, and 
combined with the cell lines allow comparison of results between labs. The results with 
PN517 in the cell lines demonstrate that both it and the control treatments aspirin and 
cisplatin generally show their greatest efficacy in the GOS-3 cell line (Table 8.1).  
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Table 8.1 Summary of assay results for the glioma and control cell lines. The table illustrates protein expression and efficacy of drug treatment 
in the cell lines, with * indicating the lowest expression or efficacy and **** the highest. 
 
Treatment 1321N1 GOS-3 U87 MG SVG-p12
Doubling Time (Hrs) n/a 24 24 36 48
EGFR Expression n/a *** *** **** *
CD90 Expression n/a **** **** - -
COX-2 Expression 
(predicted)
n/a ** *** **** *
Viability
PN517 * **** ** *
Aspirin **** * * *
Cisplatin *** **** * **
Proliferation
PN517 * *** ** ****
Aspirin * **** ** ***
Cisplatin * **** ** ***
Apoptosis
PN517 *** **** ** *
Aspirin **** *** * **
Cisplatin **** *** ** *
Migration
PN517 *** **** ** *
Aspirin **** **** * **
Cisplatin *** *** **** *
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This finding has many potential explanations, one of which could simply be the doubling 
time of the cells, as cells that are more rapidly proliferating are more sensitive to drug 
treatment in a cell viability assay. In addition, the GOS-3 cell lines showed high levels of 
EGFR expression, a know target for aspirin related compounds in vitro, and would be 
predicted to have lower levels of CYP2C9 expression which would result in prolonged 
compound stability compared to higher grade cells.  
 
Another model utilised in the project was spheroid cultures. 3D cell structures offer a high 
degree of clinical and biological relevance to in vivo models, stimulating the growth and 
micro-environmental conditions not replicated by monolayer cultures. First described over 
thirty years ago, they can be used to evaluate cellular responses novel compounds in the 
hope that in vitro results will more closely translate to the in vivo environment (Sutherland 
et al., 1981; Lee et al., 2008). Several studies have compared monolayer cell cultures to 
3D cultures to assess the efficiency of drug toxicity in glioma (Thore, 1984; Glimelius et 
al., 1988; Kolchinsky and Roninson, 1997; Joki et al., 2000). U87 MG cells have been 
shown to form and proliferate in vitro as spheroids, where as U251 MG cells formed 
spheroids, but did not continue to proliferate (Kolchinsky and Roninson, 1997). 
Interestingly, the monolayer and 3D structures of U87 MG cells did not show any 
difference in vinblastine resistance, but the U251 MG cells were 4.5 times more resistant 
in the spheroid form. The multicellular spheroids in most cases are more resistant than the 
corresponding monolayers to drug treatment, especially when limited drug penetration 
would be expected, suggesting that the spheroid system is more representative of the in 
vivo situation than monolayer cultures (Nederman et al., 1981). 
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As already discussed, comparison of the U87 MG and U251 MG cell lines found that NS-
398 (a COX-2 inhibitor) reduced the proliferation and migration in both models (Joki et 
al., 2000). However, there was no effect of drug treatment on invasion in the spheroid 
model, a finding that we have confirmed with PN517. However, while the time period of 
both assays varied largely (18 hours for the current study versus 4 days), the lack of efficacy 
for drug treatment may be related to this prolonged treatment. Over 4 days, it is very likely 
that aspirin related compounds would be rapidly metabolised and thus have no effect on 
invasion. This may also be the case in our experiment, or it may be related to concentration 
where any inhibition of invasion was masked by giving the cells sufficient time to invade, 
while it might be at a slower rate. 
 
Various pathways have been linked with aspirin and glioma, regulating processes such as 
proliferation, apoptosis, and migration. However, many of the pathways are interlinked, 
and either directly or indirectly regulated by COX enzymes or prostaglandins, making it 
difficult to isolate any one particular protein as being critical for efficacy (Fig 8.2).  
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Figure 8.2 Pathways implicated in aspirin regulation  
 
Aspirin was first linked to cancer prevention following the demonstration of low colorectal 
cancer incidence in long time aspirin users (Kune et al., 1988). This effect is mainly 
believed to involve the suppression of inflammation, since colorectal cancer is caused by 
chronic inflammation (Itzkowitz and Yio, 2004). However, proteins such as NF-B, which 
up-regulates major inflammatory factors, such as TNFα and IL-6, are critical for the 
process of tumourigenesis (Prasad et al., 2010).  IL-6 activates STAT3, a transcription 
factor known to be involved in cancer progression and a further link between inflammation 
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and tumourigenesis (Yihui et al., 2012).  STAT-3 has been also found to activate anti-
apoptotic proteins such as Bcl-XL and Bcl-2 in multiple myeloma cells (Bhardwaj et al., 
2007). A further protein linking aspirin and cancer is the EGFR, the stimulation of which 
activates STAT-3 and triggers signalling cascades like MAPK which result in turn can 
result in NF-B activation (Indranil et al., 2013). The phosphorylation, and thus activation 
of both EGFR and STAT-3 is inhibited by aspirin treatment (Karuppaiyah et al., 2007), 
resulting in the down regulation of Bcl-2 and Bcl-XL, and the up-regulation of Bax and 
Bak. EGFR activation has also been shown to stimulate cyclin D1 expression, resulting in 
increased proliferation and invasion, and a reduction in apoptosis (Wang, 2011). The 
Wnt/β-catenin pathway, involved in proliferation and tumourigenesis, can be activated by 
EGFR via PI3K/Akt (Sharma et al., 2002), NF-B (Agarwal et al., 2005), and in glioma 
by STAT3 (Fig 8.3) (Paul et al., 2013).  
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Pathways affected by EGFR 
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It is widely known that COX-2 and inflammatory cancers are linked, however the exact 
role of COX in glioma biology remains unclear. Deininger et al.1999 detected COX-1 in 
20-50% of all cells in both low- and high-grade gliomas, the COX-2 protein has been found 
in one study to be expressed in all human glioma specimens tested (Joki et al., 2000) but 
in another was found more commonly in high-grade gliomas (70%) than in low-grade 
gliomas (30%) or normal brain cells (Shono et al., 2001). COX-2 is involved in 
proliferation, apoptosis, angiogenesis and metastasis (Steele et al., 2003; Farrow et al., 
1998; Prescott et al., 2000; Hwang et al., 1998), and the products of the COX-2 enzyme 
are prostaglandins, are key mediators of inflammation. The expression of COX-2 is 
regulated by NF-B (Lee et al., 2004; Ulivi et al., 2008) and the EGFR-STAT-3 pathway 
in GBM cells. Finally, wild-type p53 inhibits COX-2 expression (Subbaramaiah et al., 
1999), a pathway demonstrated in glioma (Seijiro et al., 2008). The crosstalk of these 
pathways, each linked to aspirin, demonstrates the complexity of signalling and the 
challenges to characterising the mechanism of action of novel drugs. 
 
Conclusion  
Important molecular events have been described such as overactivation of the EGFR and 
PI3K/Akt pathways, and inactivation of the p53/Rb pathways to be important contributors 
for glioma development. NF-kB and Wnt/β-catenin signalling pathways have also been 
linked, as well as cyclin D, STAT3, IL-6 and many more.  All of these pathways contribute 
to cell survival, proliferation, apoptosis, migration, invasion and angiogenesis, and thus are 
crucial for tumourigenesis. COX inhibition has been shown to be involved nearly in every 
pathway discussed, and also expressed, according to literature, in glioma cell lines and 
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primary tissue. Therefore, the regulation of COX-2 activity in glioma is likely to involve 
many factors, so further studies are required to fully elucidate the mechanism. In summary, 
the results of this project have shown that the aspirin analogue PN517 reduces viability, 
inhibits proliferation, induces apoptosis through both extrinsic and intrinsic pathways, 
induces cell cycle arrest, regulates the activation of cyclin D1 and the EGFR, and inhibits 
migration. It has demonstrated greater efficacy than aspirin, and in some assays and cell 
lines cisplatin, and has demonstrated efficacy in both established cell lines and short term 
cultures derived from high grade gliomas. In conclusion, PN517 represents a novel aspirin 
analogue with significant therapeutic potential for the treatment of glioma and warrants 
further investigation.  
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Future Work  
Although high efficacy of the aspirin analogue PN517 was observed in various 
experiments, it is still essential to further characterise the mechanisms involved in its 
effects. These would include characterisation of intracellular signalling pathways and also 
the use of an in vivo model. 
 
Throughout the thesis, a number of different signalling pathways have been described that 
may be involved in the mechanism of action of PN517, however, definitive assays would 
need to be performed to establish these. For example, we have demonstrated that PN517 
inhibits both COX-1 and COX-2 in an isolated enzyme assay, but ideally the expression 
and activity of both enzymes in the cell lines and primary cultures should be established. 
This could be done using western blotting, a technique that could also be used to determine 
any inhibition of activation by PN517. A different approach could be to use a similar kit to 
the isolated enzyme assay, where instead of a purified enzyme, cell lysates are used and a 
direct assay of COX activity is obtained. It would also be interesting to compare PN517 
with other NSAIDs such as the COX-2 selective compounds like NS398 or celecoxib, a 
comparison that may help to delineate drug specific pathways in each assay. 
 
It has also been suggested that PN517 could be being metabolised in vitro by CYP2C9. An 
unrelated project in the school has actually demonstrated both expression and activity of 
this enzyme in U87 MG cells, however, this result would require confirmation and either 
HPLC or ICPMS could be used to detect both the loss of PN517 and appearance of 
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metabolites in the culture media over time. Similar assays should also be performed using 
the short term cultures to establish a stronger link to the in vivo pathological state.  
 
With regards signalling pathways, the involvement of the -catenin pathway needs to be 
examined. This could be achieved by evaluating the activity of the -catenin/TCF4 
transcriptional complex using luciferase reporter construct based assays. It is also essential 
to evaluate the NF-B pathway, as it is involved directly with COX-2 inhibition.  The link 
between COX enzymes and the different signalling pathways could be confirmed using an 
siRNA approach, where either COX-1, COX-2, or a combination of both enzymes could 
be knocked down and the effects of PN517 again examined.   
 
Glioblastoma cancer stem cells (GSCs) are a subgroup of tumour cells that are radiation 
and chemotherapy resistant and likely contribute to tumour recurrence. We’ve tentatively 
identified GSCs in our short term cultures using CD90 staining, but this result could be 
confirmed using other stem cell markers such as CD133, a marker linked to spheroid 
growth and tumour development in animal models. Using cell sorting, CD90 and CD133 
positive cells could be isolated and their sensitivity to drug treatment compared to the 
remaining marker negative populations. This may help in the development of new 
therapeutic approaches to GBM treatment.  
 
In addition to PN517 monotherapy, the efficacy of the novel aspirin analogue in 
combination with other chemotherapeutics should be examined. A recently completed 
project in the lab demonstrated significantly increased efficacy of the combination of 
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PN517 and cisplatin using the cell lines. This project, and the combination with other 
chemotherapeutics should be continued to confirm the results and also to establish the 
mechanism(s) of action involved. 
 
Finally, while we have used monolayer and spheroid cultures in addition to short term 
cultures, the gold standard model would be to determine the efficacy of PN517 in a nude 
mouse model. This system is currently being established at UCLan, where intracranial 
tumours will be established using both cell lines like U87 MG and short term cultures. The 
efficacy of peripheral delivery of PN517 in either the prevention of tumour development 
or in the treatment of established tumours will be examined.  
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Cell Line Supplementary Data 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1 Cell proliferation measured by flow cytometry following drug treatment in SVG-p12 cell line. The figure illustrates the effect of drug treatment 
on proliferation over three days where the red peak corresponds to day 1, black to day 2, and blue to day 3. A leftward shift indicates a decrease in fluorescence 
indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; panel C PN517; panel D PN508; panel E aspirin; and 
panel F double aspirin. 
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Figure 10.2 Cell proliferation measured by flow cytometry following drug treatment in 1321N1 cell line. The figure illustrates the effect of drug treatment 
on proliferation over three days where the red peak corresponds to day 1, black to day 2, and blue to day 3. A leftward shift indicates a decrease in fluorescence 
indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; panel C PN517; panel D PN508; panel E aspirin; and 
panel F double aspirin. 
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Figure 10.3 Cell proliferation measured by flow cytometry following drug treatment in U87 MG cell line. The figure illustrates the effect of drug treatment 
on proliferation over three days where the red peak corresponds to day 1, black to day 2, and blue to day 3. A leftward shift indicates a decrease in fluorescence 
indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; panel C PN517; panel D PN508; panel E aspirin; and 
panel F double aspirin. 
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Figure 10.4 Cell proliferation measured by flow cytometry following drug treatment in GOS-3 cell line. The figure illustrates the effect of drug treatment 
on proliferation over three days where the red peak corresponds to day 1, black to day 2, and blue to day 3. A leftward shift indicates a decrease in fluorescence 
indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; panel C PN517; panel D PN508; panel E aspirin; and 
panel F double aspirin. 
A B C 
D E 
F 
 310 
 
 
 
Figure 10.5 Representative dot plots illustrating the induction of apoptosis following cisplatin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in SVG-p12 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with cisplatin at 0.1 mM, and panel C 1 mM treatment over 
time with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin 
V+/PI+ (upper right quadrant) represent late apoptotic cells.  
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Figure 10.6 Representative dot plots illustrating the induction of apoptosis following aspirin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in SVG-p12 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with aspirin at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Figure 10.7 Representative dot plots illustrating the induction of apoptosis following PN517 treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in SVG-p12 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with PN517 at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Figure 10.8 Representative dot plots illustrating the induction of apoptosis following cisplatin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in 1321N1 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with cisplatin at 0.1 mM, and panel C 1 mM treatment over 
time with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin 
V+/PI+ (upper right quadrant) represent late apoptotic cells.  
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Figure 10.9 Representative dot plots illustrating the induction of apoptosis following aspirin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in 1321N1 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with aspirin at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Figure 10.10 Representative dot plots illustrating the induction of apoptosis following PN517 treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in 1321N1 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with PN517 at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Figure 10.11 Representative dot plots illustrating the induction of apoptosis following cisplatin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in Gos-3 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with cisplatin at 0.1 mM, and panel C 1 mM treatment over 
time with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin 
V+/PI+ (upper right quadrant) represent late apoptotic cells.  
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Figure 10.12 Representative dot plots illustrating the induction of apoptosis following aspirin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in Gos-3 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with aspirin at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Figure 10.13 Representative dot plots illustrating the induction of apoptosis following PN517 treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in Gos-3 cell line. Panel A illustrates the control untreated sample, panel B drug treatment with PN517 at 0.1 mM, and panel C 1 mM treatment over time with 
flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ (upper 
right quadrant) represent late apoptotic cells.  
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Figure 10.14 Representative dot plots illustrating the induction of apoptosis following cisplatin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in U87 MG cell line. Panel A illustrates the control untreated sample, panel B drug treatment with cisplatin at 0.1 mM, and panel C 1 mM treatment over 
time with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin 
V+/PI+ (upper right quadrant) represent late apoptotic cells.  
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Figure 10.15 Representative dot plots illustrating the induction of apoptosis following aspirin treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 
mM in U87 MG cell line. Panel A illustrates the control untreated sample, panel B drug treatment with aspirin at 0.1 mM, and panel C 1 mM treatment over 
time with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin 
V+/PI+ (upper right quadrant) represent late apoptotic cells.  
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Figure 10.16 Representative dot plots illustrating the induction of apoptosis following PN517 treatment for 4, 8, 12, 24 and 48 hrs at 0.1 mM and 1 mM 
in U87 MG cell line. Panel A illustrates the control untreated sample, panel B drug treatment with PN517 at 0.1 mM, and panel C 1 mM treatment over time 
with flow cytometric analysis of FITC-annexin V and PI staining. Annexin V+/PI− (lower right quadrant) represents early apoptotic cells, and annexin V+/PI+ 
(upper right quadrant) represent late apoptotic cells.  
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Short Term Culture Supplementary Data 
 
 
 
Figure 10.17 Cell proliferation measured by flow cytometry following drug treatment in BTNW911 short term culture. The figure illustrates the effect 
of drug treatment on proliferation over three days where the black peak corresponds to day 2, red to day 4, and green to day 6 and blue to day 8. A leftward 
shift indicates a decrease in fluorescence indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; panel C 
aspirin; panel D PN517. 
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Figure 10.18 Cell proliferation measured by flow cytometry following drug treatment in BTNW914 short term culture. The figure illustrates the effect 
of drug treatment on proliferation over three days where the black peak corresponds to day 2, red to day 4, and purple to day 6, green to day 8 and blue to day 
10. A leftward shift indicates a decrease in fluorescence indicating proliferation. Panel A illustrates representative results for control treatment; panel B cisplatin; 
panel C aspirin; panel D PN517. 
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